Medicinal Chemistry Updates on Bacterial Efflux Pump Modulators by Durães F. et al.
For Review Only
 
 
 
 
 
 
Medicinal Chemistry Updates on Bacterial Efflux Pump 
Modulators 
 
 
Journal: Current Medicinal Chemistry 
Manuscript ID Draft 
Manuscript Type: Review 
Date Submitted by the Author: n/a 
Complete List of Authors: Durães, Fernando; Faculty of Pharmacy University of Porto 
Pinto, Madalena; Faculty of Pharmacy University of Porto, Deptm Chemical 
Sciences, Lab Organic and Medicinal Chemistry 
Sousa, Maria Emília; Faculty of Pharmacy University of Porto,  
Keywords: 
Antimicrobial resistance, efflux pump inhibitors, natural products, synthetic 
compounds, existing drugs, structure-activity relationship 
  
Note: The following files were submitted by the author for peer review, but cannot be converted to 
PDF.  You must view these files (e.g. movies) online. 
Figure 3.cdx 
Figure 5 (1).cdx 
Figure 5 (2).cdx 
Figure 5 (3).cdx 
Figure 5 (4).cdx 
Figure 5 (5).cdx 
Figure 5 (6).cdx 
Figure 13 (1).cdx 
Figure 13 (2).cdx 
Figure 13 (3).cdx 
Figure 17.cdx 
Figure 19.cdx 
 
 
https://mc04.manuscriptcentral.com/crmc
Current Medicinal Chemistry
For Review Only
Send Orders for Reprints to reprints@benthamscience.ae 
 Journal Name, Year, Volume 1 
 XXX-XXX/14 $58.00+.00 © 2014 Bentham Science Publishers 
Medicinal Chemistry Updates on Bacterial Efflux Pump Modulators 
Abstract: Antibiotic resistance is one of the most pressing health issues of our days. It can arise due to a multiplicity of 
factors, such as target modification, decrease in the drug uptake, changes in the metabolic pathways and activation of efflux 
pumps. The overexpression of efflux pumps is responsible for the extrusion of drugs, making antibiotic therapy fail, as the 
quantity of intracellular antibiotic is not enough to provide the desired therapeutic effect. 
Efflux pumps can be included in five families according to their composition, nature of substrates, energy source, and number 
of transmembrane spanning regions. The ABC superfamily are mainly found in Gram-positive bacteria, use ATP as an 
energy source, and only a limited number of ABC pumps confer multidrug resistance (MDR). 
On the other hand, the MFS family, most present in Gram-positive bacteria, and the RND family, characteristic of Gram-
negative bacteria, are the most associated with antibiotic resistance. A wide variety of inhibitors have been disclosed for both 
families, from either natural or synthetic sources, or even drugs that are currently in therapy for other diseases. 
The other two families are the SMR, which are the smallest drug efflux proteins known, and the MATE family, whose pumps 
can also resort to the sodium gradient as an energy source. 
In this review, it is intended to present a comprehensive review of the classes of efflux pump inhibitors from the various 
sources, highlighting their structure-activity relationships, which can be useful for medicinal chemists in the pursuit of novel 
efflux pump inhibitors. 
 
Keywords: Antimicrobial resistance; efflux pump inhibitors; natural products; synthetic compounds; existing drugs; structure-activity 
relationship. 
1. INTRODUCTION 
Bacteria were discovered the late 19
th
 century as infectious 
agents. It was, however, half a century later that antibiotics 
completely revolutionized medicine and became a turning 
point in human history. Unfortunately, the misruled use of 
these drugs led to the appearance of resistant strains, and to 
the concern of a return to the pre-antibiotic era, where the 
simplest, most treatable infections can become deadly [1-2]. 
Antibiotic resistance can arise due to multiple causes. The 
most common are the overuse and/or inappropriate 
prescribing, as well as extensive veterinary and agricultural 
use. These factors are especially alarming if it is taken into 
account the very few new antibiotics that were discovered in 
the past years [3]. Due to their genetic plasticity, bacteria can 
develop defense mechanisms in response to environmental 
threats. As far as antibiotics are concerned, bacteria use two 
major strategies to adapt to these drugs, which are mutations 
in genes and the acquisition of resistance genes through 
horizontal gene transfer. The first strategy can be manifested 
through modification of the target, decrease in the drug 
uptake, activation of efflux pumps to extrude the drug or 
changes in metabolic pathways. The latter is related to the 
acquisition of external genetic material through 
transformation, transduction, or conjugation [4-5]. Recently, 
vesicle-mediated resistance has also been regarded as a 
mechanism of resistance acquisition [6]. 
Efflux pumps are ubiquitous in bacteria, and can be encoded 
by genes present either in the bacterial chromosomes or in 
plasmids [7-8]. They concern five families, according to 
their composition, substrates, energy sources, and number of 
transmembrane spanning regions: the adenosine triphosphate 
(ATP)-binding cassette (ABC) superfamily, the resistance-
nodulation-division family (RND), the major facilitator 
superfamily (MFS), the small multidrug resistance (SMR) 
family, and the multidrug and toxic compound extrusion 
(MATE) family (Figure 1) [7-12].  
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390; E-mail: esousa@ff.up.pt 
Efflux pumps can be further divided into two major families, 
the primary transporters, which hydrolyze ATP as a source 
of energy, as is the case of the ABC family, and secondary 
transporters, which use the proton or sodium gradient as a 
source of energy [13]. Overexpression of multidrug efflux 
pumps is correlated with an increase in the minimum 
inhibitory concentration (MIC) of antibiotics, and thus, these 
pumps can be considered potential antibacterial targets. 
Therefore, the development of efflux pump inhibitors may 
be a way of fighting against resistant microorganisms. 
Studies have been carried out on the structure of efflux 
pumps, as well as on their mechanisms of binding and 
extrusion, leading to the possibility of structure-based design 
of efflux pump inhibitors (EPIs). The rationale for the 
development of these EPIs could be, for instance, the 
inhibition of the energy sources required for the ability to 
extrude antibiotics, and the development of compounds that 
compete with the antibiotics for their extrusion. However, 
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the main challenge lies in the fact that many compounds that 
present EPI activity and are already used for the treatment of 
other diseases are toxic for human cells in the concentrations 
required to present EPI activity and, therefore, clinically 
useless [7-9, 13]. 
Even though there are already several reviews which 
describe different classes of EPIs [11, 13-31], most focus on 
a particular source of compounds or on a class of pumps or 
bacteria. Herein, it is intended to present a comprehensive 
review of the several classes of EPIs from natural and 
synthetic sources and from existing drugs in therapeutics and 
to highlight structure-activity relationship studies in the 
referred efflux pumps (ABC, RND, MFS, SMR and MATE), 
which can be useful for medicinal chemists in the pursuit of 
novel compounds for this goal.  
 
2. ABC 
The ABC transporters are primary transporters, and they 
exist in every membrane systems, whether the organism is 
prokaryotic or eukaryotic. P-Glycoprotein (P-gp) is a very 
well known human ABC transporter, involved in the 
resistance of cytotoxic drugs used in cancer therapy [32-34], 
whose modulation has been regarded as a study field [35-
37]. Structurally, an ABC transporter consists of four 
conserved domains, two transmembrane domains, and two 
cytoplasmic domains, which bind to nucleotides and, 
therefore, are involved in ATP binding [32, 38]. In fact, the 
nucleotide binding domains are responsible for hydrolyzing 
ATP, which will lead to conformational changes in the 
attached transmembrane domains, making it possible for 
substrates to cross the lipid bilayer of the membrane, either 
in an inwards or an outwards fashion [39]. 
The bacterial transporters are highly selective for sugars, 
amino acids, metallic cations, organo-iron complexes, 
vitamins, and antibiotics [32, 40]. They are found in Gram-
positive bacteria, such as Enterococcus faecalis and 
Staphylococcus aureus, and confer resistance to macrolides 
and bacitracin. However, only a limited number of ABC 
pumps are associated with MDR, which means that ABC 
pumps do not play a pivotal role in conferring antibiotic 
resistance in bacteria [32-33]. 
As such, bacterial ABC transporter inhibitors are scarce. The 
few EPIs discovered in this context are mainly against MsrA 
(Figure 2, PDB 1NWA), whose tridimensional structure has 
been elucidated [41]. 
The structures of the ABC inhibitors that will be further 
detailed throughout this section are comprised in Figure 3. 
 
2.1. ABC inhibitors 
2.1.1. Natural Products 
The search for natural products comes from the reason that 
plants produce antimicrobials to protect themselves from 
exogenous organisms. It is thought that plants can produce 
anti-MDR compounds to fight the microbial resistance 
phenomenon. Carnosic acid (1) was one of the major 
products isolated from the plant Rosmarinus officinalis. 
When tested against the macrolide resistant strain of S. 
aureus, expressing the MsrA pump, compound 1 displayed 
favorable results, showing an impressive 8-fold potentiation 
of erythromycin [42]. 
An extract of Lycopus europaeus led to the isolation of two 
new isopimarane diterpenes, methyl-1α-acetoxy-7α,14α-
dihydroxy-8,15-isopimarandien-18-oate (2) and methyl-
1α,14α- diacetoxy-7α-hydroxy-8,15-isopimarandien-18-oate 
(3), which showed no antibacterial activity, but were able to 
reduce erythromycin’s MIC from 256 µg/ml to128 µg/ml, 
therefore causing a 2-fold potentiation. This behavior was 
similar to other isopimarane diterpenes isolated in this study, 
as well as for 5,9-dihydroxygeranyllinalool (4) and 9-
acetoxy-5-hydroxygeranyllinalool (5), two diterpenoids [43-
44]. 
Phytol (6) is an acyclic isoprenoid, and its EPI activity 
against the ABC pumps of E. coli was assessed in 
combination with nalidixic acid. Additionally, 15 derivatives 
were synthesized. One derivative in particular, compound 7, 
was able to decrease the MIC of nalidixic acid by 16-fold, 
and four other derivatives reduced the MIC by 8-fold. This 
effect was caused by the inhibition of ATP-dependent efflux 
pump and down-regulation of the efflux gene. In silico 
absorption, distribution, metabolism, and excretion (ADME) 
analysis was performed, taking into account parameters such 
as solubility in water, human intestinal absorption, plasma 
protein binding, blood-brain barrier penetration, 
hepatotoxicity and cytochrome P450 (CYP450) inhibition. 
Results showed all five active derivatives presented low 
permeability into the central nervous system and displayed 
moderate intestinal absorption. In terms of plasma protein 
binding level, all five compounds exhibited levels below 
90%, suggesting favorable distribution of the compounds 
into the blood. They also did not present hepatotoxicity, 
unlike reserpine, making them good lead compounds [45]. 
Ursolic acid (8) is a pentacyclic triterpenoid isolated from 
diverse natural sources. Its wide activity includes anti-
inflammatory, antimicrobial, diuretic, and antitumor activity, 
among others. When tested against Escherichia coli strains 
that were resistant and susceptible to nalidixic acid, ursolic 
acid did not display intrinsic antibacterial activity. However, 
ursolic acid (8) was able to reduce the MIC of nalidixic acid 
by 2-fold, when both drugs were used in combination. This 
synergy led to further research on this scaffold. The first 
derivative prepared was the 3-O-acetyl ursolic acid, and 
showed a 4-fold decrease in the MIC of nalidixic acid. The 
lipophilic nature of this derivative, allied with the increased 
potency, led to the synthesis of other lipophilic ester 
derivatives. The methyl and ethyl esters of 3-O-acetyl ursolic 
acid did not show any increment in the activity. However, a 
further increase in the ester carbon chain increased the drug 
reversal potential by 2-fold, in comparison to 3-O-acetyl 
ursolic acid, against the resistant strain. This is the case of 
the isopropyl (9) and the n-butyl (10) derivatives. The 
addition of a pentyl group led to a decrease in activity. 
Furthermore, ursolic acid (8), and derivatives 9 and 10, 
reduced the MIC of tetracycline by 2-fold, 8-fold, and 8-fold, 
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respectively. When these compounds were tested against 
ATP-dependent efflux pumps, it was found that derivatives 9 
and 10 were successful in inhibiting these pumps in terms of 
the liberated inorganic phosphate. Molecular modeling 
studies with the YojI pump, using maltose/maltodextrin 
transport ATP-binding protein as a homology model, showed 
that 9 was bound to the nucleophilic Ser-78, to the aromatic 
Phe-81, Trp-85 and Leu-86, the acidic Glu-94 and Glu-144 
and the basic Ala-79, Ala-139, Ala-140, Ala-141, Ala-143, 
Arg-74, Arg-122, Arg-146, Leu-107, Val-80, Lys-96, and 
Ile-123 in the nucleotide binding domain. Derivative 10 was 
also subjected to the same kind of studies using the same 
model, and was predicted to bind in the same region [46]. 
A study with flavones and isoflavones from the plant 
Sophora moorcroftiana revealed that diosmetin (11) was 
able to inhibit three drug resistant strains of S. aureus, 
including the ABC family MsrA overexpressing strain, 
potentiating the effects of norfloxacin and streptomycin [47]. 
These results corroborate the works of Chan et al (2013), 
who had previously studied the effects of diosmetin (11) as 
an EPI [48]. This group observed a synergistic effect of this 
flavonoid with erythromycin, which was 5-fold greater than 
that of verapamil [48]. 
4-Hydroxy-α-tetralone (12) isolated from the plant 
Ammannia multiflora, showed enhancement against nalidixic 
acid resistant strains of Escherichia coli, prompting the 
synthesis of derivatives in order to infer their mechanism of 
action. Five derivatives were synthesized, and it was shown 
that compound 13 was able to inhibit the expression of the 
ABC transporter protein gene yojI, which encodes the ABC 
protein YojI, and was successful in combination with 
tetracycline [49]. Molecular modelling studies with 
compound 13 and a homology model of the YojI protein 
revealed the following bound residues: Ser-78 
(nucleophilic), Leu-86, Ile-123, Ala-137, Ala-140, Ala-141, 
and Ala-143 (hydrophobic), Glu-144 (acidic), Arg-122 
(basic), Phe-81 (aromatic), Glu-144 (acidic), Arg-146 and 
Lys-96 (basic), and Trp-85 (hydrophobic), the same region 
as noted for ursolic acid derivatives 9 and 10. Compound 13 
showed good affinity and strong hydrophobic interaction 
with the YojI protein, corroborating the fact that this 
compound acts by the inhibition of ATP dependent efflux 
pumps [49]. 
The plant Portulaca oleraceae is used in folk medicine for 
its anti-inflammatory, anti-septic and diuretic effects, among 
others. A study of its fatty acids demonstrated that linoleic 
(14) and oleic acids (15) had synergistic activity with 
macrolides for the MsrA overexpressing strain of 
methicillin-resistant S. aureus (MRSA). In fact, 
erythromycin’s activity was enhanced when in combination 
with either of these two compounds, likely through the 
inhibition of the MsrA ATP dependent pump. Since these 
fatty acids are essential for humans, low toxicity is expected, 
making them promising agents to use in combination with 
antibiotics [50]. 
Lysergol (16) is a clavine alkaloid of the ergoline family. 
Recently, its EPI activity was studied, and derivatives were 
synthesized [51]. The compounds were tested against 
susceptible and resistant to nalidixic acid strains of E. coli 
and a tetracycline resistant strain. While not possessing 
antibacterial activity, lysergol (16) showed synergy with 
nalidixic acid at the concentration of 10 µg/ml, reducing its 
MIC by 8-fold in the resistant strain of E. coli and 4-fold in 
the susceptible strain. Of the thirteen semi-synthetic 
derivatives prepared, derivatives 17 and 18 reduced nalidixic 
acid’s MIC by 8-fold, twice as much as lysergol (16), in the 
susceptible strain. A 4-fold potentiation of nalidixic acid was 
observed for the three compounds when tested against the 
resistant strain. As for the tetracycline resistant strain, all 
three compounds were able to reduce tetracycline’s MIC by 
8-fold. Further studies were performed, in order to conclude 
whether or not these compounds were capable of interfering 
with ATP-dependent efflux pumps, and it was proven that all 
three compounds inhibited ATPase activity, concerning the 
liberation of inorganic phosphate. A down-regulation of the 
gene yojI was also observed when the tetracycline resistant 
strain was treated with lysergol (16) and its two most potent 
derivatives, 17 and 18, which further confirms the activity of 
these compounds as ABC transporter inhibitors [51]. 
 
2.1.2. Existing Drugs 
As part of a screening program for P-gp inhibitors, 
GG918 (19) was discovered. This synthetic compound had 
already showed success in increasing the intracellular 
concentration of paclitaxel in cancer cells. In S. aureus, this 
compound was able to slightly potentiate the activity of 
norfloxacin in a strain overexpressing the ABC efflux pump 
MsrA, suggesting that it may possess minimal activity over 
this pump [52]. 
The human P-gp inhibitors, vanadates, have been 
studied as inhibitors of the MutS pumps, belonging to the 
ABC ATPase superfamily. In fact, these compounds have 
demonstrated activity against the MutS in P. aeruginosa and 
E. coli. Decavanadate was the most effective, followed by 
orthovanadate (20), and they act non-competitively, possibly 
by replacing the inorganic phosphate. The fact that the ABC 
ATPases inhibited by orthovanadate are phosphorylated 
leads to the assumption that the low inhibitory effect could 
be attributed to the absence of a stable phosphorylation state 
of MutS [53]. 
 
3. MFS 
The MFS is the most extensively studied family of 
transporters, present in both Gram-positive and Gram-
negative bacteria, and comprises uniporters, symporters and 
antiporters. It also constitutes the largest family of secondary 
transporters, with over 10 000 sequenced members. Its 
substrates are diverse, and can range from ions, to 
carbohydrates, lipids, amino acids, nucleosides, among 
others. As many members of the MFS originate bacterial 
MDR, these transporters can pose as a good system for 
modulation studies [7, 19, 38, 54]. 
With the elucidation of the crystal structure of the MFS 
pump EmrD of E. coli (Figure 4, PDB 2GFP) [55], a general 
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structure could be proposed for MFS transporters: twelve 
transmembrane helices that form a compact structure, with 
four of these transmembrane helices facing away from the 
interior cavity and the rest forming the internal cavity, 
constituted mostly by hydrophobic residues [7]. 
The efflux of drugs is only possible if the carrier alternates 
between two conformations, so that the substrate can bind to 
the convenient site in either side of the membrane. However, 
a limitation concerning the energy involved to displace the 
exposed hydrophilic surface of a protein can be inferred. It 
has been proved that either the oligomerization domain or 
the transport subunit provide the support needed to the 
movement of the substrate binding site, through a rigid-body 
rotation of the substrate binding domain, referred to as the 
“elevator mechanism” [56-57]. For this family, the most 
extensively studied efflux pump is the NorA pump of S. 
aureus. 
The inhibitors that have proven activity against efflux pumps 
of the MFS family are gathered in Figure 5. 
 
3.1. MFS inhibitors 
3.1.1. Natural Products and Derivatives 
Terpenes and terpenoids, existent in the essential oils of 
plants, have showed promising therapeutic potential in 
various fields. Therefore, studies about EPI potential of these 
compounds were carried out. Monoterpenes nerol (21), 
estragole (22), and dimethyl-octanol (23) were tested against 
S. aureus. Compounds 21 and 23 were able to enhance the 
activity of norfloxacin, decreasing its MIC against the NorA 
overexpressing strain while not displaying intrinsic 
antibacterial activity. These open chain terpenes proved to be 
more effective than 22, which carried a benzene ring, at 
inhibiting the NorA pumps [58]. 
Citronellal (24) and citral (25) are monoterpenes, and were 
chosen as starting material for the synthesis of new amide 
derivatives. The basis for this study was the fact that 
aromatic amides are recognized as potent EPIs, whereas 
alkyl, alkenyl, and alkynil amides had not yet been explored. 
The compounds obtained were 5,9-dimethyldeca-2,4,8-
trienoic acid amides and 5,9-dimethyldeca-2,8-dienoic acid 
amides, whose activity for the potentiation of ciprofloxacin 
in S. aureus was assessed. Of the first 22 synthesized 
compounds, seven were able to reduce ciprofloxacin’s MIC 
by 4-fold. Further modifications were performed, and the C-
9 methyl group was replaced by an amide, yielding 
compounds with similar potency as the previous ones. 
Derivatives subjected to hydrogenation led to decreased 
activity, which reveals that unsaturation is an important 
feature for antimicrobial potentiation. The mechanism of 
inhibition was assessed through ethidium bromide efflux, 
confirming these compounds act by inhibiting NorA, being 
compound 26, a 9-formyl-5-methyldeca-2,4,8-trienoic acid 
amide, the most potent inhibitor [59]. 
Ferruginol (27), a diterpene, showed efficiency in inhibiting 
the efflux of ethidium bromide, proving its activity as a 
NorA inhibitor. It also showed a decrease in norfloxacin 
efflux in S. aureus [60]. Totarol (28), a phenolic diterpene, 
also showed a reduction in ethidium bromide efflux, 
suggesting activity against NorA pump, even though its 
mechanism is not yet known [61]. 
The triterpene ginsenoside 20(S)-Rh2 (29), a trace compound 
from red ginseng, also enhanced the effect of ciprofloxacin 
against S. aureus, through a NorA-mediated efflux 
inhibition, promoting the antibiotic accumulation in the 
bacteria [62]. 
Reserpine (30) is a natural alkaloid derived from Rauwolfia 
vomitoria, known as an anti-hypertensive agent, with 
inhibitory activity against human P-gp and breast cancer 
resistance protein (BCRP) [63-64]. Reserpine (30) has 
proven to be an effective inhibitor of the Bmr multidrug 
transporter in Bacillus subtilis, diminishing the efflux of 
ethidium bromide. Its structural analogue rescinnamine also 
had EPI activity, in a smaller extension than reserpine (30) 
[65]. Through DNA sequencing of the bmr genes of mutants, 
it was shown that reserpine (30) interacts with the residues 
Phe-143, Val-286, and Phe-306 of Bmr pumps, inhibiting 
drug transport [19]. Compound 30 has shown potential as an 
EPI for the inhibition of NorA efflux pumps in S. aureus, 
which are structurally related to Bmr pumps, reversing 
susceptibility to fluoroquinolones, demonstrating reductions 
up to 4-fold in MIC for some tested strains. It has been 
shown that 30’s effect is more pronounced in hydrophilic 
fluoroquinolones, such as ciprofloxacin [66].  The 
mechanism by which 30 performs the inhibitory activity is 
through direct binding to the transporters that mediate drug 
efflux, acting as a competitive inhibitor [19, 67]. Reserpine 
(30) also succeeded in inhibiting the chloramphenicol efflux 
by CmlR1 and CmlR2 of Streptomyces coelicolor, the 
ciprofloxacin and norfloxacin efflux in Listeria 
monocytogenes’s pump Lde, and the kanamycin and fusidic 
acid efflux by LmrS from a MRSA clinical isolate. On the 
other hand, for L. monocytogenes, 30 was not able to reverse 
susceptibility to linezolid and lincomycin, which suggests 
that 30 does not completely overlap with the structure 
binding sites of efflux pumps, being the inhibition dependent 
on the type and nature of the substrate [19]. However, 
reserpine (30) shows neurotoxicity at the concentration 
required to inhibit NorA, leading to the need to investigate 
new inhibitors [67]. 
Piperine (31), an alkaloid found in the fruits of Piper nigrum, 
was found to be an inhibitor of ciprofloxacin efflux in S. 
aureus, reducing the MIC by 2-fold. It is thought that 
compound 31 acts as a direct inhibitor of drug efflux. 
Compound 31 inhibits drug transport of the pump MdeA, 
potentiating the effects of benzalkonium chloride, 
doxorubicin, daunorubicin, novobiocin, 
tetraphenylphosphonium chloride, rhodamine 6G, 
virginiamycin and mupirocin [17, 19-20]; it also inhibits 
ciprofloxacin efflux by NorA [68]. 
Given these positive results obtained with piperine (31), 
further research into this scaffold was performed. Kumar et 
al. (2008) performed a screening of about 200 structurally 
diverse compounds for the inhibition of NorA efflux pump, 
choosing ethidium bromide as a substrate, since the only 
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mechanism through which this compound is expelled is 
active transport (68). About 50 compounds were able to 
increase the intracellular concentration of ethidium bromide 
by 4-fold, while not displaying antibacterial activity. Five of 
these compounds were more potent than piperine (31), being 
three of these compounds selected for further studies: 32, 33, 
and 34, being 32 and 34 more potent than 31 by 40-fold [18, 
68]. Assumptions regarding structure-activity relationship 
(SAR) studies of these molecules could be drawn (Figure 6). 
It was demonstrated that the introduction of an alkyl group at 
C-4 position, mainly an isopropyl, isobutyl or di-isopropyl 
group, coupled with the substitution of the piperidinyl 
moiety with an aromatic amine, such as aniline, would lead 
to maximum potentiation of ciprofloxacin; if the anilinyl 
moiety is substituted with a 2-hydroxymethyl group or a 
nitrile, regardless of the positional isomery, ciprofloxacin 
activity would increase. Replacing the piperidinyl moiety 
with a phenylacetamide yields good potentiation of 
ciprofloxacin, reducing its MIC by 4-fold, regardless of the 
isomery. Unsaturation is crucial for the potentiation, as well 
as the amide. Lastly, the retention of 3,4-
methylenedioxyphenyl or 4-methoxyphenyl groups in the 
1,3-benzodiol moiety also gives favorable results [68-70]. 
Plants of the Berberis species have the ability to produce the 
alkaloid berberine, which is a plant secondary metabolite 
produced in response to microbial invasion, whose activity is 
enhanced by a flavolignane also produced by these species, 
5’-methoxyhydnocarpin (35) [71]. Compound 35 exists in a 
mixture of anion and neutral compound at physiological pH, 
since it has a phenolic group with a pKa of 7.3. Due to the 
acidic properties of this 7-OH group, 35 is likely to be a 
specific microbial MDR inhibitor, as flavonoids with P-gp 
inhibitor properties usually possess alkylated 7-O groups. In 
fact, when added to a wild type strain of S. aureus, 
compound 35 caused a decrease in norfloxacin’s MIC to 
0.25 µg/ml. Furthermore, when tested with berberine and 
palmatine, 35 appeared to completely inhibit NorA, 
suggesting it acts as a non-competitive inhibitor [71]. 
A number of hydnocarpin-type flavolignanes were 
synthesized in order to perform SAR studies. Flavolignanes 
with and without phenolic groups at the 5 and 7 positions 
had comparable activity. Diosmetin (11), the parent 
compound, presents hydroxyl groups in the A ring and was 
the most potent compound. Peracetate derivatives of 35 have 
approximately the same potency as their parent compounds, 
and could be considered prodrugs, if deacetylated by S. 
aureus, which seems unlikely. Considering the D ring, 
compounds bearing a 3’’-methoxy-4’’-hydroxy moiety 
displayed good activity, and 3’’,5’’-dimethoxy-4’’-hydroxy 
moieties conferred a slightly less active compound. As for 
the B ring, the presence of an H or an OH is not critical for 
activity [72]. In addition, a flavone isolated from Alkanna 
orientalis, sarothrin (36), blocked ethidium bromide efflux 
by S. aureus, suggesting its potential activity as a NorA 
inhibitor [73]. 
Biochanin A (37), an isoflavone, also showed potentiation of 
norfloxacin and berberine against wild-type S. aureus and 
Bacillus megaterium. An analogue of luteolin, orobol (38), 
was quite active as a NorA inhibitor, unlike luteolin itself. It 
was shown that flavones which have a single methoxy in its 
B-ring are more potent than flavones with two methoxy 
groups in the B-ring [74]. 
Another flavone, baicalein (39), was capable of potentiating 
the effect of ciprofloxacin in S. aureus. Studies aimed at 
measuring the efflux of ciprofloxacin and pefloxacin, a poor 
NorA substrate, were performed, and showed that compound 
39 was much more potent at restoring ciprofloxacin 
sensitivity than pefloxacin, leading to the conclusion that this 
flavone acts as a NorA efflux inhibitor, even though its 
mechanism remains unknown [75]. 
Maia et al. (2011) identified six flavonoids from the plant 
Praxelis clematidea: apigenine, genkwanin, 7,4’-
dimethylapigenin, trimethylapigenin, cirsmaritin, and 
tetramethylscutellarein (40) [76]. These methoxylated 
flavones showed no antibacterial activity, but were able to 
reduce the MIC of norfloxacin at least by 2-fold and up to 
16-fold, as was the case of 40, at a concentration of 8 µg/ml, 
being therefore considered NorA efflux pump modulators. It 
is thought that the lipophilicity of the flavonoids, 
strengthened by the presence of methoxyl groups, is 
responsible for this activity [21]. Presence of a methoxy in 
the 4’ position proved to be decisive for activity, as 
flavonoids containing this group were more potent. The 
number of methoxy groups is also essential for potency, 
being the most metoxylated compounds the most active [76]. 
Tiliroside (41), an amphipathic kaempferol glycoside, 
reduced the concentration of antibiotic needed to inhibit the 
growth of bacteria. The lipophilicity of the flavone moiety 
may be a determinant factor for the activity displayed. 
Tiliroside (41) showed no antibacterial activity against S. 
aureus, but showed a decrease in the MIC of 
fluoroquinolones up to 16-fold, when at a concentration of 
64 µg/ml. The reduction in the MIC of biocides, such as 
ethidium bromide and benzalkonium chloride, was 
impressive, with the MIC of acriflavine showing a decrease 
by 128-fold at the concentration of 64 µg/ml and 32 µg/ml. 
These results suggest that 41 might additionally act on 
pumps other than NorA [77]. 
Kaempferol 3-O-α-L-(2, 4-bis-E-p-coumaroyl)rhamnoside 
(42) was also able to potently inhibit in a concentration 
dependent manner NorA-mediated ethidium bromide efflux 
in S. aureus. This compound also increased the antibiotic 
effect of norfloxacin against a wild-type and a NorA 
overexpressing strain of S. aureus. However, it has to be 
considered that 41 and 42 are flavonoid glycosides and 
cinnamoyl esters, and that their activity can become 
compromised with the activity small intestine β-glucosidases 
or plasma esterases, even though the activity might possibly 
lie in the kaempferol moiety, with 41 and 42 acting as 
prodrugs. The authors hypothesized that if the activity of 
compound 42 is compromised, this compound could be used 
as adjuvant of ciprofloxacin for topical infections [78]. 
Since 42 showed promising results as a NorA EPI, the same 
group performed a screening of a library of 117 chalcones, 
due to their structural similarities with the coumaroyl 
substituents [79]. Ten out of the 117 screened chalcones 
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presented medium efflux inhibition at 20 µg/ml. The most 
potent chalcones, such as 43, bear a dimethylaminoethoxy 
moiety, which might disrupt the proton gradient, thus 
eliminating the energy source of NorA. Five of these 
chalcones possessed a hydroxyl group at the 4’-position, and 
potentiated the activity of berberine against S. aureus and B. 
cereus, suggesting that this substituent is also important for 
activity. The compound with a methoxy group at position C-
2 has shown to present the best activity. The majority of 
chalcones tested showed a 4-fold reduction of 
ciprofloxacin’s MIC in S. aureus, suggesting the presence of 
a NorA efflux pump inhibitory activity. Compound 43 
showed 8-fold and 16-fold reduction of the MIC of 
ciprofloxacin at 6.25 and 12.5 µg/ml, respectively. However, 
it also showed antibacterial activity at 25 µg/ml. Some 
chalcones also presented antiparasitic activity, namely 
against Leishmania major and Plasmodium yoelii [79]. 
Another chalcone, 4’,6’-dihydroxy-3’,5’-dimethyl-2’-
methoxychalcone (44), showed good activity as a MDR, 
causing complete growth inhibition at a very low 
concentration (3.3 µg/ml) when combined with a sub 
inhibitory concentration of berberine. When tested in 
combination with berberine, erythromycin, and tetracycline 
against strains of S. aureus, there was an increase in the 
activity of all tested compounds in the wild-type S. aureus, 
indicating a mode of action likely related to the NorA pump. 
This compound was also tested against B. cereus, 
potentiating the effects of the tested antibiotics as well, and 
displaying a favorable effect, particularly in the case of 
berberine, where a 30-fold increase in the activity was 
observed [80]. 
Pheophorbide A (45) is an intermediate of the natural 
breakdown of chlorophyll. Concentrations as low as 0.5 
µg/ml of pheophorbide A with sub-inhibitory concentrations 
of berberine were enough to completely inhibit S. aureus 
growth.  When extended to fluoroquinolones, this compound 
also proved efficient in potentiating the effect of norfloxacin 
by 4-fold in a wild-type strain, being its action directed 
towards NorA [81]. 
Orizabins, oligosaccharides from resin glycosides, were 
evaluated for their efflux pump inhibitory activity on strains 
of S. aureus. These amphipathic compounds showed synergy 
with norfloxacin, whilst showing no antibacterial activity by 
themselves. Orizabin IX (46) completely inhibited the 
growth of a NorA overexpressing strain at 1 µg/ml, while 
orizabin XIX (47) reversed norfloxacin resistance by 4-fold 
at 25 µg/ml for the same strain [82]. Murucoidins, which are 
also resin glycosides, strongly potentiated the action of 
norfloxacin against a S. aureus NorA overexpressing strain 
by 4-fold at concentrations ranging from 5 to 25 µg/ml. 
Stoloniferin I potentiated the same activity by 8-fold at a 
concentration of 5 µg/ml [83]. 
A study aiming to find new EPIs from the plant Geranium 
caespitosum led to the isolation of novel acylated 
neohesperidosides. It was found that two compounds, 
compound 48 and 49, were successful at restoring 
susceptibility to berberine, norfloxacin, and ciprofloxacin at 
sub inhibitory concentrations, possibly due to NorA 
inhibition [84].  
Capsaicin (50), the major constituent of the fruits of the 
Capsicum genus, is a known P-gp inhibitor. Studies were 
performed, in order to evaluate if its inhibitory activity was 
also applied to MDR pumps in bacteria. In a strain of S. 
aureus overexpressing the NorA efflux pump, and therefore 
resistant to fluoroquinolones, 50 proved efficient in 
increasing the susceptibility to ciprofloxacin, while reducing 
the emergence of ciprofloxacin-resistant mutants. Molecular 
modelling studies of the complex capsaicin (50)-NorA, using 
the glycerol-3-phosphate transporter to predict the structure 
of NorA, showed that compound 50 aliphatic chain extended 
into NorA’s hydrophobic cleft. Furthermore, a weak 
hydrogen bond between Arg-98 and the aryl hydroxyl 
contributed to the stability of the complex [85]. 
Studies in the aqueous extract of Artemisia absinthium 
showed promise in the inhibition of MDR efflux pumps. It 
was proven that this activity came from caffeoylquinic acids. 
At a concentration of 20 µM, 4’-5’-O-dicaffeoylquinic acid 
(51) potentiated the activity of berberine by 16-fold and of 
norfloxacin, by 10-fold against a wild-type strain of S. 
aureus, while not displaying effects in a norA-deleted strain, 
confirming this compound’s NorA inhibition ability [86]. 
Olympicin A (52) is an acylphloroglucinol, found in the 
aerial parts of Hypericum olympicum. This molecule had 
some efflux impeding ability, proven by the improvement of 
intracellular accumulation of enoxacin in a NorA 
overexpressing strain of S. aureus, at 50 µg/ml [87]. 
Riparins are natural alkylamides found in the plant Aniba 
riparia. Since the extraction of these compounds comes with 
very low yields, synthetic approaches were developed. As 
such, the fundamental core of riparins, Rip-A (53), was 
synthesized and derivatives were prepared, Rip-B (54) to E 
(55). Rip-E (55) showed good growth inhibitory activity 
against S. aureus, attributed to their lipophilic nature and the 
presence of hydroxyl groups at the benzamide moiety. 
Oppositely, Rip-B (54), with two methoxy groups at the 
phenyl-ethyl moiety did not present antibacterial activity, 
presenting instead a decrease in the MIC of ciprofloxacin 
and norfloxacin, similarly to reserpine. Combined with the 
ability of decreasing ethidium bromide’s MIC, the activity of 
compound 54 was attributed to NorA inhibition, suggesting 
its potential as an EPI [88]. 
Extracts of Mirabilis jalapa have shown good results in 
reversing fluoroquinolone resistance in strains of S. aureus 
overexpressing the NorA efflux pump. One compound in 
particular, N-trans-feruloyl-4’-O-methyldopamine (56), 
caused an 8-fold reduction in the MIC of norfloxacin, 
making it a potential lead in the search for structurally 
similar synthetic alkylamines [89]. 
Synthesis of derivatives was undertaken, taking N-trans-
feruloyl-4’-O-methyldopamine (56) as a model. The aim was 
to identify active compounds from natural sources and, as 
such, couplings between cinnamic acid derivatives and 
natural-occurring amines were chosen. SAR criteria was 
taken into account, as it is known that substitution of the 
aromatic rings, methoxy or hydroxyl substitution, double 
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bonds and aromatic ring nature in the amine part influence 
the activity. The lead compound was N-trans-3,4-O-
dimethylcaffeoyl dopamine (57) since it showed the same 
activity as the natural compound. It was found that, for the 
cinnamic moiety, a hydroxyl substitution on the aromatic 
ring appears to be better than a methoxy group or 
unsubstituted derivatives and the double bond is essential for 
activity. As for the amine part, trisubstitution on the aromatic 
ring increases antibacterial activity, at the cost of decreased 
efflux pump inhibition. Methoxy substitution yields 
compounds with better results than hydroxyl substitution, 
which was better than no substitution and tryptamine 
combinations showed the best results (Figure 7). Among the 
compounds tested, compound 58 showed potentiation of 
norfloxacin comparable to that of reserpine (30). At a 
concentration of 30 µM, 58 showed good results for the 
inhibition of ethidium bromide efflux. For these compounds, 
it was shown that the activity reaches its highpoint when the 
phenyl ring is substituted with two hydroxyls [89]. 
Grapefruit oil fractionation led to the isolation of three 
compounds, two coumarin derivatives and one bergamottin 
derivative. The bergamottin epoxide (59) showed a reduction 
of ethidium bromide’s MIC by 6-fold on different MRSA 
strains, and a 20-fold reduction in norfloxacin’s MIC. This 
reduction was also achieved when the coumarin epoxide (60) 
was present, and suggests an activity towards NorA efflux 
pumps [90].  
Coumarins isolated from Mesua ferrea were also studied for 
their efflux pump inhibitor activity against clinical strains 
and NorA overexpressing strains of S. aureus. Seven 
coumarins were tested, and showed good results in inhibiting 
ethidium bromide efflux. Two compounds, 61 and 62, 
showed potential EPI activity against the NorA 
overexpressing strain and a MRSA strain, using norfloxacin 
as a substrate, which makes them desirable compounds for 
the synthesis of derivatives [91]. 
Screening of natural products with P-gp inhibitory effects 
(92, 93) led to the identification of two compounds with 
NorA inhibitory activity, osthol (63) and curcumin (64) [36, 
92-93]. Curcumin (64), derived from the rhizomes of 
Curcuma longa, has additionally already shown activity as 
an anti-inflammatory, antioxidant, antiviral, and anticancer 
agent [36, 92-93]. These compounds were effective in 
reducing the MIC of ciprofloxacin by 4- and 8-fold, 
respectively [94]. 
A penta-substituted pyridine, 2,6-dimethyl-4-phenyl-
pyridine-3,5-dicarboxilic acid diethyl ester (65), was isolated 
from the rhizomes of Jatropha elliptica. This compound, 
when in association with ciprofloxacin, showed a strong 
effect against NorA efflux pumps in S. aureus [95]. 
A methanol extract of the plant Dalea spinosa yielded the 
isolation of six compounds, whose EPI potential was 
analyzed against wild-type S. aureus and mutant strains. It 
was shown that spinosan A (66), at a concentration of 48 
µg/ml, and its acetate 67, at a concentration 42 µg/ml, were 
able to decrease berberine’s MIC by 8- and 62-fold, 
respectively, against the wild-type. Other compounds were 
also able to reduce berberine’s MIC, but to a lesser extent. 
Compound 67 also managed to decrease berberine’s MIC in 
the NorA overexpressing strain, suggesting inhibitory 
activity in this efflux pump [96]. 
 
3.1.2. Synthetic Compounds 
The INF series (compounds 68-72) resulted from an initial 
screening of 9600 structurally diverse compounds, in order 
to find NorA inhibitors for B. subtilis, not expressing Bmr. 
The NorA substrate chosen was ethidium bromide [67]. 
Since this screening did not focus on a specific chemical 
group, the most active compounds were divided into several 
groups. Several indole derivatives were active, which did not 
come as a surprise, since reserpine (30) itself has an indole 
moiety. Another large group was the trichloromethylaminal 
containing compounds, which were not further explored as 
their likelihood to be toxic was high. Biphenyl urea 
derivatives were also active, and other compounds, with no 
obvious similarities, showed activity as well. Five 
compounds were selected for further tests, INF 55 (68), INF 
240 (69), INF 271 (70), INF 277 (71) and INF 392 (72). 
These compounds were active at concentrations of 5 µg/ml 
or less, and included the most potent compound, 72, the most 
potent indole, 68, and the most potent biphenyl urea, 71. 
Derivative 72 was able to reduce resistance to ethidium 
bromide and ciprofloxacin by 8-fold at a concentration of 0.4 
µg/ml. All five inhibitors were more potent than reserpine 
(30) at promoting the activity of ciprofloxacin in S. aureus 
and, by being structurally different, it was hypothesized that 
a potent, nontoxic lead would be identified. These 
compounds also proved effective in inhibiting the Bmr 
multidrug transporter in B. subtilis and two compounds, 68 
and 71, also enhance fluoroquinolone activity in 
Streptococcus pneumoniae [67]. 
The results obtained with INF 55 (68) in S. aureus as an 
inhibitor of the NorA efflux pump led to an increased 
interest in this kind of scaffold. SAR studies regarding the C-
5 proved that substitution in this carbon is crucial for 
activity. Substitution with a nitrile group leads to retention of 
potency, and carbonyl based electron-withdrawing groups at 
C-5 would result in molecules with no activity [97]. Three 
dimensional-quantitative structure-activity relationship (3D-
QSAR) studies predicted that 2-aryl indole derivatives would 
be NorA inhibitors. Functionalized INF 55 (68) showed a 
decreased MIC for berberine, a MDR transporter substrate. 
Berberine is an amphipathic cation alkaloid. From the series 
of 2-aryl-5-nitroindoles synthesized by Samosorn et al. 
(2009), the alcohol 73 was the most effective in inhibiting 
berberine efflux, as well as other antibiotics, such as 
ciprofloxacin, in S. aureus [98]. Later, the same group 
developed a strategy that consisted in a molecule presenting 
dual action: an antibiotic and a MDR inhibitor. Therefore, 
they combined berberine, a hydrophobic cation that is a 
MDR substrate, with INF 55 (68), a MFS inhibitor. These 
efforts yielded compound 74 [17-18, 99]. In terms of 
antibacterial activity in S. aureus, the hybrid was about 100 
times more active than berberine alone, and the difference 
was even higher when tested against a NorA overexpressing 
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strain of S. aureus. Enterococcus faecalis also presented 
resistance to berberine, but was susceptible to 74. [99] 
Synthesis of sulfur derivatives was achieved based on the 
premise that the activity of 68 is less dependent on the nitro 
group than the 2-arylindole. Benzothiophene, thiophene, and 
benzofuran derivatives, such as compounds 75, 76, and 77, 
respectively, were able to synergize with ciprofloxacin and 
ethidium bromide, increasing their intracellular 
concentration and leading to the conclusion that these 
compounds inhibit NorA in S. aureus. [100]  
Taking into account the fact that the indole NH is not 
essential for efflux pump inhibition, Samosorn et al. (2009) 
simplified the indole moiety of berberine-based hybrids, 
along with the effect of a methylene ether linking group. 
Their results showed that a hybrid molecule with oxygen in 
the linkage chain had stronger antibacterial and MDR pump 
inhibitory activity than the original 74 [101]. On the other 
hand, removal of the indole moiety produced compounds 
with lower dual activity, and this structural simplification led 
to compounds with low antibacterial activity, but with 
retained NorA pump inhibitory activity. These data suggest 
that while the indole moiety is not necessary for NorA pump 
inhibition, it is required for the antibacterial activity of 
hybrid compounds [101]. 
A recent study identified a novel class of NorA EPIs with a 
polysubstituted indole moiety. Twenty molecules were 
highly active in inhibiting ethidium bromide efflux in S. 
aureus. However, the best results were obtained with 
compounds 78 and 79, which were derivatives that presented 
three and four carbon atom chains, respectively. Compound 
78 presented the best half maximal inhibitory concentration 
(IC50), with a concentration of 1.8 µM. Compound 79 
exhibited similar IC50 (2 µM) and ethidium bromide 
inhibition as 78. Compounds with shorter or longer carbon 
chains did not present such good results, leading to the 
conclusion that three or four carbons make up the right 
distance between the indole scaffold and the basic center, 
thus presenting the best inhibitory effect. When tested for 
their synergy with ciprofloxacin, both 78 and 79 were able to 
restore the antibiotic’s activity [102]. It was found that the 
substitution of the C-5 in the indole results in a potent EPI, 
particularly if there is a propoxyl chain carrying terminal 
cyclic amino groups, which appears to be crucial for NorA 
inhibition at low concentrations. The presence of the N-
benzyl moiety preserves inhibition and contributes to the 
modulation of the biological effects and ADME properties, 
depending on its substituents [103]. 
Another successful example of a hybrid antibacterial/EPI is 
the fluoroquinolone scaffold accommodating a bis-aryl urea 
EPI moiety at the C-7 position. This kind of compounds was 
successful in inhibiting NorA pumps in S. aureus. 
Compound 80, which incorporates a bis-aryl urea motif into 
the ofloxacin core, proved to be a potent inhibitor of MFS 
efflux pump systems, achieving 84 % inhibition rate at 10 
µM. Moreover, these compounds also successfully inhibit 
MepA pump systems from the MATE family [17-18, 104]. 
Fluoroquinolones containing a thiopyranopyridine moiety at 
the C-7 position were synthesized and their activity was 
tested against strains of S. aureus. However, these 
derivatives did not seem to be NorA substrates. Further 
investigations into thiopyranopyridinylquinolone esters were 
carried out. Some of the synthesized compounds displayed 
better inhibitory activity than reserpine (30), namely 
quinolone esters 81, 82 and 83, and showed significant MIC 
reduction of ciprofloxacin.  Compounds 82 and 83 also 
showed a 32-fold MIC reduction of ciprofloxacin for strains 
of S. aureus overexpressing MepA pumps from the MATE 
family [18, 105]. In terms of established SAR, these 
compounds definitely do not need the fluorine atom at the C-
6 position for the antibacterial activity of 
thiopyridinylquinolones. A methyl at the C-8 position yields 
a compound with enhanced activity against Gram-positive 
bacteria for 6-amino derivatives. The thiopyranopyridine 
moiety at the C-7 position is crucial for NorA and MepA 
inhibition (Figure 8) [105]. 
Derivatives of 2-(4-propoxyphenyl)quinolone were 
synthesized based on the premise that its large hydrophobic 
area and ability to establish an electrostatic interaction would 
make them suitable inhibitors of NorA. These derivatives 
also mimic the quinolone antibacterial core and possess a 
versatile scaffold, making it prone to be very simply 
chemically modified. These classes of compounds were 
obtained by performing modifications in the 2-phenyl-4H-
chromen-4-one moiety, which is a common feature of 
flavone and flavolignane EPIs [106]. 
Studies showed that the O-substituted 2-phenyl-4-
hydroxyquinoline derivatives displayed the best activity as 
NorA inhibitors. Compounds 84 and 85 showed synergistic 
activity against a strain of S. aureus overexpressing NorA 
efflux pumps comparable to reserpine (30) and, comparing 
the results obtained with a mutant strain, absent of NorA, it 
was found that these compounds are able to completely 
restore the antibacterial activity of ciprofloxacin in the 
resistant strain [18, 106]. Preliminary SAR studies for this 
new class of EPIs showed that the best activity is when the 
quinolone core is replaced with the 2-phenyl-4-
hydroxyquinoline group with an alkylation in the C-4 
hydroxyl group. 2-Ethylamino chains inserted at the N-1 
position of the quinolone nucleus or at the C-4 hydroxyl of 
the quinoline moiety provided compounds with better 
activity than those carrying the same chain at the C-2 of the 
phenyl ring. The best substituent for the C-2 phenyl ring 
appears to be the C-4’ propoxy group (Figure 9) [106]. 
Taking these results into account, efforts have been placed to 
obtain more potent NorA inhibitors, introducing O-alkyl or 
different O-alkylamino chains at the C-4 position. The 
strategy was to determine the essential 3D structural 
requirements for the inhibition of NorA, based on the NorA 
EPIs described in literature through the use of computational 
methods, since the 3D structure of this pump was not 
elucidated yet. The results led to the building of a possible 
pharmacophore, which was used to design novel compounds, 
with different substituents at the C-4 position, which were 
synthesized and biologically evaluated [107]. The 
compounds were assayed for their ability to reduce the MIC 
of ciprofloxacin in S. aureus strains, and all compounds 
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displayed this decrease for the strain overexpressing NorA 
pumps. One compound in particular, 86, showed a 16-fold 
reduction in this strain for ciprofloxacin’s MIC. SAR studies 
for this emerging class show that the best activities come 
from the compounds bearing the 2-ethylaminoalkyl chains 
linked to the C-4 hydroxyl group, such as compound 87. The 
inclusion of an aliphatic ring including the side chain 
nitrogen atom led to retention of activity, whereas inclusion 
in an aromatic ring led to loss of activity, where the nitrogen 
nucleophilicity was reduced. The mono-substituted 
compounds, like 88, with a benzyl group were well tolerated, 
and showed higher ethidium bromide inhibitory activity than 
compounds with two benzyl groups as substituents (Figure 
9) [107]. 
3-(Dihydronaphtyl)-propenoic acid amines were evaluated 
for their EPI activity. Five compounds were synthesized, and 
two of them showed good results in inhibiting ciprofloxacin 
efflux in strains of wild-type and NorA overexpressing S. 
aureus. Further studies were performed, given the low EPI 
activity of this kind of compounds. Fifteen different 
compounds were synthesized, taking α-tetralone (12) as 
starting material. Out of these, four compounds showed 
significant MIC reductions for ciprofloxacin for the NorA 
overexpressing strain. One compound, 89, even displayed a 
16-fold reduction, while other remained in the range of 4- to 
8-fold. These studies allowed SAR to be established. 
Addition of methoxy or allyloxy substituents at the 6,7-
position of the 3,4-dihydronaphtalene leads to lower or no 
activity, whereas no substitution originated better EPIs. 
Saturation of the double bonds lowered the potentiating 
activity (about 2-fold), while unsaturated derivatives made 
much more potent compounds [108]. 
Boronic species have been described for a variety of 
activities, namely antimicrobial and antineoplasic. 
Organoboron compounds, oxazaborolidines, boronic esters, 
and boronic acids are of particular interest, within this class. 
Fontaine et al. (2014) developed studies on these molecules, 
starting from a screening of a library of approximately 150 
compounds, out of which 24 were hit compounds 
(exemplified with compounds 90 and 91), and were able to 
restore the activity of ciprofloxacin by 4-fold at 
concentrations of 0.5 to 8 µg/ml against the NorA 
overexpressing strain of S. aureus [109]. Preliminary SAR 
studies demonstrated the need of the boron atom for activity. 
Most pyridine-3-boronic acids showed best potentiating 
activity (e.g., compound 90), whereas pyridine-4-boronic 
derivatives showed no activity, with exceptions, including a 
fluorinated ester. The shift of the boronic moiety from C-3 to 
C-4 led to a loss of activity and the trigonal boronic acid 
function gave better results that the sodium boronate salts 
and the potassium trifluoroborate. Concerning the pyridine-
3-boronic acids, the most promising compounds appear to be 
the 6- and the 5,6-disubstituted ones, being the latter 
compounds less potent. Cyclisation at the C-5 and C-6 
positions was well tolerated, as was the introduction of a 
methyl at the C-5 position. For the benzene analogues, which 
displayed good activity, cyclisation at the C-3 or C-4 was 
also well tolerated, as was the introduction of a methyl. A 
substituent at the para position to the boronic moiety proved 
to be very important. Two compounds were particularly 
efficient in inhibiting NorA, and did not display intrinsic 
antibacterial activity and cytotoxicity: the 6-
benzyloxypridine-3-boronic acid 90, which displayed the 
highest activity, potentiating ciprofloxacin by 4-fold at a 
concentration of 16 µg/ml, and the 4-benzylxybenzene 
boronic acid 91 [109]. 
Compound 90, being the most promising compound, was 
considered a hit, and its structure was used as a model for the 
synthesis of new derivatives. Therefore, the 6-benzyloxy 
group was substituted with (aryl)alkoxy chains with variable 
lengths (compounds 92 and 93 as examples), in an attempt to 
explore the putative hydrophobic binding site of NorA, and 
substituents were added to the phenyl ring. The ether linkage 
between the pyridine ring and the 6-benzyloxy group was 
substituted as well. The first substitution made was the 
replacement of the 6-benzyloxy group with alkoxy chains of 
diverse lengths, as to explore the size of the hydrophobic 
pocket of NorA. The potency of the compounds increased 
with the increase of the size of the side chain, although the 
compound with a 11-carbon side chain displayed no activity 
whatsoever. A new series of compounds with a phenyl ring 
at the end of the side chain were synthesized, with the aim of 
enhancing hydrophobicity, and the results showed these 
compounds were more efficient. It was concluded that the 
compound with the best performance possessed a side chain 
with seven carbon atoms and a phenyl group: compounds 92, 
6-(3-phenylpropoxy)pyridine-3-boronic acid, and 93, 6-(4-
phenylbutoxy)pyridine-3-boronic acid, showed the highest 
activity in the potentiation of ciprofloxacin (4-fold). The 
introduction of substituents in the phenyl ring of compound 
90 led to unsatisfactory results, with the best compound 
displaying moderate antibacterial activity. A methyl group in 
the C-5 position did not show influence on the activity, and 
the modification of the ether linkage led to varied effects: 
introduction of a sulfanyl, thus conserving the H-bonding 
acceptor capacity, led to similar potentiating activity, 
whereas the introduction of an amine linkage, an H-bond 
donor, led to a decrease in the activity. Finally, the shift of 
the benzyloxy group from the C-6 to the C-5 resulted in no 
activity [110]. 
Compounds AE-848/42434549 (94) and AN-465/42885978 
(95) were hits in a virtual screening of novel NorA efflux 
pump inhibitors in S. aureus. The structures deemed as 
active in silico were later synthesized and evaluated on their 
ability to prevent ethidium bromide efflux, as well as 
ciprofloxacin potentiation. Compound 94 and 95 were as 
potent as reserpine (30) for ethidium bromide efflux and 
more potent at synergizing with ciprofloxacin. These hit 
compounds 94 and 95 paved way for the synthesis of new 
analogues, which allowed SAR studies to be made, in order 
to assess which parts of their structure were determinant for 
the inhibition of NorA. For compound 94, it was shown that 
limited modifications to the sulfone and amide group do not 
cause significant changes in activity. On the other hand, 
modifications to the imidazole ring result in a reduction of 
activity. Replacement of the 1-methylpyrrole ring with a 
86 
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furan also shows a decrease in the activity of the compound. 
As for compound 95, the O-benzyl group is essential and the 
introduction of a benzyl in the secondary nitrogen leads to a 
complete loss of activity. Furthermore, the methyl group of 
the 2-(1-phenyl-1-propanol) moiety can be replaced with a 2-
(1-phenyl-1-ethanol) portion without a decrease in the 
activity [111]. 
 
3.1.3. Existing Drugs 
Several drugs already available for the treatment of various 
diseases have shown potential to be used as MFS EPIs. 
Reserpine (30), mentioned before, is one of them. Other 
drugs include verapamil, omeprazole, paroxetine and 
chlorpromazine. Even though bacterial MFS transporters and 
mammalian ABC efflux systems, as P-gp, lack structural 
homology, they share similar substrate profiles, which means 
that mammalian MDR inhibitors can also present bacterial 
efflux inhibition. However, the concentrations needed for 
efflux pump inhibition are too high, which means that toxic 
effects can arise if these compounds are used for this purpose 
[18], [112]. In fact, the addition of verapamil to 
chemotherapy was accompanied with cardiac arrhythmia and 
hypotension [113]. This leads to the requirement of 
developing analogues of these existing drugs maintaining the 
desired EPI activity at concentrations that do not display 
toxicity [112]. 
The antiarrhythmic verapamil, a known P-gp inhibitor, has 
shown moderate NorA inhibitory activity in both B. subtilis 
and S. aureus, enhancing fluoroquinolone activity [114-115]. 
However, the best results were obtained with proton pump 
inhibitors omeprazole (96) and lansoprazole. Therefore, a 
series of pyrrolo[1,2-a]quinoxaline derivatives mimicking 
the omeprazole structure (96) were designed, with the aim of 
evaluating their EPI activity against NorA. All the eleven 
derivatives showed a reduction in norfloxacin’s MIC, being 
compound 97 the most active, reducing the MIC by 16-fold 
at 128 µg/ml. These compounds did not show disturbance of 
the electrical potential and the transmembrane pH, excluding 
the alteration of the proton-dependent pump as the 
mechanism of action. Instead, it is thought that these 
compounds interact directly with NorA. It was shown that 
the benzimidazole moiety is critical for the activity of these 
compounds (Figure 10), and replacing it with an imidazole, 
a pyridine or a pyrrolo[1,2-a]quinoxaline ring resulted in 
loss of potency. Furthermore, if there is a methoxy-
substituent in the benzimidazole ring, potency increases. 
Introduction of chlorine in the C-7 of the pyrroloquinoxaline 
heterocycle provided an efficient restoration of norfloxacin’s 
bactericidal activity. Finally, the benzimidazolyl group was 
also important for activity [112].  
This was not the first time that pyrrolo[1,2-a]quinoxaline 
derivatives were described as EPIs. In fact, a previous study 
by the same group produced 12 new 4-[116]pyrrolo[1,2-
a]quinoxalines and one pyrrolo[1,2-α]thieno[3,2-e]pyrazine 
compound. Two compounds, 98 and 99, were more active 
than reserpine (30), diminishing norfloxacin’s MIC by 16-
fold in a NorA overexpressing strain of S. aureus. This study 
showed that 4-[116]pyrrolo[1,2-a]quinoxalines and their 7-
methoxy analogues were more active, in contrast with the 
chlorine- and 8-phenyl-substituted compounds, that 
presented the lowest effects. Replacement of the N,N-
diethylamino group by pyrrolidine, its isomer with restricted 
conformation, led to enhanced EPI activity, whereas 
replacing it with a piperidine ring led to more flexible and, 
consequently, less active compounds. The 
pyrrolothienopyrazine 99 moiety yielded the best results, 
suggesting that sulfur, an electron-rich atom, potentiates the 
EPI activity [116]. 
GG918 (19) was discovered in a screening program aimed to 
identify inhibitors of mammalian P-gp, and was able to 
increase the concentrations of paclitaxel. This compound did 
not present antibacterial activity against the strains of S. 
aureus tested. However, the co-administration with 
norfloxacin resulted in a 4-fold reduction in the MIC of the 
NorA overexpressing strain [52]. 
Two mammalian MDR inhibitors, biricodar (100) and 
timcodar (101), confer increased drug sensitivity to cells 
expressing both the P-gp and multidrug resistance protein 
(MRP)-1 efflux systems. They also show potentiation of 
multiple antibiotics in Gram-positive bacteria. In fact, both 
compounds were able to potentiate the activity of ethidium 
bromide against S. aureus, E. faecalis, and S. pneumoniae. 
For the specific case of S. aureus, both compounds were able 
to partially reverse fluoroquinolone resistance. The fact that 
the MIC of ethidium bromide was non-saturable for the three 
bacteria tested suggests that 100 targets multiple efflux 
pumps [117]. 
A series of polysubstituted pyrroles was screened for their P-
gp inhibition activity, which made way for the identification 
of a lead, and the compounds were further investigated for 
their bacterial efflux pump inhibition activity. A simplified 
pyrrole alkaloid, 102, displayed dual activity as both a P-gp 
and a NorA inhibitor against S. aureus. This compound led 
to 4-fold improvement in the MIC of ethidium bromide in 
the NorA overexpressing strain. Compound 102 was also 
able to reduce ciprofloxacin’s MIC by 8-fold when at 50 µM 
[118]. 
Tariquidar (103), a third generation MDR modulator, with 
activity in inhibiting P-gp and BCRP efflux systems, has 
shown promise in inhibiting efflux pumps in S. aureus. In 
fact, this compound showed an increase of the isotopic form 
of ciprofloxacin in all investigated strains, displaying best 
results in the strain that overexpresses the NorA pump. [119] 
The class of phenylpiperidine selective serotonin reuptake 
inhibitors (PSSRI), which includes the antidepressant 
paroxetine (104), showed efflux-related potential against S. 
aureus, particularly that conferred by NorA. In fact, 
paroxetine and its isomer, 105, showed potency with respect 
to inhibition of this efflux pump against ethidium bromide. 
The isomer 105 also interfered with the accumulation of 
norfloxacin by NorA, reducing by 4- to 8-fold its MIC. [120] 
Femoxetine (106) is a paroxetine derivative, with activity as 
an EPI. [120] Studies were performed as to determine which 
moieties in paroxetine- and femoxetine-like PSSRI were 
detrimental for efflux pump inhibition in S. aureus, and 
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conclusions from SAR are highlighted in Figure 11. 
Synthesis of derivatives showed that the fluorine atom on the 
phenylpiperidine moiety is not associated with the activity. 
The N-substitution of the piperidine ring yields different 
kinds of activity, suggesting that the NH group forms a 
positive binding contact with the target pump, which does 
not happen if there is a N-substitution (compound 106). The 
phenyl ether substituents also play an important role as 
determining the EPI activity. [121] 
Also for this kind of compounds, a study was performed, in 
order to conclude whether the 4-phenyl ring is required for 
EPI activity and the effects of changes in the two-atom 
aryloxymethyl linker, replacing it with a thioether, amine, 
and alkene linker portions. Compounds 107 and 108 
displayed the lowest MIC against S. aureus. Synthesis of 
multiple derivatives proved that the 4-phenyl moiety is not 
vital for EPI activity and that a variety of two-atom linker 
groups for the 3-aryl piperidine moiety can maintain EPI 
activity [122]. 
The ciclooxigenase-2 (COX-2) inhibitor celecoxib (109) has 
also received attention for its MDR inhibitory activity. There 
had been a link between COX-2 and mdr1 gene expression, 
which has consequences in cancer chemo resistance, and the 
use of celecoxib (109) reversed drug resistance. If this is true 
for mammalian efflux pumps, for bacteria there is no 
evidence of a COX-2-like gene, suggesting that celecoxib 
acts differently in inhibiting MDR in bacteria. A study was 
carried out in order to prove this hypothesis, which 
demonstrated that this drug helped in increasing sensitivity 
to antibiotics in S. aureus and Mycobacterium smegmatis. 
These effects probably occur due to the blockage of MDR 
transporters involved in the efflux of antibiotics, such as 
ampicillin, ciprofloxacin, kanamycin, and chloramphenicol. 
The observation of the accumulation of ethidium bromide 
intracellularly leads to the conclusion that this compound 
acts as a NorA inhibitor [123]. 
As celecoxib (109) demonstrated such promising activity, 
analogues were tested, which bore low or none anti-
inflammatory activity and possessed the 1,4-
dihydropyrazolo[4,3-c]-benzothiazine-5,5-dioxide nucleus. 
Ethidium bromide efflux inhibition was tested first in silico, 
and the 17 molecules that fit the chemical space 
requirements were then reduced to six, based on the activity 
prediction. These compounds were then screened for their in 
vitro NorA inhibitory activity, using an overexpressing strain 
of S. aureus. One derivative in particular, compound 110, 
showed the best activity concerning ethidium bromide efflux 
(76.9%) which is better than celecoxib (109) (64.5%). When 
in combination with ciprofloxacin, 110 displayed results 
comparable to reserpine (30) and better than paroxetine 
(104), which makes it a lead compound for the development 
of inhibitors of this kind [124]. 
Phenothiazine and thioxanthene derivatives are currently 
used as neuroleptic and antiemetic agents, and have been 
described as modest, but broad, antibacterial agents. 
Although their antibacterial activity is not enough to be 
clinically relevant, they have shown synergy with standard 
antibiotic agents, and have also been associated with the 
inhibition of eukaryotic MDR efflux pumps, such as P-gp. 
The mechanism through which these compounds exert their 
antimicrobial potentiation is not yet fully understood. 
However, it is thought that it might have to do with the 
inhibition of efflux pumps [125]. A study focusing on the 
activity of several compounds of these families against S. 
aureus was carried out, with the main aim of showing their 
potential in inhibiting NorA. The compounds tested, 
chlorpromazine, fluphenazine, thioridazine, prochlorperazine 
(111), cis(Z)-flupentixol, and trans(E)-flupentixol (112), 
displayed intrinsic antimicrobial activity and good results 
when ethidium bromide efflux was assayed against a NorA 
overexpressing strains of S. aureus. Additionally, 
phenothiazine 111 and thioxanthene 112 were also able to 
reduce the proton motor force of S. aureus, by reducing the 
transmembrane potential [125]. 
Since the phenothiazine moiety proved itself to work as a 
template for the synthesis of new MDR EPIs, it was chosen 
to be the scaffold for derivatives with improved activity. The 
logic for these studies lied in the elimination of the structural 
features that were responsible for neuroleptic activity. As 
such, drastic modifications were made, such as the 
elimination of one ring of the tricyclic benzothiazine 
backbone and of the chain linked to the N-10 atom, a tertiary 
amine whose protonation is crucial for the interaction with 
the dopaminergic receptor, and the addition of a substituted 
phenyl ring at the C-3 position, to guarantee better 
lipophilicity. Therefore, a prototype of new 3-phenyl-2H-
1,4-benzothiazines was developed. Preliminary screening on 
the derivatives using a wild-type S. aureus strain, both with 
and without ciprofloxacin, showed variable intrinsic and 
synergistic activity. Two compounds, 113 and 114, displayed 
the best activity, while displaying no and weak antibacterial 
activity, respectively. These compounds were able to inhibit 
NorA efflux of ciprofloxacin, being suggested that 114 was 
even able to completely inhibit this pump [126]. 
Thioridazine (115), a phenothiazine, was also tested for its 
antibiotic potentiation, either in racemate or in its 
enantiomeric forms. All the forms were able to reduce the 
MIC of oxacillin in S. aureus and erythromycin in 
Streptococcus pyogenes, being the L-enantiomer more 
effective in the last case [127-128]. 
 
4. RND 
RND pumps are found mostly in Gram-negative bacteria, 
being the most responsible pumps for MDR in this kind of 
organisms. They present a wide variety of lipophilic and 
amphiphilic substrates, which include several classes of 
antibiotics, antiseptics, dyes, and detergents. RND 
transporters present a unique tripartite complex, constituted 
by a minimum of twelve transmembrane segments: the 
transmembrane pump, the outer membrane channel, and the 
periplasmic adaptor protein, which puts the other two 
components in contact. This structural organization makes 
the extrusion of substrates directly into the external medium 
possible [32, 38]. Even though it has always been thought 
that RND transporters were exclusive to Gram-negative 
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bacteria, it has recently been identified and characterized 
FarE in S. aureus, homolog to the AcrB protein in E. coli 
[129-130]. 
Within this family, the most studied system is the AcrAB-
TolC, from E. coli. This efflux pump is composed by three 
essential parts: a resistance-nodulation-division transporter, 
AcrB; a membrane fusion protein, AcrA; and a 
multifunctional outer membrane channel, TolC [7, 131-133]. 
It transports a wide variety of toxic compounds from the 
intracellular space directly into the medium, evading the 
periplasm, and using a proton gradient as the energy source 
[132-133]. Pseudomonas aeruginosa also possesses an 
efflux system of the RND family, the MexAB-OprM efflux 
pump, which confers resistance to a wide variety of 
antibiotics. This was the first and best characterized efflux 
system in bacteria. It was found that AcrB (Figure 12, PDB 
4ZLJ) is homolog to MexB (Figure 12, PDB 2V50), being 
their structure very similar [7, 134]. 
Figure 13 comprises all the RND pump inhibitors that will 
be discussed in the following section. 
 
4.1. RND inhibitors 
4.1.1. Natural Products and Derivatives 
One study revealed that the essential oil of Helichrysum 
italicum can reduce the resistance to chloramphenicol in E. 
aerogenes, P. aeruginosa, and A. baumanii. These data 
suggested that one or more EPIs are present within the 
essential oil since it was shown that geraniol (116) produced 
significant restoration of sensitivity to chloramphenicol by 
16-fold, and rendered a total sensitivity of the organism 
when combined with of phenyl-arginine β-naphtylamide 
(PAβN), which will be discussed further ahead [135]. 
A study published by Aparna et al. (2014) had the aim of 
identifying natural compounds from plants that present 
efficacy in potentiating effects of antibiotics in P. 
aeruginosa overexpressing MexAB-OprM and E. coli 
overexpressing AcrAB-TolC through in silico virtual 
screening and pharmacophore approaches [136]. The 
compounds with the best in silico results were then tested for 
their EPI activity. The two compounds that showed the best 
activity in potentiating the activity of carbenicillin and 
levofloxacin in P. aeruginosa and E. coli were lanatoside C 
(117) and daidzein (118). Lanatoside C (117) is cardiac 
glycoside that inhibits the Na
+
-K
+
-ATPase, which can also 
be the explanation for its EPI activity against MexB and 
AcrB. Daidzein (118) is an isoflavone that has previously 
showed slight EPI activity in Mycobacterium smegmatis and 
as a modulator of P-glycoprotein, in human cervical 
carcinoma KB-V1 cells [136]. 
An in silico study by Ohene-Agyei et al. (2014) identified 
five phytochemicals that could be docked similarly to PAβN 
in the binding pocket of AcrB. Of these five, three of them 
were able to decrease resistance to antibiotics by inhibiting 
the AcrAB-TolC system: plumbagin (119) increased 
sensitivity to erythromycin, chloramphenicol, and 
tetraphenylphosphonium; nordihydroguaretic acid (NDGA) 
(120) potentiated the activity of erythromycin, 
chloramphenicol, tetraphenylphosphonium, novobiocin, and 
tetracycline; and shikonin (121) decreased resistance to 
tetraphenylphosphonium [137]. 
A study proved the usefulness of curcumin (64) as a RND 
EPI at a concentration of 50 µg/ml, increasing the sensitivity 
of carbenicillin, ceftazidime, and meropenem in P. 
aeruginosa, in decreasing order. It also managed to 
circumvent the resistance to gentamicin and ciprofloxacin in 
resistant isolates, which PAβN failed, leading to the 
assumption that curcumin inhibits efflux pumps differently 
from PAβN [138]. 
A screening of 85 000 microbial fermentation extracts 
derived from 3 600 strains of actinomycetes and 3 500 
strains of fungi was made, with the aim of discovering EPIs 
that increased sensitivity of levofloxacin in P. aeruginosa 
overexpressing the MexAB-OprM or the MexEF-OprN 
pump. Two compounds, EA-371α (122) and EA-371-δ 
(123), produced by a strain of Streptomyces sp., 
demonstrated inhibitory activity against MexAB-OprM 
[139]. 
 
4.1.2. Synthetic Compounds 
The first compound with potent inhibition of RND efflux 
pumps was PAβN (124), a dipeptide amine. This dipeptide 
was identified as a hit compound from the screening of 200 
000 samples of small molecules that potentiate the activity of 
antibacterial levofloxacin against strains of P. aeruginosa 
that overexpressed MexAB, MexCD and MexEF pumps [28, 
140]. Compound 124 is a peptidomimetic, developed for 
using in adjunctive therapy. This compound is a substrate for 
RND pumps, acting as a competitive inhibitor of multidrug 
efflux systems, such as MexB, MexD, and MexF, binding to 
the substrate pocket, impeding antibiotic binding and/or 
extrusion. Particularly, this EPI binds in a location close to 
the antibiotic binding site, generating steric hindrance, 
making it more difficult for the antibiotic to bind. In other 
words, less quantity of antibiotic is exported, making its 
intracellular levels higher, thus restoring antibiotic 
sensitivity [11, 25, 27-28, 141-143]. However, 124 can affect 
the integrity of the membrane when used in high 
concentrations, making it prone to the emergency of resistant 
profiles, namely the modification of the lipopolysaccharide 
structure, leading to changes in drug penetration [24].  
PAβN (124) has been validated against the AcrAB-TolC in 
Klebsiella pneumonia, E. coli, Salmonella enterica serovar 
Typhimurium and Enterobacter aerogenes, and in multiple 
homologous systems including Acinetobacter baumanii, 
Campylobacter jejuni, and Campylobacter coli [11, 142]. Its 
potency has been demonstrated against the norfloxacin 
resistance conferred by the Mex efflux system of 
Pseudomonas aeruginosa, the AcrAB efflux systems of the 
Enterobacteriaceae, and the erythromycin efflux system of C. 
jejuni [19]. 
Studies of SAR demonstrated that the basic middle amino 
acid, arginine, was detrimental for activity, although a 
substitution with L-lysine showed the same potency as the 
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lead, and the introduction of L-ornithine, originating 
compound L-Phe-L-Orn-β-Na, showed a 2-fold increased 
potency. As the ornithine moiety provided a simpler 
synthesis, it became the standard middle residue in 
successive compounds [25, 142, 144]. However, these 
compounds were not stable upon incubation with human 
serum, due to the occurrence of cleavage of peptide linkage 
between both amino acids, which is explained by the fact 
that natural (L) amino acids are contained within its 
structure. In order to overcome this problem, methylation of 
the NH that links both amino acids was achieved, 
maintaining potency and being this derivative able to resist 
serum proteases. Serum stability was also increased by 
replacing the L-amino acid with D-amino acid [25, 142].  In 
the same study, the authors also proved that the amino acid 
in the aa1 position (Figure 13, 124) should be appropriately 
substituted, and the replacement of phenylalanine with a 
homophenylalanine led to improved potency. The problem 
with this compound was the fact that the ornithine moiety 
could easily form a lactam, rendering the compound inactive. 
This was overcome by switching the L-ornithine with the L-
phenylalanine, which originated L-Orn-L-hPhe-β-Na, which 
originated a compound just as potent, but with no propensity 
to form a lactam. As for the β-aminonaphtalene moiety, it 
was proven that replacing it with 3-aminoquinoline led to 
reduced cytotoxicity and intrinsic antibacterial activity, even 
though its potency was slightly reduced [25, 142]. These 
efforts originated the compound L-Orn-L-hPhe-3-NHQ 
(125). In conclusion, the analogues synthesized by Renau et 
al. (1999) did not show improvements in potency when 
compared to PAβN (124), but showed increased stability 
[142]. 
The same group developed further studies with this type of 
molecules and demonstrated that conformational restriction 
of the amino group of ornithine showed less toxicity, while 
maintaining potency. Such compounds were attained by 
adding a proline substituent, thus incorporating the two basic 
residues necessary for activity, which resulted in the 
successful synthesis of constrained derivatives, more potent 
and less toxic than 125. The most interesting derivative, 
compound 126, was as potent as 125, but more than 4-fold 
less toxic. This compound also retained the activity against 
RND efflux pumps MexAB-OprM, MexCD-OprJ and 
MexEF-OprN. Although this compound showed similar 
protein binding in rats as 125, its pharmacokinetic 
parameters were improved, and its efficacy in combination 
with levofloxacin was demonstrated in an in vivo model 
[145]. 
In a latter study developed by the same group, several non-
peptide analogues were synthesized, and it was hypothesized 
that the peptide backbone is not essential for the activity of 
this type of compounds. The results suggested that the 
inhibition of pumps was possible due to the di-cationic 
nature of the compound, the appropriate lipophilicity and a 
disposition similar to that of compound 125 [146]. 
MBX2319 (127) is a pyranopyrimidine EPI inhibitor of 
AcrAB-TolC efflux pump in E.coli and other 
Enterobacteriaceae [141]. Compound 127 did not show any 
antibacterial activity, which is a positive feature for EPIs. It 
also potentiated the antibacterial activity of 
fluoroquinolones, such as ciprofloxacin and levofloxacin, 
and β-lactams, such as piperacillin against strains of E. coli 
that presented AcrAB-TolC efflux pumps [28, 141].  In P. 
aeruginosa, although compound 127 presents activity 
against RND-type pumps, it is unable to penetrate the outer 
membrane, which is highly selective [28]. 
In E. coli, the target of compound 127 is the membrane 
transporter AcrB. This molecule binds to the hydrophobic 
trap of the T protomer, interacting with the hydrophobic 
residues that constitute the deep binding pocket as a 
hydrophobic trap. π-π Interactions also occurs, between the 
pyridine ring of 127 and the aromatic side chain of Phe-628. 
The phenyl and morpholinyl groups also interact with Phe-
178 and Phe-615. The dimethylenesulfide linker and the 
geminal dimethyl group present van der Waals interactions 
between the side chain of Phe-178, and Tyr-327 and Met-
573, respectively [28, 147].  
SAR studies demonstrated that the maintenance of activity 
depended on the geminal dimethyl moiety of the 
tetrahydropyran, the nitrile group and the length of the 
dimethylenesulfide linker. This data is presented in Figure 
14.  On the other hand, the morpholine moiety and aryl 
group are both prone to substitution, originating more stable 
derivatives in terms of activity, solubility, and metabolism 
[28]. Studies with this scaffold have shown that non-acidic 
substituents can be added to the phenyl group, in order to 
improve potency and CYP450 inhibition, and modifications 
to the morpholinyl group has greater effects on solubility and 
stability [140]. 
Analogues were synthesized by Sjuts et al. (2016), by 
changing the structure and functional groups of compound 
127 (148). They reached the conclusions that the 
introduction of a 2,6-dimethyl to the morpholinyl group 
improved both microsomal stability and EPI activity. The 
replacement of the morpholinyl group with 2-
methoxyethylpiperazinyl improved aqueous solubility, at the 
cost of a slight reduction of EPI activity. Two analogues, 128 
and 129, resultant of the combination of 2,6-
dimethylmorpholinyl and acetamide or acrylamide, 
respectively, on the phenyl group, resulted in a 10-fold to 20-
fold increase in EPI activity against E. coli, respectively, 
comparing to MBX2319 (127) [28, 148]. The increased EPI 
activity of these compounds has its basis in the acetamide 
and acrylamide groups and the morpholinyl group. The 
acetamide groups are engaged in highly ordered and 
complex hydrogen bonds, with its center in a solvent water 
molecule, which plays the role of a hydrogen bond donor to 
the carbonyl backbone oxygen of Ala-286 and Gln-151 side 
chain of AcrB. The acrylamide group forms a bridging 
hydrogen bond through a water molecule to the side chain of 
Gln-176 [28]. 
Nguyen et al. (2015) also synthesized a series of analogues, 
with the morpholine scaffold substituted by a 2,6-
dimethylmorpholinyl group (140). Many of these analogues 
exhibited a solubility improvement of 10-fold, compared to 
compound 127. The most potent and promising compounds 
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of these series were compounds 130, 131, 132, 133 and 134 
[140]. 
Through a screening of an N-heterocyclic organic compound 
library, Bohnert and Kern (2005) were able to find a novel 
class of EPIs, the arylpiperazines [25, 149]. The aim of their 
work was to find compounds that would potentiate 
levofloxacin potency against strains of E. coli 
overexpressing acrAB and acrEF. This was fulfilled when 
they found phenylpiperazine derivatives with promising 
activity [25, 149]. SAR studies suggested that elongation of 
the spacer between the benzene ring and the piperazine ring 
would enhance potency. Also, substitutions on the benzene 
ring by halogen atoms led to an increase in potency [24, 
149]. On the other hand, the potency would decrease when 
an ethyl or phenyl group was added to the piperazine ring. 
With this, the authors found the most potent 
phenylpiperazine, meta-TFMPP (135), and 
naphthylpiperazine, 1-(1-naphthylmethyl)-piperazine (NMP) 
(136) [149]. 
NMP (136) was the most potent unsubstituted 
arylpiperazine, able to increase the intracellular 
concentration of chloramphenicol, tetracycline, linezolid, 
fluoroquinolones, and macrolides. Although it does not 
display action in P. aeruginosa, it shows effectiveness in A. 
baumanii and several Enterobacteriaceae [11, 23]. EPI 
activity was also reported in clinical isolates of E. coli, most 
relevantly in fluoroquinolone resistance [150]. Through 
computational analysis, it was found that NMP (136) binds 
with high affinity to the lower part of the deep pocket of the 
B monomer, overlapping in part the binding site of 
chloramphenicol [11]. The binding site for NMP (136) 
includes interactions with hydrophobic residues near the 
hydrophobic patch and Gly-617 of the G-loop. This data 
suggests that NMP (136) interferes with the movement of the 
G-loop, important for extruding substrates, thus inhibiting 
the action of AcrB [25]. 
Nakayama et al. (2003) performed a series of syntheses in 
order to attain a compound specific for the inhibition of a 
MexAB-OprM specific EPI [151-152]. They identified a hit, 
compound 137, through high-throughput screening for 
levofloxacin potentiation using a strain of P. aeruginosa 
strain overexpressing MexAB-OprM. The features this group 
was looking for was the effective inhibition of efflux pump 
and the lack of intrinsic antibacterial activity, since efflux 
pumps are not vital for the organism’s survival [151-152]. It 
was shown that this compound effectively potentiated the 
activity of levofloxacin, leading to an 8-fold decrease in the 
antibiotic’s MIC. However, its physicochemical properties 
were problematic: water solubility was poor and it presented 
high affinity to serum albumin. Therefore, they divided the 
molecule into three parts, A, B, and C (137) and looked for 
alternative scaffolds and substituted polar groups, in order to 
reduce serum protein binding [152]. 
It was shown that when a carboxamide was introduced in A, 
the affinity to serum albumin was diminished, as was its 
activity. More polar moieties led to a complete loss of 
activity. The strategy for the styrene portion (B) that was the 
most successful was to substitute the benzene ring to a 3,5-
disubstituted pyridine, which had both good activity and no 
major serum influence. As for the vinyl group in B, it was 
demonstrated that molecules bearing methyloxy and ethylene 
moieties displayed favorable activity profiles. As for part C, 
the basis of the modifications was the fact that the 
introduction of bulky or hydrophilic groups adjacent to the 
carboxyl group would reduce protein binding. An 
enantiomeric pair containing a dioxolane moiety presented 
both activity and serum stability, being the S enantiomer 
more active [152]. 
Regarding the general scaffold, new compounds were 
designed, keeping in mind that the thiazole moiety was 
crucial for activity. Therefore, a molecule having a thiazole 
side chain attached to the C-7 position of a quinolone was 
synthesized. Substitution with a tetrazole portion yielded 
better results than substitution with a carboxylic acid. One 
compound (138) presented the best activity and serum 
stability [153]. 
Further efforts were placed in order to increase the potency 
of this compound. The in vitro activity was enhanced by the 
introduction of a hydrophobic group at the 2-position of the 
pyridopyrimidine scaffold, and hydrophilic substitution 
would not compromise the activity. The most promising 
compound had the inclusion of an olefin spacer between the 
tetrazole and the pyridopyrimidine scaffold, with the 
limitation of being prone to photoisomerization [154]. To 
circumvent this, the ethylene tether between the 
pyridopyrimidine was replaced with an amide bond, 
providing stability against photoisomerization and, 
unexpectedly, improving potency. However, another 
problem arose: the lack of solubility for intravenous use 
[155]. The following step was the introduction of a 
secondary amine, giving a zwitterionic analogue, with 
retention of activity. C-2 Analogues, namely with cyclic 
substituents, also showed promising results [156]. Once 
again, the problem of solubility arose. Therefore, efforts 
were placed in making the molecule more hydrophilic, with 
the introduction of substituted aromatic moieties. Analogues 
4-substituted were the most potent, and the introduction of a 
morpholine moiety led to increased solubility, maintaining 
the serum stability. Compound 139 was the most balanced 
molecule in terms of the desired features [157]. The last 
refinement made was the introduction of a quaternary 
ammonium salt, which led to D13-9001 (140). Adding to its 
high solubility and safety, it was able to potentiate the 
activity of aztreonam [158]. Figure 15 illustrates the SAR 
established for 140 and derivatives. 
3D Crystal structures of 140 bound to the target, either AcrB 
or MexB, show that the tert-butyl thiazolyl aminocarboxyl 
pyridopyrimidine moiety of this compound binds tightly to a 
narrow depression, designated by hydrophobic trap, close to 
the deep substrate binding pocket. Additionally, the tetrazole 
ring and the piperidine acetoamino ethylene ammonio-
acetate moiety interact with ionic and/or hydrophilic residues 
in the substrate translocation channel. The piperidine 
acetoamino ethylene ammonio-acetate moiety also covers 
part of the minocycline and doxorubicin binding site [23, 28, 
151]. 
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Quinoline derivatives with EPI activity include a multiplicity 
of derivatives, including pyrrido-, alkoxy-, thioalkoxy-, 
alkylamino- and chloro- derivatives. These compounds were 
able to restore an intracellular concentration of antibiotic 
drugs expelled by efflux pumps, as well as to induce the 
increase in antibiotic susceptibility, acting as competitive 
inhibitors of the antibiotic flux. In E. aerogenes and K. 
pneumoniae, quinolines were more effective than PAβN 
(124) in inhibiting the activity of the AcrB pump, 
potentiating the activity of fluoroquinolones, tetracycline, 
and chloramphenicol [11, 24, 26].  Among the different 
classes of substituted quinolines, it was proven that the best 
side chain was piperidinoethyl, which potentiated efficiently 
the restoration of drug susceptibility in alkoxy- and 
thioalkoxyquinolines. The heteroatom connecting the side 
chain is also crucial for activity, being the most potent the 
amino substituent, then the thioalkyl-, followed by the oxo-
derivative. The position of the branched substituted groups is 
also detrimental for the EPI activity [24]. Branched side 
chains containing piperidinoethyl and morpholinopropyl 
groups were associated with the most interesting results, 
being compound 141, containing a piperidinoethyl side 
chain, the most active when in combination with 
chloramphenicol [159]. It has been hypothesized that the 
pump inhibition is greatly influenced by the branched side 
chain, and takes place either in the inner-membrane 
transporter or at the junction between the inner pump and the 
outer channel [159]. 
Given these promising results, further research in this kind of 
compounds was performed. Alkoxyquinolines were 
synthesized and tested against a strain of E. aerogenes 
overexpressing the AcrAB efflux pump. Compound 142 
induced an increase in the susceptibility of chloramphenicol, 
tetracycline, and fluoroquinolone. This could happen due to 
interference during active pumping out of the antibiotic 
[160].  
Chloroquinolines also demonstrated efficacy as EPIs, 
modulating chloramphenicol activity, decreasing its MIC 8-
fold for resistant strains. Synthesis of analogues led to the 
conclusion that amino derivatives are more potent than thiol 
derivatives, pointing out the importance of the side chain for 
the efflux inhibition. Protonation of the nitrogen could also 
play an important role at environmental pH, stimulating 
recognition and binding of the drug to the sites located 
within the pump’s cavity. The heteroatom is also crucial for 
the activity, being nitrogen the most efficient. Compound 
143 is the chloroquinoline with the best results found for the 
inhibition of the main efflux pump of E. aerogenes [161].  
Alkylaminoquinazoline derivatives lacking a nitro group 
were also evaluated for their ability to decrease 
chloramphenicol and quinolone efflux in E. aerogenes, 
through the inhibition of AcrAB efflux pump. The results 
obtained suggest that this family of compounds recognizes 
the same pump site responsible for the transport of 
chloramphenicol and quinolones, competing with them. 
Structurally, it has been shown that a morpholine group with 
a propyl chain makes a more active alkylaminoquinazoline. 
The most active compound of this family is compound 144 
[162]. 
Benzothiazoles 2-substituted were first tested for the 
potentiation of ciprofloxacin in AdeABC overexpressing A. 
baumanii. These compounds did not show antibacterial 
activity when tested alone in bacteria. However, when 
combined with ciprofloxacin, there was an observation of a 
reversal in antibacterial susceptibility. The synthesis of 
several derivatives of this family led to pharmacophore 
studies, regarding the features of the most promising 
compounds. Using computational methods, it was revealed 
that, in order for the compounds to be biologically active, the 
following features should be present: the nitrogen atom in 
the thiazole ring and the carbonyl oxygen in the amide 
function substituted on the second position of the 
benzothiazole ring must have an hydrogen bonding acceptor 
property; the benzene ring in the fused ring system, the 
phenyl group attached to the second position of the 
benzothiazole ring and the phenyl ring in the 2-
phenylacetamide and/or 3-phenylpropionamide moiety are 
essential, since they provide a hydrophobic aromatic 
property. Of the synthesized compounds, the ones that 
gathered these features and, therefore, presented the most 
promising activity, were compounds 145, 146, and 147 
[163]. These compounds were also tested for their activity 
against AcrAB-TolC, in an overexpressing strain of E. coli, 
reducing the MIC of ciprofloxacin 10-fold, in the case of 146 
and 147, and 8-fold, for 145 [164]. Unlike AdeABC, 
AcrAB-TolC’s crystal structure is elucidated, making 
docking studies possible. This predicted that all three 
compounds act as AcrB substrates, binding to the distal 
pocket site in the AcrB porter domain by blocking or 
inhibiting the ciprofloxacin binding site, generating steric 
hindrance and thus impeding the binding of the antibiotic. 
Furthermore, 146 and 147 showed stronger binding 
interactions than ciprofloxacin [164].  
Indole derivatives have been useful in inhibiting protein 
targets of virus, tumors and bacteria. Since small molecules 
with conjugated aromatic rings, in which indoles fit, present 
high potential as EPIs, efforts were placed in synthesizing 
derivatives that presented this kind of activity. The TolC 3D 
structure has already been disclosed, making possible the 
structure-based design of inhibitors. Indoles 148 and 149 
were proven efficient inhibitors of TolC in E. coli, 
potentiating the effects of chloramphenicol, tetracycline, 
erythromycin, and ciprofloxacin, with decreased MIC values 
of 2-fold for tetracycline and erythromycin and 8-fold for the 
other two [165].  
 
4.1.3. Existing Drugs 
Other drugs used for treatments other than antibacterial have 
demonstrated EPI activity. Tetracycline resistance in P. 
aeruginosa was reduced 8-fold when the phenothiazine 
fluphenazine, an antipsychotic, was present. Chlorpromazine 
(150) also showed EPI-like activity for the BpeAB-OprB 
system in Burkholderia pseudomallei and a reduction of the 
expression of acrB in E. coli and S. enterica samovar 
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Typhimurium, suggesting an inhibition of AcrB production 
[11, 27, 128]. 
Selective serotonin-reuptake inhibitors have been studied for 
their ability to act as EPIs for RND efflux pumps in E. coli. 
It was found that sertraline (151) was capable of potentiating 
the activity of fluoroquinolones. However, its activity is 
limited, since it is possible that this compound also acts as an 
inductor of efflux pumps. Studies have shown that this 
compound could accumulate in tissues or cells, and 
therefore, sertraline’s (151) concentration may be higher 
than that measured in plasma. This means that a standard 
dose of this drug could enhance antibiotic efficacy. It has not 
yet been studied if a sertraline (151) metabolite could be 
administered at a dose higher than sertraline. However, it 
was hypothesized that it could have a better EPI activity, 
while causing less undesired effects on the central nervous 
system [166]. 
Through the observation of previously reported EPIs, 
Piddock et al. (2010) suggested that simple heterocyclic 
nitrogen-containing compounds could also act as EPIs and 
synergize with ciprofloxacin in strains of S. enterica serovar 
Typhimurium that overexpressed the AcrAB-TolC efflux 
pump [167]. It has been shown that compounds containing a 
phenylethylamine moiety, as PAβN (126) does, such as 
epinephrine, norepinephrine, and cathinone, are able to 
potentiate the activity of ciprofloxacin. Of the compounds 
tested, trimethoprim (152) and epinephrine (153), showed 
the best results for the tested strains, which included, apart 
from S. enterica serovar Typhimurium, P. aeruginosa, E. 
coli, and K. pneumoniae. These compounds showed synergy 
for the strains where AcrAB-TolC was active, but showed no 
activity when the pump was inactive. Thus, it can be 
hypothesized that these compounds either inhibit the 
expression of the genes encoding AcrAB-TolC, or interact 
directly with the pump [167]. Both compounds possess 
structural features similar to previously described EPIs, such 
as PAβN (124), L-Orn-L-hPhe-3-NHQ (125), and NMP 
(136), such as an aromatic ring linked to a basic nitrogen, in 
the case of epinephrine (153), or a pyrimidine ring, for 
trimethoprim (152). Trimethoprim (152) is already used in 
combination with another antibiotic, sulfamethoxazole, and 
combination with a quinolone was hypothesized to be a 
viable choice. On the other hand, a combination of 
epinephrine (153) with an antibiotic does not seem a viable 
option, because of the likelihood of the occurrence of 
sympathomimetic effects [167]. 
The antimalarial artesunate (154) has also shown EPI 
activity, enhancing the effects of β-lactam antibiotics, such 
as penicillin G, oxacillin, and ampicillin, and novobiocin 
against E. coli. The mechanism through which 154 expresses 
its activity is by the inhibition of the expression of the 
AcrAB-TolC system, not exhibiting antibiotic activity by 
itself [168]. 
 
5. SMR 
The SMR family comprises the smallest drug efflux proteins 
known, possessing only four transmembrane segments in its 
composition, and are exclusive to bacteria. They are 
involved in the efflux of lipophilic compounds, such as 
quaternary ammonium salts and a variety of antibiotics. 
These pumps also use an electrochemical proton gradient in 
order to exert its efflux activity [7, 32, 38, 169]. 
One example of a SMR-type pump is the EmrE transporter 
(Figure 16, PDB 3B61), present in E. coli. In the absence of 
the ligand, the asymmetric unit of EmrE contains eight EmrE 
monomers, with four transmembrane helices composing 
each of them. If a ligand is present, it can function as an 
inverted homodimer [7, 170]. 
There have not been many studies concerning inhibitors of 
this family of efflux pumps, and the few that have been 
performed were only in silico. Figure 17 shows the 
structures of the SMR inhibitors that will be further 
discussed. 
   
5.1. SMR inhibitors 
5.1.1. Natural Products 
Quercetin (155) is a flavonol, present in many plants. This 
compound is very well tolerated in humans, as are its 
glycoconjugates, and presents a multiplicity of activities, 
such as antioxidant, anti-inflammatory and 
antimycobacterial. Only docking studies of this compound 
with two pumps belonging to the SMR family, the Mmr, in 
Mycobacterium smegmatis, and the EmrE pumps, in E. coli, 
were carried out. In Mmr, the hydroxyl groups present in the 
3’ and 4’ positions of the B ring of quercetin were predicted 
to interact with Glu-14 in the helix 1, and the keto group of 
the hydroxychromen ring of the ligand interacts with the 
Trp-48 of the helix 1. Additionally, hydrophobic interactions 
were shown by the residues Phe-44, Tyr-40 and Trp-48, and 
π-π interactions were found with Phe-44. Furthermore, 155 
was also predicted of interacting with dimeric forms of the 
protein [171]. In the case of EmrE, the interaction between 
the 3’ and 4’ hydroxyls with Glu-14 can also be observed, as 
can the hydroxyl in the C-7 position with Tyr-60. 
Hydrophobic interactions are present, with the residues Ile-
11, Ser-64, Gly-67 and Leu-70, and π-π interactions exist 
with the residues Tyr-60 and Trp-63. Structural studies 
suggest that EmrE is mostly in the dimer state, which also 
interacts with quercetin (155) [171]. 
 
5.1.2. Synthetic Compounds 
Cation ligands were subjected to docking studies with the 
Mmr protein of the SMR family in Mycobacterium 
tuberculosis and the EmrE dimer from E. coli. The rationale 
behind this study is the fact that SMR can extrude cations. 
This study led to the identification of new virtual leads, 
amongst which is compound 156. ADME studies prove that 
all the molecules present in this study obey the Lipinski rule 
of five and the Jorgenson rule of three, which shows that the 
compounds possess good drug-like properties [172]. 
 
6. MATE 
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MATE transporters are responsible for the efflux of cationic, 
lipophilic substances, providing bacteria and cancer cells 
with MDR, using Na
+ 
or H
+
 influx. They have 12 
transmembrane helices, constituted by 400 to 700 amino 
acids. The mechanism of efflux is thought to happen by a 
rocker-switch mechanism. Members of the MATE family 
include the MepA (Figure 18, PDB 1TZP) transporter, in S. 
aureus, even though seventeen MATE proteins have been 
identified in eleven species, capable of extruding antibiotics. 
Ethidium bromide, tetraphenylphosphonium, acriflavine, 
berberine, and norfloxacin have been reported as MATE 
substrates [38, 173-181]. 
In Figure 19 are compiled the structures of the compounds 
that have so far proven their usefulness as MATE inhibitors. 
 
6.1. MATE inhibitors 
6.1.1. Natural Products 
A study performed by Kesherwani et al. (2017) 
accomplished the docking of phytochemicals with the NorM 
transporter, belonging to the MATE family [182]. After a 
screening of a library of natural products, three hits were 
identified: derhamnosyl suspenaside (157), prunin 7’’-O-
gallate (158), and quercetin diglucoside (159). These were 
the best compounds, as their results in binding free energy 
calculation were the most favorable. When binding free 
energy decomposition and hydrogen and hydrophobic 
statistics were taken into account, 158 was elected the best 
hit compound. Furthermore, this compound was stable 
during the simulation. Overall, it has been suggested that the 
compounds which interact towards the cation binding 
residue in the central cavity of NorM will have better results, 
and that good inhibitors should have interaction with a few 
key residues, Gln-34, Val-35, Gly-38, Phe-63, Tyr-67, Ile-
68, Glu-261, Tyr-294, and Asp-377, which will lead to 
maximum stability and affinity with the NorM transporter 
[182]. 
 
6.1.2. Synthetic Compounds 
These compounds have been previously described as MFS 
inhibitors, namely of the NorA pump. However, similar 
activity has been described for the MepA pump, of the 
MATE family. Compound 80 (Figure 5), incorporating a 
bisaryl urea moiety at the 7-position, was able to 
successfully inhibit approximately 84% of ethidium bromide 
efflux in a MepA overexpressing strain of S.aureus [104]. 
Phenylquinoline derivatives also proved efficient against the 
same strain. Differently from what was observed with NorA, 
the compounds that inhibited MepA most efficiently were 86 
(Figure 5) and 160 (Figure 19), which were able to reduce 
ethidium bromide’s MIC by 16-fold at concentrations of 
0.78 and 1.56 µg/ml, respectively, in the MepA 
overexpressing strain. Ethidium bromide was chosen, instead 
of ciprofloxacin, as it is a better MepA substrate and other 
derivatives were able to inhibit both NorA and MepA efflux 
pumps, being able to completely restore the activity of 
ciprofloxacin and ethidium bromide against strains 
overexpressing such pumps [107]. 
Paroxetine derivatives (104), effective against the NorA 
pump, also demonstrated potency in inhibiting the MepA 
pump in S. aureus. Oppositely to NorA, paroxetine 
derivatives do not need the fluorophenyl ring at position 4 to 
be MepA EPIs. In fact, 4-unsubstituted analogues proved to 
be more potent than 4-F-phenyl derivatives in inhibiting the 
MepA pump, as is the case of compound 161 and 162 [122]. 
 
Efflux pumps are one of the main causes for antimicrobial 
resistance. Their inhibition can lead to the restoration of 
bacteria susceptibility and antibiotic efficacy. Throughout 
this review, the data presented leads to the conclusion that 
EPIs are promising compounds and can help reversing the 
problem of antimicrobial resistance. However, the research 
into these kind of compounds is still in a very preliminary 
state, since no EPI is yet under clinical trials. 
Even though no general structural features can be pointed out 
for a molecule to be an EPI, it can be observed that small 
molecules with high lipophilicity are most likely to fulfill the 
requirements to inhibit efflux pumps. Hydrophilic 
compounds can also be transported through porins present in 
the membrane.  Heterocyclic compounds also show potential 
as EPIs, mainly nitrogen heterocycles, but also fluorine and 
boron heteroatoms, since the likelihood of bacterial exposure 
to these atoms is very low. The basis for the MDR pumps 
inhibition has to do with the penetration rules, and whether 
or not a compound is capable of penetrating the bacterial 
membrane. Therefore, a library of compounds that are able 
to do that would be something that would bring advances to 
this study field. 
One of the main aims of this review is to present SAR 
studies, so that pharmaceutical chemists can refine molecular 
structures, leading to the achievement of more potent and 
specific compounds. The use of synthetic approaches, either 
to modify molecules obtained from natural sources, or drugs 
that are already in therapeutic use, or even to develop novel 
compounds, is vital for these SAR studies. The search of 
EPIs derived from natural products comes from the fact that 
plants need to protect themselves from pathogenic 
microorganisms, and produce metabolites that act as 
antimicrobial and EPIs, that synergize with each other. 
However, the referred compounds are not specific for the 
pump they have been studied, showing a multitarget 
character: flavonoids, coumarins, cinnamic acids, among 
others, present a multiplicity of activities already described, 
suggesting their promiscuity. 
The advantage of assays with existing drugs lies in their 
safety profile and, most times, their clinical use for 
combination therapy has been characterized. In some cases, 
the compounds were even investigated as inhibitors of 
human efflux pumps, for cancer treatment. This can be 
regarded as an advantage, leading to a new class of drugs 
with dual human/bacterial EPI, particularly useful in cancer 
patients with infections, potentiating the effects of both the 
anticancer and the antibacterial drugs. 
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The future in studies in bacterial EPIs should lie either in the 
search for selectivity for the bacterial target, or in the 
disclosure of the common features of the universal bacterial 
EPI, that can successfully target all efflux pumps. The SAR 
studies gathered herein with the 3D structural information 
available are expected to accelerate the structure-based 
design of new EPIs, founded on the existing models.  
 
LIST OF ABBREVIATIONS 
3D-QSAR: Three-dimensional quantitative structure activity 
relationship; ABC: ATP-binding cassette; ADME: 
Absorption, distribution, metabolism and excretion; ATP: 
Adenosine triphosphate; BCRP: Breast cancer resistance 
protein; COX-2: Ciclooxigenase-2; CYP450: Cytochrome 
P450; EPI: Efflux pump inhibitor; IC50: Half maximal 
inhibitory concentration; MATE: Multidrug and toxic 
compound extrusion; MDR: Multidrug resistance; MIC: 
Minimum inhibitory concentration; MFS: Major facilitator 
superfamily; MRP: Multidrug resistance protein; MRSA: 
Methicillin-resistant Staphylococcus aureus; NDGA: 
Nordihydroguaretic acid; NMP: 1-(1-Naphthylmethyl)-
piperazine; P-gp: P-Glycoprotein; PAβN: Phenyl-arginine β-
naphtylamide; PDB: Protein Data Bank; PSSRI: 
Phenylpiperidine selective serotonin reuptake inhibitors; 
RND: Resistance-nodulation-division; SAR: Structure 
activity relationship; SMR: Small multidrug resistance. 
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Abstract: Antibiotic resistance is one of the most pressing health issues of our days. It can arise due to a multiplicity of 
factors, such as target modification, decrease in the drug uptake, changes in the metabolic pathways and activation of efflux 
pumps. The overexpression of efflux pumps is responsible for the extrusion of drugs, making antibiotic therapy fail, as the 
quantity of intracellular antibiotic is not enough to provide the desired therapeutic effect. 
Efflux pumps can be included in five families according to their composition, nature of substrates, energy source, and number 
of transmembrane spanning regions. The ABC superfamily are mainly found in Gram-positive bacteria, use ATP as an 
energy source, and only a limited number of ABC pumps confer multidrug resistance (MDR). 
On the other hand, the MFS family, most present in Gram-positive bacteria, and the RND family, characteristic of Gram-
negative bacteria, are the most associated with antibiotic resistance. A wide variety of inhibitors have been disclosed for both 
families, from either natural or synthetic sources, or even drugs that are currently in therapy for other diseases. 
The other two families are the SMR, which are the smallest drug efflux proteins known, and the MATE family, whose pumps 
can also resort to the sodium gradient as an energy source. 
In this review, it is intended to present a comprehensive review of the classes of efflux pump inhibitors from the various 
sources, highlighting their structure-activity relationships, which can be useful for medicinal chemists in the pursuit of novel 
efflux pump inhibitors. 
 
Keywords: Antimicrobial resistance; efflux pump inhibitors; natural products; synthetic compounds; existing drugs; Structure-activity 
relationship. 
1. INTRODUCTION 
Bacteria were discovered the late 19
th
 century as infectious 
agents. It was, however, half a century later that antibiotics 
completely revolutionized medicine and became a turning 
point in human history. Unfortunately, the misruled use of 
these drugs led to the appearance of resistant strains, and to 
the concern of a return to the pre-antibiotic era, where the 
simplest, most treatable infections can become deadly [1-2]. 
Antibiotic resistance can arise due to multiple causes. The 
most common are the overuse and/or inappropriate 
prescribing, as well as extensive veterinary and agricultural 
use. These factors are especially alarming if it is taken into 
account the very few new antibiotics that were discovered in 
the past years [3]. Due to their genetic plasticity, bacteria can 
develop defense mechanisms in response to environmental 
threats. As far as antibiotics are concerned, bacteria use two 
major strategies to adapt to these drugs, which are mutations 
in genes and the acquisition of resistance genes through 
horizontal gene transfer. The first strategy can be manifested 
through modification of the target, decrease in the drug 
uptake, activation of efflux pumps to extrude the drug or 
changes in metabolic pathways. The latter is related to the 
acquisition of external genetic material through 
transformation, transduction, or conjugation [4-5]. Recently, 
vesicle-mediated resistance has also been regarded as a 
mechanism of resistance acquisition [6]. 
Efflux pumps are ubiquitous in bacteria, and can be encoded 
by genes present either in the bacterial chromosomes or in 
plasmids [7-8]. They concern five families, according to 
their composition, substrates, energy sources, and number of 
transmembrane spanning regions: the adenosine triphosphate 
(ATP)-binding cassette (ABC) superfamily, the resistance-
nodulation-division family (RND), the major facilitator 
superfamily (MFS), the small multidrug resistance (SMR) 
Please provide 
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family, and the multidrug and toxic compound extrusion 
(MATE) family (Figure 1) [7-12].  
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Efflux pumps can be further divided into two major families, 
the primary transporters, which hydrolyze ATP as a source 
of energy, as is the case of the ABC family, and secondary 
transporters, which use the proton or sodium gradient as a 
source of energy [13]. Overexpression of multidrug efflux 
pumps is correlated with an increase in the minimum 
inhibitory concentration (MIC) of antibiotics, and thus, these 
pumps can be considered potential antibacterial targets. 
Therefore, the development of efflux pump inhibitors may 
be a way of fighting against resistant microorganisms. 
Studies have been carried out on the structure of efflux 
pumps, as well as on their mechanisms of binding and 
extrusion, leading to the possibility of structure-based design 
of efflux pump inhibitors (EPIs). The rationale for the 
development of these EPIs could be, for instance, the 
inhibition of the energy sources required for the ability to 
extrude antibiotics, and the development of compounds that 
compete with the antibiotics for their extrusion. However, 
the main challenge lies in the fact that many compounds that 
present EPI activity and are already used for the treatment of 
other diseases are toxic for human cells in the concentrations 
required to present EPI activity and, therefore, clinically 
useless [7-9, 13]. 
Even though there are already several reviews which 
describe different classes of EPIs [11, 13-31], most focus on 
a particular source of compounds or on a class of pumps or 
bacteria. Herein, it is intended to present a comprehensive 
review of the several classes of EPIs from natural and 
synthetic sources and from existing drugs in therapeutics and 
to highlight structure-activity relationship studies in the 
referred efflux pumps (ABC, RND, MFS, SMR and MATE), 
which can be useful for medicinal chemists in the pursuit of 
novel compounds for this goal.  
 
2. ABC 
The ABC transporters are primary transporters, and they 
exist in every membrane systems, whether the organism is 
prokaryotic or eukaryotic. P-Glycoprotein (P-gp) is a very 
well known human ABC transporter, involved in the 
resistance of cytotoxic drugs used in cancer therapy [32-34], 
whose modulation has been regarded as a study field [35-
37]. Structurally, an ABC transporter consists of four 
conserved domains, two transmembrane domains, and two 
cytoplasmic domains, which bind to nucleotides and, 
therefore, are involved in ATP binding [32, 38]. In fact, the 
nucleotide binding domains are responsible for hydrolyzing 
ATP, which will lead to conformational changes in the 
attached transmembrane domains, making it possible for 
substrates to cross the lipid bilayer of the membrane, either 
in an inwards or an outwards fashion [39]. 
The bacterial transporters are highly selective for sugars, 
amino acids, metallic cations, organo-iron complexes, 
vitamins, and antibiotics [32, 40]. They are found in Gram-
positive bacteria, such as Enterococcus faecalis and 
Staphylococcus aureus, and confer resistance to macrolides 
and bacitracin. However, only a limited number of ABC 
pumps are associated with MDR, which means that ABC 
pumps do not play a pivotal role in conferring antibiotic 
resistance in bacteria [32-33]. 
As such, bacterial ABC transporter inhibitors are scarce. The 
few EPIs discovered in this context are mainly against MsrA 
(Figure 2, PDB 1NWA), whose tridimensional structure has 
been elucidated [41]. 
The structures of the ABC inhibitors that will be further 
detailed throughout this section are comprised in Figure 3. 
 
2.1. ABC inhibitors 
2.1.1. Natural Products 
The search for natural products comes from the reason that 
plants produce antimicrobials to protect themselves from 
exogenous organisms. It is thought that plants can produce 
anti-MDR compounds to fight the microbial resistance 
phenomenon. Carnosic acid (1) was one of the major 
products isolated from the plant Rosmarinus officinalis. 
When tested against the macrolide resistant strain of S. 
aureus, expressing the MsrA pump, compound 1 displayed 
favorable results, showing an impressive 8-fold potentiation 
of erythromycin [42]. 
An extract of Lycopus europaeus led to the isolation of two 
new isopimarane diterpenes, methyl-1α-acetoxy-7α,14α-
dihydroxy-8,15-isopimarandien-18-oate (2) and methyl-
1α,14α- diacetoxy-7α-hydroxy-8,15-isopimarandien-18-oate 
(3), which showed no antibacterial activity, but were able to 
reduce erythromycin’s MIC from 256 µg/ml to128 µg/ml, 
therefore causing a 2-fold potentiation. This behavior was 
similar to other isopimarane diterpenes isolated in this study, 
as well as for 5,9-dihydroxygeranyllinalool (4) and 9-
acetoxy-5-hydroxygeranyllinalool (5), two diterpenoids [43-
44]. 
Phytol (6) is an acyclic isoprenoid, and its EPI activity 
against the ABC pumps of E. coli was assessed in 
combination with nalidixic acid. Additionally, 15 derivatives 
were synthesized. One derivative in particular, compound 7, 
was able to decrease the MIC of nalidixic acid by 16-fold, 
and four other derivatives reduced the MIC by 8-fold. This 
effect was caused by the inhibition of ATP-dependent efflux 
pump and down-regulation of the efflux gene. In silico 
absorption, distribution, metabolism, and excretion (ADME) 
analysis was performed, taking into account parameters such 
as solubility in water, human intestinal absorption, plasma 
protein binding, blood-brain barrier penetration, 
hepatotoxicity and cytochrome P450 (CYP450) inhibition. 
Results showed all five active derivatives presented low 
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permeability into the central nervous system and displayed 
moderate intestinal absorption. In terms of plasma protein 
binding level, all five compounds exhibited levels below 
90%, suggesting favorable distribution of the compounds 
into the blood. They also did not present hepatotoxicity, 
unlike reserpine, making them good lead compounds [45]. 
Ursolic acid (8) is a pentacyclic triterpenoid isolated from 
diverse natural sources. Its wide activity includes anti-
inflammatory, antimicrobial, diuretic, and antitumor activity, 
among others. When tested against Escherichia coli strains 
that were resistant and susceptible to nalidixic acid, ursolic 
acid did not display intrinsic antibacterial activity. However, 
ursolic acid (8) was able to reduce the MIC of nalidixic acid 
by 2-fold, when both drugs were used in combination. This 
synergy led to further research on this scaffold. The first 
derivative prepared was the 3-O-acetyl ursolic acid, and 
showed a 4-fold decrease in the MIC of nalidixic acid. The 
lipophilic nature of this derivative, allied with the increased 
potency, led to the synthesis of other lipophilic ester 
derivatives. The methyl and ethyl esters of 3-O-acetyl ursolic 
acid did not show any increment in the activity. However, a 
further increase in the ester carbon chain increased the drug 
reversal potential by 2-fold, in comparison to 3-O-acetyl 
ursolic acid, against the resistant strain. This is the case of 
the isopropyl (9) and the n-butyl (10) derivatives. The 
addition of a pentyl group led to a decrease in activity. 
Furthermore, ursolic acid (8), and derivatives 9 and 10, 
reduced the MIC of tetracycline by 2-fold, 8-fold, and 8-fold, 
respectively. When these compounds were tested against 
ATP-dependent efflux pumps, it was found that derivatives 9 
and 10 were successful in inhibiting these pumps in terms of 
the liberated inorganic phosphate. Molecular modeling 
studies with the YojI pump, using maltose/maltodextrin 
transport ATP-binding protein as a homology model, showed 
that 9 was bound to the nucleophilic Ser-78, to the aromatic 
Phe-81, Trp-85 and Leu-86, the acidic Glu-94 and Glu-144 
and the basic Ala-79, Ala-139, Ala-140, Ala-141, Ala-143, 
Arg-74, Arg-122, Arg-146, Leu-107, Val-80, Lys-96, and 
Ile-123 in the nucleotide binding domain. Derivative 10 was 
also subjected to the same kind of studies using the same 
model, and was predicted to bind in the same region [46]. 
A study with flavones and isoflavones from the plant 
Sophora moorcroftiana revealed that diosmetin (11) was 
able to inhibit three drug resistant strains of S. aureus, 
including the ABC family MsrA overexpressing strain, 
potentiating the effects of norfloxacin and streptomycin [47]. 
These results corroborate the works of Chan et al (2013), 
who had previously studied the effects of diosmetin (11) as 
an EPI [48]. This group observed a synergistic effect of this 
flavonoid with erythromycin, which was 5-fold greater than 
that of verapamil [48]. 
4-Hydroxy-α-tetralone (12) isolated from the plant 
Ammannia multiflora, showed enhancement against nalidixic 
acid resistant strains of Escherichia coli, prompting the 
synthesis of derivatives in order to infer their mechanism of 
action. Five derivatives were synthesized, and it was shown 
that compound 13 was able to inhibit the expression of the 
ABC transporter protein gene yojI, which encodes the ABC 
protein YojI, and was successful in combination with 
tetracycline [49]. Molecular modelling studies with 
compound 13 and a homology model of the YojI protein 
revealed the following bound residues: Ser-78 
(nucleophilic), Leu-86, Ile-123, Ala-137, Ala-140, Ala-141, 
and Ala-143 (hydrophobic), Glu-144 (acidic), Arg-122 
(basic), Phe-81 (aromatic), Glu-144 (acidic), Arg-146 and 
Lys-96 (basic), and Trp-85 (hydrophobic), the same region 
as noted for ursolic acid derivatives 9 and 10. Compound 13 
showed good affinity and strong hydrophobic interaction 
with the YojI protein, corroborating the fact that this 
compound acts by the inhibition of ATP dependent efflux 
pumps [49]. 
The plant Portulaca oleraceae is used in folk medicine for 
its anti-inflammatory, anti-septic and diuretic effects, among 
others. A study of its fatty acids demonstrated that linoleic 
(14) and oleic acids (15) had synergistic activity with 
macrolides for the MsrA overexpressing strain of 
methicillin-resistant S. aureus (MRSA). In fact, 
erythromycin’s activity was enhanced when in combination 
with either of these two compounds, likely through the 
inhibition of the MsrA ATP dependent pump. Since these 
fatty acids are essential for humans, low toxicity is expected, 
making them promising agents to use in combination with 
antibiotics [50]. 
Lysergol (16) is a clavine alkaloid of the ergoline family. 
Recently, its EPI activity was studied, and derivatives were 
synthesized [51]. The compounds were tested against 
susceptible and resistant to nalidixic acid strains of E. coli 
and a tetracycline resistant strain. While not possessing 
antibacterial activity, lysergol (16) showed synergy with 
nalidixic acid at the concentration of 10 µg/ml, reducing its 
MIC by 8-fold in the resistant strain of E. coli and 4-fold in 
the susceptible strain. Of the thirteen semi-synthetic 
derivatives prepared, derivatives 17 and 18 reduced nalidixic 
acid’s MIC by 8-fold, twice as much as lysergol (16), in the 
susceptible strain. A 4-fold potentiation of nalidixic acid was 
observed for the three compounds when tested against the 
resistant strain. As for the tetracycline resistant strain, all 
three compounds were able to reduce tetracycline’s MIC by 
8-fold. Further studies were performed, in order to conclude 
whether or not these compounds were capable of interfering 
with ATP-dependent efflux pumps, and it was proven that all 
three compounds inhibited ATPase activity, concerning the 
liberation of inorganic phosphate. A down-regulation of the 
gene yojI was also observed when the tetracycline resistant 
strain was treated with lysergol (16) and its two most potent 
derivatives, 17 and 18, which further confirms the activity of 
these compounds as ABC transporter inhibitors [51]. 
 
2.1.2. Existing Drugs 
As part of a screening program for P-gp inhibitors, 
GG918 (19) was discovered. This synthetic compound had 
already showed success in increasing the intracellular 
concentration of paclitaxel in cancer cells. In S. aureus, this 
compound was able to slightly potentiate the activity of 
norfloxacin in a strain overexpressing the ABC efflux pump 
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MsrA, suggesting that it may possess minimal activity over 
this pump [52]. 
The human P-gp inhibitors, vanadates, have been 
studied as inhibitors of the MutS pumps, belonging to the 
ABC ATPase superfamily. In fact, these compounds have 
demonstrated activity against the MutS in P. aeruginosa and 
E. coli. Decavanadate was the most effective, followed by 
orthovanadate (20), and they act non-competitively, possibly 
by replacing the inorganic phosphate. The fact that the ABC 
ATPases inhibited by orthovanadate are phosphorylated 
leads to the assumption that the low inhibitory effect could 
be attributed to the absence of a stable phosphorylation state 
of MutS [53]. 
 
3. MFS 
The MFS is the most extensively studied family of 
transporters, present in both Gram-positive and Gram-
negative bacteria, and comprises uniporters, symporters and 
antiporters. It also constitutes the largest family of secondary 
transporters, with over 10 000 sequenced members. Its 
substrates are diverse, and can range from ions, to 
carbohydrates, lipids, amino acids, nucleosides, among 
others. As many members of the MFS originate bacterial 
MDR, these transporters can pose as a good system for 
modulation studies [7, 19, 38, 54]. 
With the elucidation of the crystal structure of the MFS 
pump EmrD of E. coli (Figure 4, PDB 2GFP) [55], a general 
structure could be proposed for MFS transporters: twelve 
transmembrane helices that form a compact structure, with 
four of these transmembrane helices facing away from the 
interior cavity and the rest forming the internal cavity, 
constituted mostly by hydrophobic residues [7]. 
The efflux of drugs is only possible if the carrier alternates 
between two conformations, so that the substrate can bind to 
the convenient site in either side of the membrane. However, 
a limitation concerning the energy involved to displace the 
exposed hydrophilic surface of a protein can be inferred. It 
has been proved that either the oligomerization domain or 
the transport subunit provide the support needed to the 
movement of the substrate binding site, through a rigid-body 
rotation of the substrate binding domain, referred to as the 
“elevator mechanism” [56-57]. For this family, the most 
extensively studied efflux pump is the NorA pump of S. 
aureus. 
The inhibitors that have proven activity against efflux pumps 
of the MFS family are gathered in Figure 5. 
 
3.1. MFS inhibitors 
3.1.1. Natural Products and Derivatives 
Terpenes and terpenoids, existent in the essential oils of 
plants, have showed promising therapeutic potential in 
various fields. Therefore, studies about EPI potential of these 
compounds were carried out. Monoterpenes nerol (21), 
estragole (22), and dimethyl-octanol (23) were tested against 
S. aureus. Compounds 21 and 23 were able to enhance the 
activity of norfloxacin, decreasing its MIC against the NorA 
overexpressing strain while not displaying intrinsic 
antibacterial activity. These open chain terpenes proved to be 
more effective than 22, which carried a benzene ring, at 
inhibiting the NorA pumps [58]. 
Citronellal (24) and citral (25) are monoterpenes, and were 
chosen as starting material for the synthesis of new amide 
derivatives. The basis for this study was the fact that 
aromatic amides are recognized as potent EPIs, whereas 
alkyl, alkenyl, and alkynil amides had not yet been explored. 
The compounds obtained were 5,9-dimethyldeca-2,4,8-
trienoic acid amides and 5,9-dimethyldeca-2,8-dienoic acid 
amides, whose activity for the potentiation of ciprofloxacin 
in S. aureus was assessed. Of the first 22 synthesized 
compounds, seven were able to reduce ciprofloxacin’s MIC 
by 4-fold. Further modifications were performed, and the C-
9 methyl group was replaced by an amide, yielding 
compounds with similar potency as the previous ones. 
Derivatives subjected to hydrogenation led to decreased 
activity, which reveals that unsaturation is an important 
feature for antimicrobial potentiation. The mechanism of 
inhibition was assessed through ethidium bromide efflux, 
confirming these compounds act by inhibiting NorA, being 
compound 26, a 9-formyl-5-methyldeca-2,4,8-trienoic acid 
amide, the most potent inhibitor [59]. 
Ferruginol (27), a diterpene, showed efficiency in inhibiting 
the efflux of ethidium bromide, proving its activity as a 
NorA inhibitor. It also showed a decrease in norfloxacin 
efflux in S. aureus [60]. Totarol (28), a phenolic diterpene, 
also showed a reduction in ethidium bromide efflux, 
suggesting activity against NorA pump, even though its 
mechanism is not yet known [61]. 
The triterpene ginsenoside 20(S)-Rh2 (29), a trace compound 
from red ginseng, also enhanced the effect of ciprofloxacin 
against S. aureus, through a NorA-mediated efflux 
inhibition, promoting the antibiotic accumulation in the 
bacteria [62]. 
Reserpine (30) is a natural alkaloid derived from Rauwolfia 
vomitoria, known as an anti-hypertensive agent, with 
inhibitory activity against human P-gp and breast cancer 
resistance protein (BCRP) [63-64]. Reserpine (30) has 
proven to be an effective inhibitor of the Bmr multidrug 
transporter in Bacillus subtilis, diminishing the efflux of 
ethidium bromide. Its structural analogue rescinnamine also 
had EPI activity, in a smaller extension than reserpine (30) 
[65]. Through DNA sequencing of the bmr genes of mutants, 
it was shown that reserpine (30) interacts with the residues 
Phe-143, Val-286, and Phe-306 of Bmr pumps, inhibiting 
drug transport [19]. Compound 30 has shown potential as an 
EPI for the inhibition of NorA efflux pumps in S. aureus, 
which are structurally related to Bmr pumps, reversing 
susceptibility to fluoroquinolones, demonstrating reductions 
up to 4-fold in MIC for some tested strains. It has been 
shown that 30’s effect is more pronounced in hydrophilic 
fluoroquinolones, such as ciprofloxacin [66].  The 
mechanism by which 30 performs the inhibitory activity is 
through direct binding to the transporters that mediate drug 
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efflux, acting as a competitive inhibitor [19, 67]. Reserpine 
(30) also succeeded in inhibiting the chloramphenicol efflux 
by CmlR1 and CmlR2 of Streptomyces coelicolor, the 
ciprofloxacin and norfloxacin efflux in Listeria 
monocytogenes’s pump Lde, and the kanamycin and fusidic 
acid efflux by LmrS from a MRSA clinical isolate. On the 
other hand, for L. monocytogenes, 30 was not able to reverse 
susceptibility to linezolid and lincomycin, which suggests 
that 30 does not completely overlap with the structure 
binding sites of efflux pumps, being the inhibition dependent 
on the type and nature of the substrate [19]. However, 
reserpine (30) shows neurotoxicity at the concentration 
required to inhibit NorA, leading to the need to investigate 
new inhibitors [67]. 
Piperine (31), an alkaloid found in the fruits of Piper nigrum, 
was found to be an inhibitor of ciprofloxacin efflux in S. 
aureus, reducing the MIC by 2-fold. It is thought that 
compound 31 acts as a direct inhibitor of drug efflux. 
Compound 31 inhibits drug transport of the pump MdeA, 
potentiating the effects of benzalkonium chloride, 
doxorubicin, daunorubicin, novobiocin, 
tetraphenylphosphonium chloride, rhodamine 6G, 
virginiamycin and mupirocin [17, 19-20]; it also inhibits 
ciprofloxacin efflux by NorA [68]. 
Given these positive results obtained with piperine (31), 
further research into this scaffold was performed. Kumar et 
al. (2008) performed a screening of about 200 structurally 
diverse compounds for the inhibition of NorA efflux pump, 
choosing ethidium bromide as a substrate, since the only 
mechanism through which this compound is expelled is 
active transport (68). About 50 compounds were able to 
increase the intracellular concentration of ethidium bromide 
by 4-fold, while not displaying antibacterial activity. Five of 
these compounds were more potent than piperine (31), being 
three of these compounds selected for further studies: 32, 33, 
and 34, being 32 and 34 more potent than 31 by 40-fold [18, 
68]. Assumptions regarding structure-activity relationship 
(SAR) studies of these molecules could be drawn (Figure 6). 
It was demonstrated that the introduction of an alkyl group at 
C-4 position, mainly an isopropyl, isobutyl or di-isopropyl 
group, coupled with the substitution of the piperidinyl 
moiety with an aromatic amine, such as aniline, would lead 
to maximum potentiation of ciprofloxacin; if the anilinyl 
moiety is substituted with a 2-hydroxymethyl group or a 
nitrile, regardless of the positional isomery, ciprofloxacin 
activity would increase. Replacing the piperidinyl moiety 
with a phenylacetamide yields good potentiation of 
ciprofloxacin, reducing its MIC by 4-fold, regardless of the 
isomery. Unsaturation is crucial for the potentiation, as well 
as the amide. Lastly, the retention of 3,4-
methylenedioxyphenyl or 4-methoxyphenyl groups in the 
1,3-benzodiol moiety also gives favorable results [68-70]. 
Plants of the Berberis species have the ability to produce the 
alkaloid berberine, which is a plant secondary metabolite 
produced in response to microbial invasion, whose activity is 
enhanced by a flavolignane also produced by these species, 
5’-methoxyhydnocarpin (35) [71]. Compound 35 exists in a 
mixture of anion and neutral compound at physiological pH, 
since it has a phenolic group with a pKa of 7.3. Due to the 
acidic properties of this 7-OH group, 35 is likely to be a 
specific microbial MDR inhibitor, as flavonoids with P-gp 
inhibitor properties usually possess alkylated 7-O groups. In 
fact, when added to a wild type strain of S. aureus, 
compound 35 caused a decrease in norfloxacin’s MIC to 
0.25 µg/ml. Furthermore, when tested with berberine and 
palmatine, 35 appeared to completely inhibit NorA, 
suggesting it acts as a non-competitive inhibitor [71]. 
A number of hydnocarpin-type flavolignanes were 
synthesized in order to perform SAR studies. Flavolignanes 
with and without phenolic groups at the 5 and 7 positions 
had comparable activity. Diosmetin (11), the parent 
compound, presents hydroxyl groups in the A ring and was 
the most potent compound. Peracetate derivatives of 35 have 
approximately the same potency as their parent compounds, 
and could be considered prodrugs, if deacetylated by S. 
aureus, which seems unlikely. Considering the D ring, 
compounds bearing a 3’’-methoxy-4’’-hydroxy moiety 
displayed good activity, and 3’’,5’’-dimethoxy-4’’-hydroxy 
moieties conferred a slightly less active compound. As for 
the B ring, the presence of an H or an OH is not critical for 
activity [72]. In addition, a flavone isolated from Alkanna 
orientalis, sarothrin (36), blocked ethidium bromide efflux 
by S. aureus, suggesting its potential activity as a NorA 
inhibitor [73]. 
Biochanin A (37), an isoflavone, also showed potentiation of 
norfloxacin and berberine against wild-type S. aureus and 
Bacillus megaterium. An analogue of luteolin, orobol (38), 
was quite active as a NorA inhibitor, unlike luteolin itself. It 
was shown that flavones which have a single methoxy in its 
B-ring are more potent than flavones with two methoxy 
groups in the B-ring [74]. 
Another flavone, baicalein (39), was capable of potentiating 
the effect of ciprofloxacin in S. aureus. Studies aimed at 
measuring the efflux of ciprofloxacin and pefloxacin, a poor 
NorA substrate, were performed, and showed that compound 
39 was much more potent at restoring ciprofloxacin 
sensitivity than pefloxacin, leading to the conclusion that this 
flavone acts as a NorA efflux inhibitor, even though its 
mechanism remains unknown [75]. 
Maia et al. (2011) identified six flavonoids from the plant 
Praxelis clematidea: apigenine, genkwanin, 7,4’-
dimethylapigenin, trimethylapigenin, cirsmaritin, and 
tetramethylscutellarein (40) [76]. These methoxylated 
flavones showed no antibacterial activity, but were able to 
reduce the MIC of norfloxacin at least by 2-fold and up to 
16-fold, as was the case of 40, at a concentration of 8 µg/ml, 
being therefore considered NorA efflux pump modulators. It 
is thought that the lipophilicity of the flavonoids, 
strengthened by the presence of methoxyl groups, is 
responsible for this activity [21]. Presence of a methoxy in 
the 4’ position proved to be decisive for activity, as 
flavonoids containing this group were more potent. The 
number of methoxy groups is also essential for potency, 
being the most metoxylated compounds the most active [76]. 
Tiliroside (41), an amphipathic kaempferol glycoside, 
reduced the concentration of antibiotic needed to inhibit the 
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growth of bacteria. The lipophilicity of the flavone moiety 
may be a determinant factor for the activity displayed. 
Tiliroside (41) showed no antibacterial activity against S. 
aureus, but showed a decrease in the MIC of 
fluoroquinolones up to 16-fold, when at a concentration of 
64 µg/ml. The reduction in the MIC of biocides, such as 
ethidium bromide and benzalkonium chloride, was 
impressive, with the MIC of acriflavine showing a decrease 
by 128-fold at the concentration of 64 µg/ml and 32 µg/ml. 
These results suggest that 41 might additionally act on 
pumps other than NorA [77]. 
Kaempferol 3-O-α-L-(2, 4-bis-E-p-coumaroyl)rhamnoside 
(42) was also able to potently inhibit in a concentration 
dependent manner NorA-mediated ethidium bromide efflux 
in S. aureus. This compound also increased the antibiotic 
effect of norfloxacin against a wild-type and a NorA 
overexpressing strain of S. aureus. However, it has to be 
considered that 41 and 42 are flavonoid glycosides and 
cinnamoyl esters, and that their activity can become 
compromised with the activity small intestine β-glucosidases 
or plasma esterases, even though the activity might possibly 
lie in the kaempferol moiety, with 41 and 42 acting as 
prodrugs. The authors hypothesized that if the activity of 
compound 42 is compromised, this compound could be used 
as adjuvant of ciprofloxacin for topical infections [78]. 
Since 42 showed promising results as a NorA EPI, the same 
group performed a screening of a library of 117 chalcones, 
due to their structural similarities with the coumaroyl 
substituents [79]. Ten out of the 117 screened chalcones 
presented medium efflux inhibition at 20 µg/ml. The most 
potent chalcones, such as 43, bear a dimethylaminoethoxy 
moiety, which might disrupt the proton gradient, thus 
eliminating the energy source of NorA. Five of these 
chalcones possessed a hydroxyl group at the 4’-position, and 
potentiated the activity of berberine against S. aureus and B. 
cereus, suggesting that this substituent is also important for 
activity. The compound with a methoxy group at position C-
2 has shown to present the best activity. The majority of 
chalcones tested showed a 4-fold reduction of 
ciprofloxacin’s MIC in S. aureus, suggesting the presence of 
a NorA efflux pump inhibitory activity. Compound 43 
showed 8-fold and 16-fold reduction of the MIC of 
ciprofloxacin at 6.25 and 12.5 µg/ml, respectively. However, 
it also showed antibacterial activity at 25 µg/ml. Some 
chalcones also presented antiparasitic activity, namely 
against Leishmania major and Plasmodium yoelii [79]. 
Another chalcone, 4’,6’-dihydroxy-3’,5’-dimethyl-2’-
methoxychalcone (44), showed good activity as a MDR, 
causing complete growth inhibition at a very low 
concentration (3.3 µg/ml) when combined with a sub 
inhibitory concentration of berberine. When tested in 
combination with berberine, erythromycin, and tetracycline 
against strains of S. aureus, there was an increase in the 
activity of all tested compounds in the wild-type S. aureus, 
indicating a mode of action likely related to the NorA pump. 
This compound was also tested against B. cereus, 
potentiating the effects of the tested antibiotics as well, and 
displaying a favorable effect, particularly in the case of 
berberine, where a 30-fold increase in the activity was 
observed [80]. 
Pheophorbide A (45) is an intermediate of the natural 
breakdown of chlorophyll. Concentrations as low as 0.5 
µg/ml of pheophorbide A with sub-inhibitory concentrations 
of berberine were enough to completely inhibit S. aureus 
growth.  When extended to fluoroquinolones, this compound 
also proved efficient in potentiating the effect of norfloxacin 
by 4-fold in a wild-type strain, being its action directed 
towards NorA [81]. 
Orizabins, oligosaccharides from resin glycosides, were 
evaluated for their efflux pump inhibitory activity on strains 
of S. aureus. These amphipathic compounds showed synergy 
with norfloxacin, whilst showing no antibacterial activity by 
themselves. Orizabin IX (46) completely inhibited the 
growth of a NorA overexpressing strain at 1 µg/ml, while 
orizabin XIX (47) reversed norfloxacin resistance by 4-fold 
at 25 µg/ml for the same strain [82]. Murucoidins, which are 
also resin glycosides, strongly potentiated the action of 
norfloxacin against a S. aureus NorA overexpressing strain 
by 4-fold at concentrations ranging from 5 to 25 µg/ml. 
Stoloniferin I potentiated the same activity by 8-fold at a 
concentration of 5 µg/ml [83]. 
A study aiming to find new EPIs from the plant Geranium 
caespitosum led to the isolation of novel acylated 
neohesperidosides. It was found that two compounds, 
compound 48 and 49, were successful at restoring 
susceptibility to berberine, norfloxacin, and ciprofloxacin at 
sub inhibitory concentrations, possibly due to NorA 
inhibition [84].  
Capsaicin (50), the major constituent of the fruits of the 
Capsicum genus, is a known P-gp inhibitor. Studies were 
performed, in order to evaluate if its inhibitory activity was 
also applied to MDR pumps in bacteria. In a strain of S. 
aureus overexpressing the NorA efflux pump, and therefore 
resistant to fluoroquinolones, 50 proved efficient in 
increasing the susceptibility to ciprofloxacin, while reducing 
the emergence of ciprofloxacin-resistant mutants. Molecular 
modelling studies of the complex capsaicin (50)-NorA, using 
the glycerol-3-phosphate transporter to predict the structure 
of NorA, showed that compound 50 aliphatic chain extended 
into NorA’s hydrophobic cleft. Furthermore, a weak 
hydrogen bond between Arg-98 and the aryl hydroxyl 
contributed to the stability of the complex [85]. 
Studies in the aqueous extract of Artemisia absinthium 
showed promise in the inhibition of MDR efflux pumps. It 
was proven that this activity came from caffeoylquinic acids. 
At a concentration of 20 µM, 4’-5’-O-dicaffeoylquinic acid 
(51) potentiated the activity of berberine by 16-fold and of 
norfloxacin, by 10-fold against a wild-type strain of S. 
aureus, while not displaying effects in a norA-deleted strain, 
confirming this compound’s NorA inhibition ability [86]. 
Olympicin A (52) is an acylphloroglucinol, found in the 
aerial parts of Hypericum olympicum. This molecule had 
some efflux impeding ability, proven by the improvement of 
intracellular accumulation of enoxacin in a NorA 
overexpressing strain of S. aureus, at 50 µg/ml [87]. 
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Riparins are natural alkylamides found in the plant Aniba 
riparia. Since the extraction of these compounds comes with 
very low yields, synthetic approaches were developed. As 
such, the fundamental core of riparins, Rip-A (53), was 
synthesized and derivatives were prepared, Rip-B (54) to E 
(55). Rip-E (55) showed good growth inhibitory activity 
against S. aureus, attributed to their lipophilic nature and the 
presence of hydroxyl groups at the benzamide moiety. 
Oppositely, Rip-B (54), with two methoxy groups at the 
phenyl-ethyl moiety did not present antibacterial activity, 
presenting instead a decrease in the MIC of ciprofloxacin 
and norfloxacin, similarly to reserpine. Combined with the 
ability of decreasing ethidium bromide’s MIC, the activity of 
compound 54 was attributed to NorA inhibition, suggesting 
its potential as an EPI [88]. 
Extracts of Mirabilis jalapa have shown good results in 
reversing fluoroquinolone resistance in strains of S. aureus 
overexpressing the NorA efflux pump. One compound in 
particular, N-trans-feruloyl-4’-O-methyldopamine (56), 
caused an 8-fold reduction in the MIC of norfloxacin, 
making it a potential lead in the search for structurally 
similar synthetic alkylamines [89]. 
Synthesis of derivatives was undertaken, taking N-trans-
feruloyl-4’-O-methyldopamine (56) as a model. The aim was 
to identify active compounds from natural sources and, as 
such, couplings between cinnamic acid derivatives and 
natural-occurring amines were chosen. SAR criteria was 
taken into account, as it is known that substitution of the 
aromatic rings, methoxy or hydroxyl substitution, double 
bonds and aromatic ring nature in the amine part influence 
the activity. The lead compound was N-trans-3,4-O-
dimethylcaffeoyl dopamine (57) since it showed the same 
activity as the natural compound. It was found that, for the 
cinnamic moiety, a hydroxyl substitution on the aromatic 
ring appears to be better than a methoxy group or 
unsubstituted derivatives and the double bond is essential for 
activity. As for the amine part, trisubstitution on the aromatic 
ring increases antibacterial activity, at the cost of decreased 
efflux pump inhibition. Methoxy substitution yields 
compounds with better results than hydroxyl substitution, 
which was better than no substitution and tryptamine 
combinations showed the best results (Figure 7). Among the 
compounds tested, compound 58 showed potentiation of 
norfloxacin comparable to that of reserpine (30). At a 
concentration of 30 µM, 58 showed good results for the 
inhibition of ethidium bromide efflux. For these compounds, 
it was shown that the activity reaches its highpoint when the 
phenyl ring is substituted with two hydroxyls [89]. 
Grapefruit oil fractionation led to the isolation of three 
compounds, two coumarin derivatives and one bergamottin 
derivative. The bergamottin epoxide (59) showed a reduction 
of ethidium bromide’s MIC by 6-fold on different MRSA 
strains, and a 20-fold reduction in norfloxacin’s MIC. This 
reduction was also achieved when the coumarin epoxide (60) 
was present, and suggests an activity towards NorA efflux 
pumps [90].  
Coumarins isolated from Mesua ferrea were also studied for 
their efflux pump inhibitor activity against clinical strains 
and NorA overexpressing strains of S. aureus. Seven 
coumarins were tested, and showed good results in inhibiting 
ethidium bromide efflux. Two compounds, 61 and 62, 
showed potential EPI activity against the NorA 
overexpressing strain and a MRSA strain, using norfloxacin 
as a substrate, which makes them desirable compounds for 
the synthesis of derivatives [91]. 
Screening of natural products with P-gp inhibitory effects 
(92, 93) led to the identification of two compounds with 
NorA inhibitory activity, osthol (63) and curcumin (64) [36, 
92-93]. Curcumin (64), derived from the rhizomes of 
Curcuma longa, has additionally already shown activity as 
an anti-inflammatory, antioxidant, antiviral, and anticancer 
agent [36, 92-93]. These compounds were effective in 
reducing the MIC of ciprofloxacin by 4- and 8-fold, 
respectively [94]. 
A penta-substituted pyridine, 2,6-dimethyl-4-phenyl-
pyridine-3,5-dicarboxilic acid diethyl ester (65), was isolated 
from the rhizomes of Jatropha elliptica. This compound, 
when in association with ciprofloxacin, showed a strong 
effect against NorA efflux pumps in S. aureus [95]. 
A methanol extract of the plant Dalea spinosa yielded the 
isolation of six compounds, whose EPI potential was 
analyzed against wild-type S. aureus and mutant strains. It 
was shown that spinosan A (66), at a concentration of 48 
µg/ml, and its acetate 67, at a concentration 42 µg/ml, were 
able to decrease berberine’s MIC by 8- and 62-fold, 
respectively, against the wild-type. Other compounds were 
also able to reduce berberine’s MIC, but to a lesser extent. 
Compound 67 also managed to decrease berberine’s MIC in 
the NorA overexpressing strain, suggesting inhibitory 
activity in this efflux pump [96]. 
 
3.1.2. Synthetic Compounds 
The INF series (compounds 68-72) resulted from an initial 
screening of 9600 structurally diverse compounds, in order 
to find NorA inhibitors for B. subtilis, not expressing Bmr. 
The NorA substrate chosen was ethidium bromide [67]. 
Since this screening did not focus on a specific chemical 
group, the most active compounds were divided into several 
groups. Several indole derivatives were active, which did not 
come as a surprise, since reserpine (30) itself has an indole 
moiety. Another large group was the trichloromethylaminal 
containing compounds, which were not further explored as 
their likelihood to be toxic was high. Biphenyl urea 
derivatives were also active, and other compounds, with no 
obvious similarities, showed activity as well. Five 
compounds were selected for further tests, INF 55 (68), INF 
240 (69), INF 271 (70), INF 277 (71) and INF 392 (72). 
These compounds were active at concentrations of 5 µg/ml 
or less, and included the most potent compound, 72, the most 
potent indole, 68, and the most potent biphenyl urea, 71. 
Derivative 72 was able to reduce resistance to ethidium 
bromide and ciprofloxacin by 8-fold at a concentration of 0.4 
µg/ml. All five inhibitors were more potent than reserpine 
(30) at promoting the activity of ciprofloxacin in S. aureus 
and, by being structurally different, it was hypothesized that 
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a potent, nontoxic lead would be identified. These 
compounds also proved effective in inhibiting the Bmr 
multidrug transporter in B. subtilis and two compounds, 68 
and 71, also enhance fluoroquinolone activity in 
Streptococcus pneumoniae [67]. 
The results obtained with INF 55 (68) in S. aureus as an 
inhibitor of the NorA efflux pump led to an increased 
interest in this kind of scaffold. SAR studies regarding the C-
5 proved that substitution in this carbon is crucial for 
activity. Substitution with a nitrile group leads to retention of 
potency, and carbonyl based electron-withdrawing groups at 
C-5 would result in molecules with no activity [97]. Three 
dimensional-quantitative structure-activity relationship (3D-
QSAR) studies predicted that 2-aryl indole derivatives would 
be NorA inhibitors. Functionalized INF 55 (68) showed a 
decreased MIC for berberine, a MDR transporter substrate. 
Berberine is an amphipathic cation alkaloid. From the series 
of 2-aryl-5-nitroindoles synthesized by Samosorn et al. 
(2009), the alcohol 73 was the most effective in inhibiting 
berberine efflux, as well as other antibiotics, such as 
ciprofloxacin, in S. aureus [98]. Later, the same group 
developed a strategy that consisted in a molecule presenting 
dual action: an antibiotic and a MDR inhibitor. Therefore, 
they combined berberine, a hydrophobic cation that is a 
MDR substrate, with INF 55 (68), a MFS inhibitor. These 
efforts yielded compound 74 [17-18, 99]. In terms of 
antibacterial activity in S. aureus, the hybrid was about 100 
times more active than berberine alone, and the difference 
was even higher when tested against a NorA overexpressing 
strain of S. aureus. Enterococcus faecalis also presented 
resistance to berberine, but was susceptible to 74. [99] 
Synthesis of sulfur derivatives was achieved based on the 
premise that the activity of 68 is less dependent on the nitro 
group than the 2-arylindole. Benzothiophene, thiophene, and 
benzofuran derivatives, such as compounds 75, 76, and 77, 
respectively, were able to synergize with ciprofloxacin and 
ethidium bromide, increasing their intracellular 
concentration and leading to the conclusion that these 
compounds inhibit NorA in S. aureus. [100]  
Taking into account the fact that the indole NH is not 
essential for efflux pump inhibition, Samosorn et al. (2009) 
simplified the indole moiety of berberine-based hybrids, 
along with the effect of a methylene ether linking group. 
Their results showed that a hybrid molecule with oxygen in 
the linkage chain had stronger antibacterial and MDR pump 
inhibitory activity than the original 74 [101]. On the other 
hand, removal of the indole moiety produced compounds 
with lower dual activity, and this structural simplification led 
to compounds with low antibacterial activity, but with 
retained NorA pump inhibitory activity. These data suggest 
that while the indole moiety is not necessary for NorA pump 
inhibition, it is required for the antibacterial activity of 
hybrid compounds [101]. 
A recent study identified a novel class of NorA EPIs with a 
polysubstituted indole moiety. Twenty molecules were 
highly active in inhibiting ethidium bromide efflux in S. 
aureus. However, the best results were obtained with 
compounds 78 and 79, which were derivatives that presented 
three and four carbon atom chains, respectively. Compound 
78 presented the best half maximal inhibitory concentration 
(IC50), with a concentration of 1.8 µM. Compound 79 
exhibited similar IC50 (2 µM) and ethidium bromide 
inhibition as 78. Compounds with shorter or longer carbon 
chains did not present such good results, leading to the 
conclusion that three or four carbons make up the right 
distance between the indole scaffold and the basic center, 
thus presenting the best inhibitory effect. When tested for 
their synergy with ciprofloxacin, both 78 and 79 were able to 
restore the antibiotic’s activity [102]. It was found that the 
substitution of the C-5 in the indole results in a potent EPI, 
particularly if there is a propoxyl chain carrying terminal 
cyclic amino groups, which appears to be crucial for NorA 
inhibition at low concentrations. The presence of the N-
benzyl moiety preserves inhibition and contributes to the 
modulation of the biological effects and ADME properties, 
depending on its substituents [103]. 
Another successful example of a hybrid antibacterial/EPI is 
the fluoroquinolone scaffold accommodating a bis-aryl urea 
EPI moiety at the C-7 position. This kind of compounds was 
successful in inhibiting NorA pumps in S. aureus. 
Compound 80, which incorporates a bis-aryl urea motif into 
the ofloxacin core, proved to be a potent inhibitor of MFS 
efflux pump systems, achieving 84 % inhibition rate at 10 
µM. Moreover, these compounds also successfully inhibit 
MepA pump systems from the MATE family [17-18, 104]. 
Fluoroquinolones containing a thiopyranopyridine moiety at 
the C-7 position were synthesized and their activity was 
tested against strains of S. aureus. However, these 
derivatives did not seem to be NorA substrates. Further 
investigations into thiopyranopyridinylquinolone esters were 
carried out. Some of the synthesized compounds displayed 
better inhibitory activity than reserpine (30), namely 
quinolone esters 81, 82 and 83, and showed significant MIC 
reduction of ciprofloxacin.  Compounds 82 and 83 also 
showed a 32-fold MIC reduction of ciprofloxacin for strains 
of S. aureus overexpressing MepA pumps from the MATE 
family [18, 105]. In terms of established SAR, these 
compounds definitely do not need the fluorine atom at the C-
6 position for the antibacterial activity of 
thiopyridinylquinolones. A methyl at the C-8 position yields 
a compound with enhanced activity against Gram-positive 
bacteria for 6-amino derivatives. The thiopyranopyridine 
moiety at the C-7 position is crucial for NorA and MepA 
inhibition (Figure 8) [105]. 
Derivatives of 2-(4-propoxyphenyl)quinolone were 
synthesized based on the premise that its large hydrophobic 
area and ability to establish an electrostatic interaction would 
make them suitable inhibitors of NorA. These derivatives 
also mimic the quinolone antibacterial core and possess a 
versatile scaffold, making it prone to be very simply 
chemically modified. These classes of compounds were 
obtained by performing modifications in the 2-phenyl-4H-
chromen-4-one moiety, which is a common feature of 
flavone and flavolignane EPIs [106]. 
Studies showed that the O-substituted 2-phenyl-4-
hydroxyquinoline derivatives displayed the best activity as 
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NorA inhibitors. Compounds 84 and 85 showed synergistic 
activity against a strain of S. aureus overexpressing NorA 
efflux pumps comparable to reserpine (30) and, comparing 
the results obtained with a mutant strain, absent of NorA, it 
was found that these compounds are able to completely 
restore the antibacterial activity of ciprofloxacin in the 
resistant strain [18, 106]. Preliminary SAR studies for this 
new class of EPIs showed that the best activity is when the 
quinolone core is replaced with the 2-phenyl-4-
hydroxyquinoline group with an alkylation in the C-4 
hydroxyl group. 2-Ethylamino chains inserted at the N-1 
position of the quinolone nucleus or at the C-4 hydroxyl of 
the quinoline moiety provided compounds with better 
activity than those carrying the same chain at the C-2 of the 
phenyl ring. The best substituent for the C-2 phenyl ring 
appears to be the C-4’ propoxy group (Figure 9) [106]. 
Taking these results into account, efforts have been placed to 
obtain more potent NorA inhibitors, introducing O-alkyl or 
different O-alkylamino chains at the C-4 position. The 
strategy was to determine the essential 3D structural 
requirements for the inhibition of NorA, based on the NorA 
EPIs described in literature through the use of computational 
methods, since the 3D structure of this pump was not 
elucidated yet. The results led to the building of a possible 
pharmacophore, which was used to design novel compounds, 
with different substituents at the C-4 position, which were 
synthesized and biologically evaluated [107]. The 
compounds were assayed for their ability to reduce the MIC 
of ciprofloxacin in S. aureus strains, and all compounds 
displayed this decrease for the strain overexpressing NorA 
pumps. One compound in particular, 86, showed a 16-fold 
reduction in this strain for ciprofloxacin’s MIC. SAR studies 
for this emerging class show that the best activities come 
from the compounds bearing the 2-ethylaminoalkyl chains 
linked to the C-4 hydroxyl group, such as compound 87. The 
inclusion of an aliphatic ring including the side chain 
nitrogen atom led to retention of activity, whereas inclusion 
in an aromatic ring led to loss of activity, where the nitrogen 
nucleophilicity was reduced. The mono-substituted 
compounds, like 88, with a benzyl group were well tolerated, 
and showed higher ethidium bromide inhibitory activity than 
compounds with two benzyl groups as substituents (Figure 
9) [107]. 
3-(Dihydronaphtyl)-propenoic acid amines were evaluated 
for their EPI activity. Five compounds were synthesized, and 
two of them showed good results in inhibiting ciprofloxacin 
efflux in strains of wild-type and NorA overexpressing S. 
aureus. Further studies were performed, given the low EPI 
activity of this kind of compounds. Fifteen different 
compounds were synthesized, taking α-tetralone (12) as 
starting material. Out of these, four compounds showed 
significant MIC reductions for ciprofloxacin for the NorA 
overexpressing strain. One compound, 89, even displayed a 
16-fold reduction, while other remained in the range of 4- to 
8-fold. These studies allowed SAR to be established. 
Addition of methoxy or allyloxy substituents at the 6,7-
position of the 3,4-dihydronaphtalene leads to lower or no 
activity, whereas no substitution originated better EPIs. 
Saturation of the double bonds lowered the potentiating 
activity (about 2-fold), while unsaturated derivatives made 
much more potent compounds [108]. 
Boronic species have been described for a variety of 
activities, namely antimicrobial and antineoplasic. 
Organoboron compounds, oxazaborolidines, boronic esters, 
and boronic acids are of particular interest, within this class. 
Fontaine et al. (2014) developed studies on these molecules, 
starting from a screening of a library of approximately 150 
compounds, out of which 24 were hit compounds 
(exemplified with compounds 90 and 91), and were able to 
restore the activity of ciprofloxacin by 4-fold at 
concentrations of 0.5 to 8 µg/ml against the NorA 
overexpressing strain of S. aureus [109]. Preliminary SAR 
studies demonstrated the need of the boron atom for activity. 
Most pyridine-3-boronic acids showed best potentiating 
activity (e.g., compound 90), whereas pyridine-4-boronic 
derivatives showed no activity, with exceptions, including a 
fluorinated ester. The shift of the boronic moiety from C-3 to 
C-4 led to a loss of activity and the trigonal boronic acid 
function gave better results that the sodium boronate salts 
and the potassium trifluoroborate. Concerning the pyridine-
3-boronic acids, the most promising compounds appear to be 
the 6- and the 5,6-disubstituted ones, being the latter 
compounds less potent. Cyclisation at the C-5 and C-6 
positions was well tolerated, as was the introduction of a 
methyl at the C-5 position. For the benzene analogues, which 
displayed good activity, cyclisation at the C-3 or C-4 was 
also well tolerated, as was the introduction of a methyl. A 
substituent at the para position to the boronic moiety proved 
to be very important. Two compounds were particularly 
efficient in inhibiting NorA, and did not display intrinsic 
antibacterial activity and cytotoxicity: the 6-
benzyloxypridine-3-boronic acid 90, which displayed the 
highest activity, potentiating ciprofloxacin by 4-fold at a 
concentration of 16 µg/ml, and the 4-benzylxybenzene 
boronic acid 91 [109]. 
Compound 90, being the most promising compound, was 
considered a hit, and its structure was used as a model for the 
synthesis of new derivatives. Therefore, the 6-benzyloxy 
group was substituted with (aryl)alkoxy chains with variable 
lengths (compounds 92 and 93 as examples), in an attempt to 
explore the putative hydrophobic binding site of NorA, and 
substituents were added to the phenyl ring. The ether linkage 
between the pyridine ring and the 6-benzyloxy group was 
substituted as well. The first substitution made was the 
replacement of the 6-benzyloxy group with alkoxy chains of 
diverse lengths, as to explore the size of the hydrophobic 
pocket of NorA. The potency of the compounds increased 
with the increase of the size of the side chain, although the 
compound with a 11-carbon side chain displayed no activity 
whatsoever. A new series of compounds with a phenyl ring 
at the end of the side chain were synthesized, with the aim of 
enhancing hydrophobicity, and the results showed these 
compounds were more efficient. It was concluded that the 
compound with the best performance possessed a side chain 
with seven carbon atoms and a phenyl group: compounds 92, 
6-(3-phenylpropoxy)pyridine-3-boronic acid, and 93, 6-(4-
86 
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phenylbutoxy)pyridine-3-boronic acid, showed the highest 
activity in the potentiation of ciprofloxacin (4-fold). The 
introduction of substituents in the phenyl ring of compound 
90 led to unsatisfactory results, with the best compound 
displaying moderate antibacterial activity. A methyl group in 
the C-5 position did not show influence on the activity, and 
the modification of the ether linkage led to varied effects: 
introduction of a sulfanyl, thus conserving the H-bonding 
acceptor capacity, led to similar potentiating activity, 
whereas the introduction of an amine linkage, an H-bond 
donor, led to a decrease in the activity. Finally, the shift of 
the benzyloxy group from the C-6 to the C-5 resulted in no 
activity [110]. 
Compounds AE-848/42434549 (94) and AN-465/42885978 
(95) were hits in a virtual screening of novel NorA efflux 
pump inhibitors in S. aureus. The structures deemed as 
active in silico were later synthesized and evaluated on their 
ability to prevent ethidium bromide efflux, as well as 
ciprofloxacin potentiation. Compound 94 and 95 were as 
potent as reserpine (30) for ethidium bromide efflux and 
more potent at synergizing with ciprofloxacin. These hit 
compounds 94 and 95 paved way for the synthesis of new 
analogues, which allowed SAR studies to be made, in order 
to assess which parts of their structure were determinant for 
the inhibition of NorA. For compound 94, it was shown that 
limited modifications to the sulfone and amide group do not 
cause significant changes in activity. On the other hand, 
modifications to the imidazole ring result in a reduction of 
activity. Replacement of the 1-methylpyrrole ring with a 
furan also shows a decrease in the activity of the compound. 
As for compound 95, the O-benzyl group is essential and the 
introduction of a benzyl in the secondary nitrogen leads to a 
complete loss of activity. Furthermore, the methyl group of 
the 2-(1-phenyl-1-propanol) moiety can be replaced with a 2-
(1-phenyl-1-ethanol) portion without a decrease in the 
activity [111]. 
 
3.1.3. Existing Drugs 
Several drugs already available for the treatment of various 
diseases have shown potential to be used as MFS EPIs. 
Reserpine (30), mentioned before, is one of them. Other 
drugs include verapamil, omeprazole, paroxetine and 
chlorpromazine. Even though bacterial MFS transporters and 
mammalian ABC efflux systems, as P-gp, lack structural 
homology, they share similar substrate profiles, which means 
that mammalian MDR inhibitors can also present bacterial 
efflux inhibition. However, the concentrations needed for 
efflux pump inhibition are too high, which means that toxic 
effects can arise if these compounds are used for this purpose 
[18], [112]. In fact, the addition of verapamil to 
chemotherapy was accompanied with cardiac arrhythmia and 
hypotension [113]. This leads to the requirement of 
developing analogues of these existing drugs maintaining the 
desired EPI activity at concentrations that do not display 
toxicity [112]. 
The antiarrhythmic verapamil, a known P-gp inhibitor, has 
shown moderate NorA inhibitory activity in both B. subtilis 
and S. aureus, enhancing fluoroquinolone activity [114-115]. 
However, the best results were obtained with proton pump 
inhibitors omeprazole (96) and lansoprazole. Therefore, a 
series of pyrrolo[1,2-a]quinoxaline derivatives mimicking 
the omeprazole structure (96) were designed, with the aim of 
evaluating their EPI activity against NorA. All the eleven 
derivatives showed a reduction in norfloxacin’s MIC, being 
compound 97 the most active, reducing the MIC by 16-fold 
at 128 µg/ml. These compounds did not show disturbance of 
the electrical potential and the transmembrane pH, excluding 
the alteration of the proton-dependent pump as the 
mechanism of action. Instead, it is thought that these 
compounds interact directly with NorA. It was shown that 
the benzimidazole moiety is critical for the activity of these 
compounds (Figure 10), and replacing it with an imidazole, 
a pyridine or a pyrrolo[1,2-a]quinoxaline ring resulted in 
loss of potency. Furthermore, if there is a methoxy-
substituent in the benzimidazole ring, potency increases. 
Introduction of chlorine in the C-7 of the pyrroloquinoxaline 
heterocycle provided an efficient restoration of norfloxacin’s 
bactericidal activity. Finally, the benzimidazolyl group was 
also important for activity [112].  
This was not the first time that pyrrolo[1,2-a]quinoxaline 
derivatives were described as EPIs. In fact, a previous study 
by the same group produced 12 new 4-[116]pyrrolo[1,2-
a]quinoxalines and one pyrrolo[1,2-α]thieno[3,2-e]pyrazine 
compound. Two compounds, 98 and 99, were more active 
than reserpine (30), diminishing norfloxacin’s MIC by 16-
fold in a NorA overexpressing strain of S. aureus. This study 
showed that 4-[116]pyrrolo[1,2-a]quinoxalines and their 7-
methoxy analogues were more active, in contrast with the 
chlorine- and 8-phenyl-substituted compounds, that 
presented the lowest effects. Replacement of the N,N-
diethylamino group by pyrrolidine, its isomer with restricted 
conformation, led to enhanced EPI activity, whereas 
replacing it with a piperidine ring led to more flexible and, 
consequently, less active compounds. The 
pyrrolothienopyrazine 99 moiety yielded the best results, 
suggesting that sulfur, an electron-rich atom, potentiates the 
EPI activity [116]. 
GG918 (19) was discovered in a screening program aimed to 
identify inhibitors of mammalian P-gp, and was able to 
increase the concentrations of paclitaxel. This compound did 
not present antibacterial activity against the strains of S. 
aureus tested. However, the co-administration with 
norfloxacin resulted in a 4-fold reduction in the MIC of the 
NorA overexpressing strain [52]. 
Two mammalian MDR inhibitors, biricodar (100) and 
timcodar (101), confer increased drug sensitivity to cells 
expressing both the P-gp and multidrug resistance protein 
(MRP)-1 efflux systems. They also show potentiation of 
multiple antibiotics in Gram-positive bacteria. In fact, both 
compounds were able to potentiate the activity of ethidium 
bromide against S. aureus, E. faecalis, and S. pneumoniae. 
For the specific case of S. aureus, both compounds were able 
to partially reverse fluoroquinolone resistance. The fact that 
the MIC of ethidium bromide was non-saturable for the three 
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bacteria tested suggests that 100 targets multiple efflux 
pumps [117]. 
A series of polysubstituted pyrroles was screened for their P-
gp inhibition activity, which made way for the identification 
of a lead, and the compounds were further investigated for 
their bacterial efflux pump inhibition activity. A simplified 
pyrrole alkaloid, 102, displayed dual activity as both a P-gp 
and a NorA inhibitor against S. aureus. This compound led 
to 4-fold improvement in the MIC of ethidium bromide in 
the NorA overexpressing strain. Compound 102 was also 
able to reduce ciprofloxacin’s MIC by 8-fold when at 50 µM 
[118]. 
Tariquidar (103), a third generation MDR modulator, with 
activity in inhibiting P-gp and BCRP efflux systems, has 
shown promise in inhibiting efflux pumps in S. aureus. In 
fact, this compound showed an increase of the isotopic form 
of ciprofloxacin in all investigated strains, displaying best 
results in the strain that overexpresses the NorA pump. [119] 
The class of phenylpiperidine selective serotonin reuptake 
inhibitors (PSSRI), which includes the antidepressant 
paroxetine (104), showed efflux-related potential against S. 
aureus, particularly that conferred by NorA. In fact, 
paroxetine and its isomer, 105, showed potency with respect 
to inhibition of this efflux pump against ethidium bromide. 
The isomer 105 also interfered with the accumulation of 
norfloxacin by NorA, reducing by 4- to 8-fold its MIC. [120] 
Femoxetine (106) is a paroxetine derivative, with activity as 
an EPI. [120] Studies were performed as to determine which 
moieties in paroxetine- and femoxetine-like PSSRI were 
detrimental for efflux pump inhibition in S. aureus, and 
conclusions from SAR are highlighted in Figure 11. 
Synthesis of derivatives showed that the fluorine atom on the 
phenylpiperidine moiety is not associated with the activity. 
The N-substitution of the piperidine ring yields different 
kinds of activity, suggesting that the NH group forms a 
positive binding contact with the target pump, which does 
not happen if there is a N-substitution (compound 106). The 
phenyl ether substituents also play an important role as 
determining the EPI activity. [121] 
Also for this kind of compounds, a study was performed, in 
order to conclude whether the 4-phenyl ring is required for 
EPI activity and the effects of changes in the two-atom 
aryloxymethyl linker, replacing it with a thioether, amine, 
and alkene linker portions. Compounds 107 and 108 
displayed the lowest MIC against S. aureus. Synthesis of 
multiple derivatives proved that the 4-phenyl moiety is not 
vital for EPI activity and that a variety of two-atom linker 
groups for the 3-aryl piperidine moiety can maintain EPI 
activity [122]. 
The ciclooxigenase-2 (COX-2) inhibitor celecoxib (109) has 
also received attention for its MDR inhibitory activity. There 
had been a link between COX-2 and mdr1 gene expression, 
which has consequences in cancer chemo resistance, and the 
use of celecoxib (109) reversed drug resistance. If this is true 
for mammalian efflux pumps, for bacteria there is no 
evidence of a COX-2-like gene, suggesting that celecoxib 
acts differently in inhibiting MDR in bacteria. A study was 
carried out in order to prove this hypothesis, which 
demonstrated that this drug helped in increasing sensitivity 
to antibiotics in S. aureus and Mycobacterium smegmatis. 
These effects probably occur due to the blockage of MDR 
transporters involved in the efflux of antibiotics, such as 
ampicillin, ciprofloxacin, kanamycin, and chloramphenicol. 
The observation of the accumulation of ethidium bromide 
intracellularly leads to the conclusion that this compound 
acts as a NorA inhibitor [123]. 
As celecoxib (109) demonstrated such promising activity, 
analogues were tested, which bore low or none anti-
inflammatory activity and possessed the 1,4-
dihydropyrazolo[4,3-c]-benzothiazine-5,5-dioxide nucleus. 
Ethidium bromide efflux inhibition was tested first in silico, 
and the 17 molecules that fit the chemical space 
requirements were then reduced to six, based on the activity 
prediction. These compounds were then screened for their in 
vitro NorA inhibitory activity, using an overexpressing strain 
of S. aureus. One derivative in particular, compound 110, 
showed the best activity concerning ethidium bromide efflux 
(76.9%) which is better than celecoxib (109) (64.5%). When 
in combination with ciprofloxacin, 110 displayed results 
comparable to reserpine (30) and better than paroxetine 
(104), which makes it a lead compound for the development 
of inhibitors of this kind [124]. 
Phenothiazine and thioxanthene derivatives are currently 
used as neuroleptic and antiemetic agents, and have been 
described as modest, but broad, antibacterial agents. 
Although their antibacterial activity is not enough to be 
clinically relevant, they have shown synergy with standard 
antibiotic agents, and have also been associated with the 
inhibition of eukaryotic MDR efflux pumps, such as P-gp. 
The mechanism through which these compounds exert their 
antimicrobial potentiation is not yet fully understood. 
However, it is thought that it might have to do with the 
inhibition of efflux pumps [125]. A study focusing on the 
activity of several compounds of these families against S. 
aureus was carried out, with the main aim of showing their 
potential in inhibiting NorA. The compounds tested, 
chlorpromazine, fluphenazine, thioridazine, prochlorperazine 
(111), cis(Z)-flupentixol, and trans(E)-flupentixol (112), 
displayed intrinsic antimicrobial activity and good results 
when ethidium bromide efflux was assayed against a NorA 
overexpressing strains of S. aureus. Additionally, 
phenothiazine 111 and thioxanthene 112 were also able to 
reduce the proton motor force of S. aureus, by reducing the 
transmembrane potential [125]. 
Since the phenothiazine moiety proved itself to work as a 
template for the synthesis of new MDR EPIs, it was chosen 
to be the scaffold for derivatives with improved activity. The 
logic for these studies lied in the elimination of the structural 
features that were responsible for neuroleptic activity. As 
such, drastic modifications were made, such as the 
elimination of one ring of the tricyclic benzothiazine 
backbone and of the chain linked to the N-10 atom, a tertiary 
amine whose protonation is crucial for the interaction with 
the dopaminergic receptor, and the addition of a substituted 
phenyl ring at the C-3 position, to guarantee better 
lipophilicity. Therefore, a prototype of new 3-phenyl-2H-
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1,4-benzothiazines was developed. Preliminary screening on 
the derivatives using a wild-type S. aureus strain, both with 
and without ciprofloxacin, showed variable intrinsic and 
synergistic activity. Two compounds, 113 and 114, displayed 
the best activity, while displaying no and weak antibacterial 
activity, respectively. These compounds were able to inhibit 
NorA efflux of ciprofloxacin, being suggested that 114 was 
even able to completely inhibit this pump [126]. 
Thioridazine (115), a phenothiazine, was also tested for its 
antibiotic potentiation, either in racemate or in its 
enantiomeric forms. All the forms were able to reduce the 
MIC of oxacillin in S. aureus and erythromycin in 
Streptococcus pyogenes, being the L-enantiomer more 
effective in the last case [127-128]. 
 
4. RND 
RND pumps are found mostly in Gram-negative bacteria, 
being the most responsible pumps for MDR in this kind of 
organisms. They present a wide variety of lipophilic and 
amphiphilic substrates, which include several classes of 
antibiotics, antiseptics, dyes, and detergents. RND 
transporters present a unique tripartite complex, constituted 
by a minimum of twelve transmembrane segments: the 
transmembrane pump, the outer membrane channel, and the 
periplasmic adaptor protein, which puts the other two 
components in contact. This structural organization makes 
the extrusion of substrates directly into the external medium 
possible [32, 38]. Even though it has always been thought 
that RND transporters were exclusive to Gram-negative 
bacteria, it has recently been identified and characterized 
FarE in S. aureus, homolog to the AcrB protein in E. coli 
[129-130]. 
Within this family, the most studied system is the AcrAB-
TolC, from E. coli. This efflux pump is composed by three 
essential parts: a resistance-nodulation-division transporter, 
AcrB; a membrane fusion protein, AcrA; and a 
multifunctional outer membrane channel, TolC [7, 131-133]. 
It transports a wide variety of toxic compounds from the 
intracellular space directly into the medium, evading the 
periplasm, and using a proton gradient as the energy source 
[132-133]. Pseudomonas aeruginosa also possesses an 
efflux system of the RND family, the MexAB-OprM efflux 
pump, which confers resistance to a wide variety of 
antibiotics. This was the first and best characterized efflux 
system in bacteria. It was found that AcrB (Figure 12, PDB 
4ZLJ) is homolog to MexB (Figure 12, PDB 2V50), being 
their structure very similar [7, 134]. 
Figure 13 comprises all the RND pump inhibitors that will 
be discussed in the following section. 
 
4.1. RND inhibitors 
4.1.1. Natural Products and Derivatives 
One study revealed that the essential oil of Helichrysum 
italicum can reduce the resistance to chloramphenicol in E. 
aerogenes, P. aeruginosa, and A. baumanii. These data 
suggested that one or more EPIs are present within the 
essential oil since it was shown that geraniol (116) produced 
significant restoration of sensitivity to chloramphenicol by 
16-fold, and rendered a total sensitivity of the organism 
when combined with of phenyl-arginine β-naphtylamide 
(PAβN), which will be discussed further ahead [135]. 
A study published by Aparna et al. (2014) had the aim of 
identifying natural compounds from plants that present 
efficacy in potentiating effects of antibiotics in P. 
aeruginosa overexpressing MexAB-OprM and E. coli 
overexpressing AcrAB-TolC through in silico virtual 
screening and pharmacophore approaches [136]. The 
compounds with the best in silico results were then tested for 
their EPI activity. The two compounds that showed the best 
activity in potentiating the activity of carbenicillin and 
levofloxacin in P. aeruginosa and E. coli were lanatoside C 
(117) and daidzein (118). Lanatoside C (117) is cardiac 
glycoside that inhibits the Na
+
-K
+
-ATPase, which can also 
be the explanation for its EPI activity against MexB and 
AcrB. Daidzein (118) is an isoflavone that has previously 
showed slight EPI activity in Mycobacterium smegmatis and 
as a modulator of P-glycoprotein, in human cervical 
carcinoma KB-V1 cells [136]. 
An in silico study by Ohene-Agyei et al. (2014) identified 
five phytochemicals that could be docked similarly to PAβN 
in the binding pocket of AcrB. Of these five, three of them 
were able to decrease resistance to antibiotics by inhibiting 
the AcrAB-TolC system: plumbagin (119) increased 
sensitivity to erythromycin, chloramphenicol, and 
tetraphenylphosphonium; nordihydroguaretic acid (NDGA) 
(120) potentiated the activity of erythromycin, 
chloramphenicol, tetraphenylphosphonium, novobiocin, and 
tetracycline; and shikonin (121) decreased resistance to 
tetraphenylphosphonium [137]. 
A study proved the usefulness of curcumin (64) as a RND 
EPI at a concentration of 50 µg/ml, increasing the sensitivity 
of carbenicillin, ceftazidime, and meropenem in P. 
aeruginosa, in decreasing order. It also managed to 
circumvent the resistance to gentamicin and ciprofloxacin in 
resistant isolates, which PAβN failed, leading to the 
assumption that curcumin inhibits efflux pumps differently 
from PAβN [138]. 
A screening of 85 000 microbial fermentation extracts 
derived from 3 600 strains of actinomycetes and 3 500 
strains of fungi was made, with the aim of discovering EPIs 
that increased sensitivity of levofloxacin in P. aeruginosa 
overexpressing the MexAB-OprM or the MexEF-OprN 
pump. Two compounds, EA-371α (122) and EA-371-δ 
(123), produced by a strain of Streptomyces sp., 
demonstrated inhibitory activity against MexAB-OprM 
[139]. 
 
4.1.2. Synthetic Compounds 
The first compound with potent inhibition of RND efflux 
pumps was PAβN (124), a dipeptide amine. This dipeptide 
was identified as a hit compound from the screening of 200 
000 samples of small molecules that potentiate the activity of 
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antibacterial levofloxacin against strains of P. aeruginosa 
that overexpressed MexAB, MexCD and MexEF pumps [28, 
140]. Compound 124 is a peptidomimetic, developed for 
using in adjunctive therapy. This compound is a substrate for 
RND pumps, acting as a competitive inhibitor of multidrug 
efflux systems, such as MexB, MexD, and MexF, binding to 
the substrate pocket, impeding antibiotic binding and/or 
extrusion. Particularly, this EPI binds in a location close to 
the antibiotic binding site, generating steric hindrance, 
making it more difficult for the antibiotic to bind. In other 
words, less quantity of antibiotic is exported, making its 
intracellular levels higher, thus restoring antibiotic 
sensitivity [11, 25, 27-28, 141-143]. However, 124 can affect 
the integrity of the membrane when used in high 
concentrations, making it prone to the emergency of resistant 
profiles, namely the modification of the lipopolysaccharide 
structure, leading to changes in drug penetration [24].  
PAβN (124) has been validated against the AcrAB-TolC in 
Klebsiella pneumonia, E. coli, Salmonella enterica serovar 
Typhimurium and Enterobacter aerogenes, and in multiple 
homologous systems including Acinetobacter baumanii, 
Campylobacter jejuni, and Campylobacter coli [11, 142]. Its 
potency has been demonstrated against the norfloxacin 
resistance conferred by the Mex efflux system of 
Pseudomonas aeruginosa, the AcrAB efflux systems of the 
Enterobacteriaceae, and the erythromycin efflux system of C. 
jejuni [19]. 
Studies of SAR demonstrated that the basic middle amino 
acid, arginine, was detrimental for activity, although a 
substitution with L-lysine showed the same potency as the 
lead, and the introduction of L-ornithine, originating 
compound L-Phe-L-Orn-β-Na, showed a 2-fold increased 
potency. As the ornithine moiety provided a simpler 
synthesis, it became the standard middle residue in 
successive compounds [25, 142, 144]. However, these 
compounds were not stable upon incubation with human 
serum, due to the occurrence of cleavage of peptide linkage 
between both amino acids, which is explained by the fact 
that natural (L) amino acids are contained within its 
structure. In order to overcome this problem, methylation of 
the NH that links both amino acids was achieved, 
maintaining potency and being this derivative able to resist 
serum proteases. Serum stability was also increased by 
replacing the L-amino acid with D-amino acid [25, 142].  In 
the same study, the authors also proved that the amino acid 
in the aa1 position (Figure 13, 124) should be appropriately 
substituted, and the replacement of phenylalanine with a 
homophenylalanine led to improved potency. The problem 
with this compound was the fact that the ornithine moiety 
could easily form a lactam, rendering the compound inactive. 
This was overcome by switching the L-ornithine with the L-
phenylalanine, which originated L-Orn-L-hPhe-β-Na, which 
originated a compound just as potent, but with no propensity 
to form a lactam. As for the β-aminonaphtalene moiety, it 
was proven that replacing it with 3-aminoquinoline led to 
reduced cytotoxicity and intrinsic antibacterial activity, even 
though its potency was slightly reduced [25, 142]. These 
efforts originated the compound L-Orn-L-hPhe-3-NHQ 
(125). In conclusion, the analogues synthesized by Renau et 
al. (1999) did not show improvements in potency when 
compared to PAβN (124), but showed increased stability 
[142]. 
The same group developed further studies with this type of 
molecules and demonstrated that conformational restriction 
of the amino group of ornithine showed less toxicity, while 
maintaining potency. Such compounds were attained by 
adding a proline substituent, thus incorporating the two basic 
residues necessary for activity, which resulted in the 
successful synthesis of constrained derivatives, more potent 
and less toxic than 125. The most interesting derivative, 
compound 126, was as potent as 125, but more than 4-fold 
less toxic. This compound also retained the activity against 
RND efflux pumps MexAB-OprM, MexCD-OprJ and 
MexEF-OprN. Although this compound showed similar 
protein binding in rats as 125, its pharmacokinetic 
parameters were improved, and its efficacy in combination 
with levofloxacin was demonstrated in an in vivo model 
[145]. 
In a latter study developed by the same group, several non-
peptide analogues were synthesized, and it was hypothesized 
that the peptide backbone is not essential for the activity of 
this type of compounds. The results suggested that the 
inhibition of pumps was possible due to the di-cationic 
nature of the compound, the appropriate lipophilicity and a 
disposition similar to that of compound 125 [146]. 
MBX2319 (127) is a pyranopyrimidine EPI inhibitor of 
AcrAB-TolC efflux pump in E.coli and other 
Enterobacteriaceae [141]. Compound 127 did not show any 
antibacterial activity, which is a positive feature for EPIs. It 
also potentiated the antibacterial activity of 
fluoroquinolones, such as ciprofloxacin and levofloxacin, 
and β-lactams, such as piperacillin against strains of E. coli 
that presented AcrAB-TolC efflux pumps [28, 141].  In P. 
aeruginosa, although compound 127 presents activity 
against RND-type pumps, it is unable to penetrate the outer 
membrane, which is highly selective [28]. 
In E. coli, the target of compound 127 is the membrane 
transporter AcrB. This molecule binds to the hydrophobic 
trap of the T protomer, interacting with the hydrophobic 
residues that constitute the deep binding pocket as a 
hydrophobic trap. π-π Interactions also occurs, between the 
pyridine ring of 127 and the aromatic side chain of Phe-628. 
The phenyl and morpholinyl groups also interact with Phe-
178 and Phe-615. The dimethylenesulfide linker and the 
geminal dimethyl group present van der Waals interactions 
between the side chain of Phe-178, and Tyr-327 and Met-
573, respectively [28, 147].  
SAR studies demonstrated that the maintenance of activity 
depended on the geminal dimethyl moiety of the 
tetrahydropyran, the nitrile group and the length of the 
dimethylenesulfide linker. This data is presented in Figure 
14.  On the other hand, the morpholine moiety and aryl 
group are both prone to substitution, originating more stable 
derivatives in terms of activity, solubility, and metabolism 
[28]. Studies with this scaffold have shown that non-acidic 
substituents can be added to the phenyl group, in order to 
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improve potency and CYP450 inhibition, and modifications 
to the morpholinyl group has greater effects on solubility and 
stability [140]. 
Analogues were synthesized by Sjuts et al. (2016), by 
changing the structure and functional groups of compound 
127 (148). They reached the conclusions that the 
introduction of a 2,6-dimethyl to the morpholinyl group 
improved both microsomal stability and EPI activity. The 
replacement of the morpholinyl group with 2-
methoxyethylpiperazinyl improved aqueous solubility, at the 
cost of a slight reduction of EPI activity. Two analogues, 128 
and 129, resultant of the combination of 2,6-
dimethylmorpholinyl and acetamide or acrylamide, 
respectively, on the phenyl group, resulted in a 10-fold to 20-
fold increase in EPI activity against E. coli, respectively, 
comparing to MBX2319 (127) [28, 148]. The increased EPI 
activity of these compounds has its basis in the acetamide 
and acrylamide groups and the morpholinyl group. The 
acetamide groups are engaged in highly ordered and 
complex hydrogen bonds, with its center in a solvent water 
molecule, which plays the role of a hydrogen bond donor to 
the carbonyl backbone oxygen of Ala-286 and Gln-151 side 
chain of AcrB. The acrylamide group forms a bridging 
hydrogen bond through a water molecule to the side chain of 
Gln-176 [28]. 
Nguyen et al. (2015) also synthesized a series of analogues, 
with the morpholine scaffold substituted by a 2,6-
dimethylmorpholinyl group (140). Many of these analogues 
exhibited a solubility improvement of 10-fold, compared to 
compound 127. The most potent and promising compounds 
of these series were compounds 130, 131, 132, 133 and 134 
[140]. 
Through a screening of an N-heterocyclic organic compound 
library, Bohnert and Kern (2005) were able to find a novel 
class of EPIs, the arylpiperazines [25, 149]. The aim of their 
work was to find compounds that would potentiate 
levofloxacin potency against strains of E. coli 
overexpressing acrAB and acrEF. This was fulfilled when 
they found phenylpiperazine derivatives with promising 
activity [25, 149]. SAR studies suggested that elongation of 
the spacer between the benzene ring and the piperazine ring 
would enhance potency. Also, substitutions on the benzene 
ring by halogen atoms led to an increase in potency [24, 
149]. On the other hand, the potency would decrease when 
an ethyl or phenyl group was added to the piperazine ring. 
With this, the authors found the most potent 
phenylpiperazine, meta-TFMPP (135), and 
naphthylpiperazine, 1-(1-naphthylmethyl)-piperazine (NMP) 
(136) [149]. 
NMP (136) was the most potent unsubstituted 
arylpiperazine, able to increase the intracellular 
concentration of chloramphenicol, tetracycline, linezolid, 
fluoroquinolones, and macrolides. Although it does not 
display action in P. aeruginosa, it shows effectiveness in A. 
baumanii and several Enterobacteriaceae [11, 23]. EPI 
activity was also reported in clinical isolates of E. coli, most 
relevantly in fluoroquinolone resistance [150]. Through 
computational analysis, it was found that NMP (136) binds 
with high affinity to the lower part of the deep pocket of the 
B monomer, overlapping in part the binding site of 
chloramphenicol [11]. The binding site for NMP (136) 
includes interactions with hydrophobic residues near the 
hydrophobic patch and Gly-617 of the G-loop. This data 
suggests that NMP (136) interferes with the movement of the 
G-loop, important for extruding substrates, thus inhibiting 
the action of AcrB [25]. 
Nakayama et al. (2003) performed a series of syntheses in 
order to attain a compound specific for the inhibition of a 
MexAB-OprM specific EPI [151-152]. They identified a hit, 
compound 137, through high-throughput screening for 
levofloxacin potentiation using a strain of P. aeruginosa 
strain overexpressing MexAB-OprM. The features this group 
was looking for was the effective inhibition of efflux pump 
and the lack of intrinsic antibacterial activity, since efflux 
pumps are not vital for the organism’s survival [151-152]. It 
was shown that this compound effectively potentiated the 
activity of levofloxacin, leading to an 8-fold decrease in the 
antibiotic’s MIC. However, its physicochemical properties 
were problematic: water solubility was poor and it presented 
high affinity to serum albumin. Therefore, they divided the 
molecule into three parts, A, B, and C (137) and looked for 
alternative scaffolds and substituted polar groups, in order to 
reduce serum protein binding [152]. 
It was shown that when a carboxamide was introduced in A, 
the affinity to serum albumin was diminished, as was its 
activity. More polar moieties led to a complete loss of 
activity. The strategy for the styrene portion (B) that was the 
most successful was to substitute the benzene ring to a 3,5-
disubstituted pyridine, which had both good activity and no 
major serum influence. As for the vinyl group in B, it was 
demonstrated that molecules bearing methyloxy and ethylene 
moieties displayed favorable activity profiles. As for part C, 
the basis of the modifications was the fact that the 
introduction of bulky or hydrophilic groups adjacent to the 
carboxyl group would reduce protein binding. An 
enantiomeric pair containing a dioxolane moiety presented 
both activity and serum stability, being the S enantiomer 
more active [152]. 
Regarding the general scaffold, new compounds were 
designed, keeping in mind that the thiazole moiety was 
crucial for activity. Therefore, a molecule having a thiazole 
side chain attached to the C-7 position of a quinolone was 
synthesized. Substitution with a tetrazole portion yielded 
better results than substitution with a carboxylic acid. One 
compound (138) presented the best activity and serum 
stability [153]. 
Further efforts were placed in order to increase the potency 
of this compound. The in vitro activity was enhanced by the 
introduction of a hydrophobic group at the 2-position of the 
pyridopyrimidine scaffold, and hydrophilic substitution 
would not compromise the activity. The most promising 
compound had the inclusion of an olefin spacer between the 
tetrazole and the pyridopyrimidine scaffold, with the 
limitation of being prone to photoisomerization [154]. To 
circumvent this, the ethylene tether between the 
pyridopyrimidine was replaced with an amide bond, 
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providing stability against photoisomerization and, 
unexpectedly, improving potency. However, another 
problem arose: the lack of solubility for intravenous use 
[155]. The following step was the introduction of a 
secondary amine, giving a zwitterionic analogue, with 
retention of activity. C-2 Analogues, namely with cyclic 
substituents, also showed promising results [156]. Once 
again, the problem of solubility arose. Therefore, efforts 
were placed in making the molecule more hydrophilic, with 
the introduction of substituted aromatic moieties. Analogues 
4-substituted were the most potent, and the introduction of a 
morpholine moiety led to increased solubility, maintaining 
the serum stability. Compound 139 was the most balanced 
molecule in terms of the desired features [157]. The last 
refinement made was the introduction of a quaternary 
ammonium salt, which led to D13-9001 (140). Adding to its 
high solubility and safety, it was able to potentiate the 
activity of aztreonam [158]. Figure 15 illustrates the SAR 
established for 140 and derivatives. 
3D Crystal structures of 140 bound to the target, either AcrB 
or MexB, show that the tert-butyl thiazolyl aminocarboxyl 
pyridopyrimidine moiety of this compound binds tightly to a 
narrow depression, designated by hydrophobic trap, close to 
the deep substrate binding pocket. Additionally, the tetrazole 
ring and the piperidine acetoamino ethylene ammonio-
acetate moiety interact with ionic and/or hydrophilic residues 
in the substrate translocation channel. The piperidine 
acetoamino ethylene ammonio-acetate moiety also covers 
part of the minocycline and doxorubicin binding site [23, 28, 
151]. 
Quinoline derivatives with EPI activity include a multiplicity 
of derivatives, including pyrrido-, alkoxy-, thioalkoxy-, 
alkylamino- and chloro- derivatives. These compounds were 
able to restore an intracellular concentration of antibiotic 
drugs expelled by efflux pumps, as well as to induce the 
increase in antibiotic susceptibility, acting as competitive 
inhibitors of the antibiotic flux. In E. aerogenes and K. 
pneumoniae, quinolines were more effective than PAβN 
(124) in inhibiting the activity of the AcrB pump, 
potentiating the activity of fluoroquinolones, tetracycline, 
and chloramphenicol [11, 24, 26].  Among the different 
classes of substituted quinolines, it was proven that the best 
side chain was piperidinoethyl, which potentiated efficiently 
the restoration of drug susceptibility in alkoxy- and 
thioalkoxyquinolines. The heteroatom connecting the side 
chain is also crucial for activity, being the most potent the 
amino substituent, then the thioalkyl-, followed by the oxo-
derivative. The position of the branched substituted groups is 
also detrimental for the EPI activity [24]. Branched side 
chains containing piperidinoethyl and morpholinopropyl 
groups were associated with the most interesting results, 
being compound 141, containing a piperidinoethyl side 
chain, the most active when in combination with 
chloramphenicol [159]. It has been hypothesized that the 
pump inhibition is greatly influenced by the branched side 
chain, and takes place either in the inner-membrane 
transporter or at the junction between the inner pump and the 
outer channel [159]. 
Given these promising results, further research in this kind of 
compounds was performed. Alkoxyquinolines were 
synthesized and tested against a strain of E. aerogenes 
overexpressing the AcrAB efflux pump. Compound 142 
induced an increase in the susceptibility of chloramphenicol, 
tetracycline, and fluoroquinolone. This could happen due to 
interference during active pumping out of the antibiotic 
[160].  
Chloroquinolines also demonstrated efficacy as EPIs, 
modulating chloramphenicol activity, decreasing its MIC 8-
fold for resistant strains. Synthesis of analogues led to the 
conclusion that amino derivatives are more potent than thiol 
derivatives, pointing out the importance of the side chain for 
the efflux inhibition. Protonation of the nitrogen could also 
play an important role at environmental pH, stimulating 
recognition and binding of the drug to the sites located 
within the pump’s cavity. The heteroatom is also crucial for 
the activity, being nitrogen the most efficient. Compound 
143 is the chloroquinoline with the best results found for the 
inhibition of the main efflux pump of E. aerogenes [161].  
Alkylaminoquinazoline derivatives lacking a nitro group 
were also evaluated for their ability to decrease 
chloramphenicol and quinolone efflux in E. aerogenes, 
through the inhibition of AcrAB efflux pump. The results 
obtained suggest that this family of compounds recognizes 
the same pump site responsible for the transport of 
chloramphenicol and quinolones, competing with them. 
Structurally, it has been shown that a morpholine group with 
a propyl chain makes a more active alkylaminoquinazoline. 
The most active compound of this family is compound 144 
[162]. 
Benzothiazoles 2-substituted were first tested for the 
potentiation of ciprofloxacin in AdeABC overexpressing A. 
baumanii. These compounds did not show antibacterial 
activity when tested alone in bacteria. However, when 
combined with ciprofloxacin, there was an observation of a 
reversal in antibacterial susceptibility. The synthesis of 
several derivatives of this family led to pharmacophore 
studies, regarding the features of the most promising 
compounds. Using computational methods, it was revealed 
that, in order for the compounds to be biologically active, the 
following features should be present: the nitrogen atom in 
the thiazole ring and the carbonyl oxygen in the amide 
function substituted on the second position of the 
benzothiazole ring must have an hydrogen bonding acceptor 
property; the benzene ring in the fused ring system, the 
phenyl group attached to the second position of the 
benzothiazole ring and the phenyl ring in the 2-
phenylacetamide and/or 3-phenylpropionamide moiety are 
essential, since they provide a hydrophobic aromatic 
property. Of the synthesized compounds, the ones that 
gathered these features and, therefore, presented the most 
promising activity, were compounds 145, 146, and 147 
[163]. These compounds were also tested for their activity 
against AcrAB-TolC, in an overexpressing strain of E. coli, 
reducing the MIC of ciprofloxacin 10-fold, in the case of 146 
and 147, and 8-fold, for 145 [164]. Unlike AdeABC, 
AcrAB-TolC’s crystal structure is elucidated, making 
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docking studies possible. This predicted that all three 
compounds act as AcrB substrates, binding to the distal 
pocket site in the AcrB porter domain by blocking or 
inhibiting the ciprofloxacin binding site, generating steric 
hindrance and thus impeding the binding of the antibiotic. 
Furthermore, 146 and 147 showed stronger binding 
interactions than ciprofloxacin [164].  
Indole derivatives have been useful in inhibiting protein 
targets of virus, tumors and bacteria. Since small molecules 
with conjugated aromatic rings, in which indoles fit, present 
high potential as EPIs, efforts were placed in synthesizing 
derivatives that presented this kind of activity. The TolC 3D 
structure has already been disclosed, making possible the 
structure-based design of inhibitors. Indoles 148 and 149 
were proven efficient inhibitors of TolC in E. coli, 
potentiating the effects of chloramphenicol, tetracycline, 
erythromycin, and ciprofloxacin, with decreased MIC values 
of 2-fold for tetracycline and erythromycin and 8-fold for the 
other two [165].  
 
4.1.3. Existing Drugs 
Other drugs used for treatments other than antibacterial have 
demonstrated EPI activity. Tetracycline resistance in P. 
aeruginosa was reduced 8-fold when the phenothiazine 
fluphenazine, an antipsychotic, was present. Chlorpromazine 
(150) also showed EPI-like activity for the BpeAB-OprB 
system in Burkholderia pseudomallei and a reduction of the 
expression of acrB in E. coli and S. enterica samovar 
Typhimurium, suggesting an inhibition of AcrB production 
[11, 27, 128]. 
Selective serotonin-reuptake inhibitors have been studied for 
their ability to act as EPIs for RND efflux pumps in E. coli. 
It was found that sertraline (151) was capable of potentiating 
the activity of fluoroquinolones. However, its activity is 
limited, since it is possible that this compound also acts as an 
inductor of efflux pumps. Studies have shown that this 
compound could accumulate in tissues or cells, and 
therefore, sertraline’s (151) concentration may be higher 
than that measured in plasma. This means that a standard 
dose of this drug could enhance antibiotic efficacy. It has not 
yet been studied if a sertraline (151) metabolite could be 
administered at a dose higher than sertraline. However, it 
was hypothesized that it could have a better EPI activity, 
while causing less undesired effects on the central nervous 
system [166]. 
Through the observation of previously reported EPIs, 
Piddock et al. (2010) suggested that simple heterocyclic 
nitrogen-containing compounds could also act as EPIs and 
synergize with ciprofloxacin in strains of S. enterica serovar 
Typhimurium that overexpressed the AcrAB-TolC efflux 
pump [167]. It has been shown that compounds containing a 
phenylethylamine moiety, as PAβN (126) does, such as 
epinephrine, norepinephrine, and cathinone, are able to 
potentiate the activity of ciprofloxacin. Of the compounds 
tested, trimethoprim (152) and epinephrine (153), showed 
the best results for the tested strains, which included, apart 
from S. enterica serovar Typhimurium, P. aeruginosa, E. 
coli, and K. pneumoniae. These compounds showed synergy 
for the strains where AcrAB-TolC was active, but showed no 
activity when the pump was inactive. Thus, it can be 
hypothesized that these compounds either inhibit the 
expression of the genes encoding AcrAB-TolC, or interact 
directly with the pump [167]. Both compounds possess 
structural features similar to previously described EPIs, such 
as PAβN (124), L-Orn-L-hPhe-3-NHQ (125), and NMP 
(136), such as an aromatic ring linked to a basic nitrogen, in 
the case of epinephrine (153), or a pyrimidine ring, for 
trimethoprim (152). Trimethoprim (152) is already used in 
combination with another antibiotic, sulfamethoxazole, and 
combination with a quinolone was hypothesized to be a 
viable choice. On the other hand, a combination of 
epinephrine (153) with an antibiotic does not seem a viable 
option, because of the likelihood of the occurrence of 
sympathomimetic effects [167]. 
The antimalarial artesunate (154) has also shown EPI 
activity, enhancing the effects of β-lactam antibiotics, such 
as penicillin G, oxacillin, and ampicillin, and novobiocin 
against E. coli. The mechanism through which 154 expresses 
its activity is by the inhibition of the expression of the 
AcrAB-TolC system, not exhibiting antibiotic activity by 
itself [168]. 
 
5. SMR 
The SMR family comprises the smallest drug efflux proteins 
known, possessing only four transmembrane segments in its 
composition, and are exclusive to bacteria. They are 
involved in the efflux of lipophilic compounds, such as 
quaternary ammonium salts and a variety of antibiotics. 
These pumps also use an electrochemical proton gradient in 
order to exert its efflux activity [7, 32, 38, 169]. 
One example of a SMR-type pump is the EmrE transporter 
(Figure 16, PDB 3B61), present in E. coli. In the absence of 
the ligand, the asymmetric unit of EmrE contains eight EmrE 
monomers, with four transmembrane helices composing 
each of them. If a ligand is present, it can function as an 
inverted homodimer [7, 170]. 
There have not been many studies concerning inhibitors of 
this family of efflux pumps, and the few that have been 
performed were only in silico. Figure 17 shows the 
structures of the SMR inhibitors that will be further 
discussed. 
   
5.1. SMR inhibitors 
5.1.1. Natural Products 
Quercetin (155) is a flavonol, present in many plants. This 
compound is very well tolerated in humans, as are its 
glycoconjugates, and presents a multiplicity of activities, 
such as antioxidant, anti-inflammatory and 
antimycobacterial. Only docking studies of this compound 
with two pumps belonging to the SMR family, the Mmr, in 
Mycobacterium smegmatis, and the EmrE pumps, in E. coli, 
were carried out. In Mmr, the hydroxyl groups present in the 
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3’ and 4’ positions of the B ring of quercetin were predicted 
to interact with Glu-14 in the helix 1, and the keto group of 
the hydroxychromen ring of the ligand interacts with the 
Trp-48 of the helix 1. Additionally, hydrophobic interactions 
were shown by the residues Phe-44, Tyr-40 and Trp-48, and 
π-π interactions were found with Phe-44. Furthermore, 155 
was also predicted of interacting with dimeric forms of the 
protein [171]. In the case of EmrE, the interaction between 
the 3’ and 4’ hydroxyls with Glu-14 can also be observed, as 
can the hydroxyl in the C-7 position with Tyr-60. 
Hydrophobic interactions are present, with the residues Ile-
11, Ser-64, Gly-67 and Leu-70, and π-π interactions exist 
with the residues Tyr-60 and Trp-63. Structural studies 
suggest that EmrE is mostly in the dimer state, which also 
interacts with quercetin (155) [171]. 
 
5.1.2. Synthetic Compounds 
Cation ligands were subjected to docking studies with the 
Mmr protein of the SMR family in Mycobacterium 
tuberculosis and the EmrE dimer from E. coli. The rationale 
behind this study is the fact that SMR can extrude cations. 
This study led to the identification of new virtual leads, 
amongst which is compound 156. ADME studies prove that 
all the molecules present in this study obey the Lipinski rule 
of five and the Jorgenson rule of three, which shows that the 
compounds possess good drug-like properties [172]. 
 
6. MATE 
MATE transporters are responsible for the efflux of cationic, 
lipophilic substances, providing bacteria and cancer cells 
with MDR, using Na
+ 
or H
+
 influx. They have 12 
transmembrane helices, constituted by 400 to 700 amino 
acids. The mechanism of efflux is thought to happen by a 
rocker-switch mechanism. Members of the MATE family 
include the MepA (Figure 18, PDB 1TZP) transporter, in S. 
aureus, even though seventeen MATE proteins have been 
identified in eleven species, capable of extruding antibiotics. 
Ethidium bromide, tetraphenylphosphonium, acriflavine, 
berberine, and norfloxacin have been reported as MATE 
substrates [38, 173-181]. 
In Figure 19 are compiled the structures of the compounds 
that have so far proven their usefulness as MATE inhibitors. 
 
6.1. MATE inhibitors 
6.1.1. Natural Products 
A study performed by Kesherwani et al. (2017) 
accomplished the docking of phytochemicals with the NorM 
transporter, belonging to the MATE family [182]. After a 
screening of a library of natural products, three hits were 
identified: derhamnosyl suspenaside (157), prunin 7’’-O-
gallate (158), and quercetin diglucoside (159). These were 
the best compounds, as their results in binding free energy 
calculation were the most favorable. When binding free 
energy decomposition and hydrogen and hydrophobic 
statistics were taken into account, 158 was elected the best 
hit compound. Furthermore, this compound was stable 
during the simulation. Overall, it has been suggested that the 
compounds which interact towards the cation binding 
residue in the central cavity of NorM will have better results, 
and that good inhibitors should have interaction with a few 
key residues, Gln-34, Val-35, Gly-38, Phe-63, Tyr-67, Ile-
68, Glu-261, Tyr-294, and Asp-377, which will lead to 
maximum stability and affinity with the NorM transporter 
[182]. 
 
6.1.2. Synthetic Compounds 
These compounds have been previously described as MFS 
inhibitors, namely of the NorA pump. However, similar 
activity has been described for the MepA pump, of the 
MATE family. Compound 80 (Figure 5), incorporating a 
bisaryl urea moiety at the 7-position, was able to 
successfully inhibit approximately 84% of ethidium bromide 
efflux in a MepA overexpressing strain of S.aureus [104]. 
Phenylquinoline derivatives also proved efficient against the 
same strain. Differently from what was observed with NorA, 
the compounds that inhibited MepA most efficiently were 86 
(Figure 5) and 160 (Figure 19), which were able to reduce 
ethidium bromide’s MIC by 16-fold at concentrations of 
0.78 and 1.56 µg/ml, respectively, in the MepA 
overexpressing strain. Ethidium bromide was chosen, instead 
of ciprofloxacin, as it is a better MepA substrate and other 
derivatives were able to inhibit both NorA and MepA efflux 
pumps, being able to completely restore the activity of 
ciprofloxacin and ethidium bromide against strains 
overexpressing such pumps [107]. 
Paroxetine derivatives (104), effective against the NorA 
pump, also demonstrated potency in inhibiting the MepA 
pump in S. aureus. Oppositely to NorA, paroxetine 
derivatives do not need the fluorophenyl ring at position 4 to 
be MepA EPIs. In fact, 4-unsubstituted analogues proved to 
be more potent than 4-F-phenyl derivatives in inhibiting the 
MepA pump, as is the case of compound 161 and 162 [122]. 
 
Efflux pumps are one of the main causes for antimicrobial 
resistance. Their inhibition can lead to the restoration of 
bacteria susceptibility and antibiotic efficacy. Throughout 
this review, the data presented leads to the conclusion that 
EPIs are promising compounds and can help reversing the 
problem of antimicrobial resistance. However, the research 
into these kind of compounds is still in a very preliminary 
state, since no EPI is yet under clinical trials. 
Even though no general structural features can be pointed out 
for a molecule to be an EPI, it can be observed that small 
molecules with high lipophilicity are most likely to fulfill the 
requirements to inhibit efflux pumps. Hydrophilic 
compounds can also be transported through porins present in 
the membrane.  Heterocyclic compounds also show potential 
as EPIs, mainly nitrogen heterocycles, but also fluorine and 
boron heteroatoms, since the likelihood of bacterial exposure 
to these atoms is very low. The basis for the MDR pumps 
inhibition has to do with the penetration rules, and whether 
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or not a compound is capable of penetrating the bacterial 
membrane. Therefore, a library of compounds that are able 
to do that would be something that would bring advances to 
this study field. 
One of the main aims of this review is to present SAR 
studies, so that pharmaceutical chemists can refine molecular 
structures, leading to the achievement of more potent and 
specific compounds. The use of synthetic approaches, either 
to modify molecules obtained from natural sources, or drugs 
that are already in therapeutic use, or even to develop novel 
compounds, is vital for these SAR studies. The search of 
EPIs derived from natural products comes from the fact that 
plants need to protect themselves from pathogenic 
microorganisms, and produce metabolites that act as 
antimicrobial and EPIs, that synergize with each other. 
However, the referred compounds are not specific for the 
pump they have been studied, showing a multitarget 
character: flavonoids, coumarins, cinnamic acids, among 
others, present a multiplicity of activities already described, 
suggesting their promiscuity. 
The advantage of assays with existing drugs lies in their 
safety profile and, most times, their clinical use for 
combination therapy has been characterized. In some cases, 
the compounds were even investigated as inhibitors of 
human efflux pumps, for cancer treatment. This can be 
regarded as an advantage, leading to a new class of drugs 
with dual human/bacterial EPI, particularly useful in cancer 
patients with infections, potentiating the effects of both the 
anticancer and the antibacterial drugs. 
The future in studies in bacterial EPIs should lie either in the 
search for selectivity for the bacterial target, or in the 
disclosure of the common features of the universal bacterial 
EPI, that can successfully target all efflux pumps. The SAR 
studies gathered herein with the 3D structural information 
available are expected to accelerate the structure-based 
design of new EPIs, founded on the existing models.  
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Abstract: Antibiotic resistance is one of the most pressing health issues of our days. It can arise due to a multiplicity of 
factors, such as target modification, decrease in the drug uptake, changes in the metabolic pathways and activation of efflux 
pumps. The overexpression of efflux pumps is responsible for the extrusion of drugs, making antibiotic therapy fail, as the 
quantity of intracellular antibiotic is not enough to provide the desired therapeutic effect. 
Efflux pumps can be included in five families according to their composition, nature of substrates, energy source, and number 
of transmembrane spanning regions. The ABC superfamily are mainly found in Gram-positive bacteria, use ATP as an 
energy source, and only a limited number of ABC pumps confer multidrug resistance (MDR). 
On the other hand, the MFS family, most present in Gram-positive bacteria, and the RND family, characteristic of Gram-
negative bacteria, are the most associated with antibiotic resistance. A wide variety of inhibitors have been disclosed for both 
families, from either natural or synthetic sources, or even drugs that are currently in therapy for other diseases. 
The other two families are the SMR, which are the smallest drug efflux proteins known, and the MATE family, whose pumps 
can also resort to the sodium gradient as an energy source. 
In this review, it is intended to present a comprehensive review of the classes of efflux pump inhibitors from the various 
sources, highlighting their structure-activity relationships, which can be useful for medicinal chemists in the pursuit of novel 
efflux pump inhibitors. 
 
Keywords: Antimicrobial resistance; efflux pump inhibitors; natural products; synthetic compounds; existing drugs; Structure-activity 
relationship. 
1. INTRODUCTION 
Bacteria were discovered the late 19
th
 century as infectious 
agents. It was, however, half a century later that antibiotics 
completely revolutionized medicine and became a turning 
point in human history. Unfortunately, the misruled use of 
these drugs led to the appearance of resistant strains, and to 
the concern of a return to the pre-antibiotic era, where the 
simplest, most treatable infections can become deadly [1-2]. 
Antibiotic resistance can arise due to multiple causes. The 
most common are the overuse and/or inappropriate 
prescribing, as well as extensive veterinary and agricultural 
use. These factors are especially alarming if it is taken into 
account the very few new antibiotics that were discovered in 
the past years [3]. Due to their genetic plasticity, bacteria can 
develop defense mechanisms in response to environmental 
threats. As far as antibiotics are concerned, bacteria use two 
major strategies to adapt to these drugs, which are mutations 
in genes and the acquisition of resistance genes through 
horizontal gene transfer. The first strategy can be manifested 
through modification of the target, decrease in the drug 
uptake, activation of efflux pumps to extrude the drug or 
changes in metabolic pathways. The latter is related to the 
acquisition of external genetic material through 
transformation, transduction, or conjugation [4-5]. Recently, 
vesicle-mediated resistance has also been regarded as a 
mechanism of resistance acquisition [6]. 
Efflux pumps are ubiquitous in bacteria, and can be encoded 
by genes present either in the bacterial chromosomes or in 
plasmids [7-8]. They concern five families, according to 
their composition, substrates, energy sources, and number of 
transmembrane spanning regions: the adenosine triphosphate 
(ATP)-binding cassette (ABC) superfamily, the resistance-
nodulation-division family (RND), the major facilitator 
superfamily (MFS), the small multidrug resistance (SMR) 
family, and the multidrug and toxic compound extrusion 
(MATE) family (Figure 1) [7-12].  
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Efflux pumps can be further divided into two major families, 
the primary transporters, which hydrolyze ATP as a source 
of energy, as is the case of the ABC family, and secondary 
transporters, which use the proton or sodium gradient as a 
source of energy [13].  
Overexpression of multidrug efflux pumps is correlated with 
an increase in the minimum inhibitory concentration (MIC) 
of antibiotics, and thus, these pumps can be considered 
potential antibacterial targets. Therefore, the development of 
efflux pump inhibitors may be a way of fighting against 
resistant microorganisms. Studies have been carried out on 
the structure of efflux pumps, as well as on their mechanisms 
of binding and extrusion, leading to the possibility of 
structure-based design of efflux pump inhibitors (EPIs). The 
rationale for the development of these EPIs could be, for 
instance, the inhibition of the energy sources required for the 
ability to extrude antibiotics, and the development of 
compounds that compete with the antibiotics for their 
extrusion. However, the main challenge lies in the fact that 
many compounds that present EPI activity and are already 
used for the treatment of other diseases are toxic for human 
cells in the concentrations required to present EPI activity 
and, therefore, clinically useless [7-9, 13]. 
Even though there are already several reviews which 
describe different classes of EPIs [11, 13-31], most focus on 
a particular source of compounds or on a class of pumps or 
bacteria. Herein, it is intended to present a comprehensive 
review of the several classes of EPIs from natural and 
synthetic sources and from existing drugs in therapeutics and 
to highlight structure-activity relationship studies in the 
referred efflux pumps (ABC, RND, MFS, SMR and MATE), 
which can be useful for medicinal chemists in the pursuit of 
novel compounds for this goal.  
 
2. ABC 
The ABC transporters are primary transporters, and they 
exist in every membrane systems, whether the organism is 
prokaryotic or eukaryotic. P-Glycoprotein (P-gp) is a very 
well known human ABC transporter, involved in the 
resistance of cytotoxic drugs used in cancer therapy [32-34], 
whose modulation has been regarded as a study field [35-
37]. Structurally, an ABC transporter consists of four 
conserved domains, two transmembrane domains, and two 
cytoplasmic domains, which bind to nucleotides and, 
therefore, are involved in ATP binding [32, 38]. In fact, the 
nucleotide binding domains are responsible for hydrolyzing 
ATP, which will lead to conformational changes in the 
attached transmembrane domains, making it possible for 
substrates to cross the lipid bilayer of the membrane, either 
in an inwards or an outwards fashion [39]. 
The bacterial transporters are highly selective for sugars, 
amino acids, metallic cations, organo-iron complexes, 
vitamins, and antibiotics [32, 40]. They are found in Gram-
positive bacteria, such as Enterococcus faecalis and 
Staphylococcus aureus, and confer resistance to macrolides 
and bacitracin. However, only a limited number of ABC 
pumps are associated with MDR, which means that ABC 
pumps do not play a pivotal role in conferring antibiotic 
resistance in bacteria [32-33]. 
As such, bacterial ABC transporter inhibitors are scarce. The 
few EPIs discovered in this context are mainly against MsrA 
(Figure 2, PDB 1NWA), whose tridimensional structure has 
been elucidated [41].  
The structures of the ABC inhibitors that will be further 
detailed throughout this section are comprised in Figure 3. 
 
Figure 1 Representation of the five efflux pump families (adapted from [8]). 
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2.1. ABC inhibitors 
2.1.1. Natural Products 
The search for natural products comes from the reason that 
plants produce antimicrobials to protect themselves from 
exogenous organisms. It is thought that plants can produce 
anti-MDR compounds to fight the microbial resistance 
phenomenon. Carnosic acid (1) was one of the major 
products isolated from the plant Rosmarinus officinalis. 
When tested against the macrolide resistant strain of S. 
aureus, expressing the MsrA pump, compound 1 displayed 
favorable results, showing an impressive 8-fold potentiation 
of erythromycin [42]. 
An extract of Lycopus europaeus led to the isolation of two 
new isopimarane diterpenes, methyl-1α-acetoxy-7α,14α-
dihydroxy-8,15-isopimarandien-18-oate (2) and methyl-
1α,14α- diacetoxy-7α-hydroxy-8,15-isopimarandien-18-oate 
(3), which showed no antibacterial activity, but were able to 
reduce erythromycin’s MIC from 256 µg/ml to128 µg/ml, 
therefore causing a 2-fold potentiation. This behavior was 
similar to other isopimarane diterpenes isolated in this study, 
as well as for 5,9-dihydroxygeranyllinalool (4) and 9-
Figure 3 Crystal structure of MsrA, from Mycobacterium 
tuberculosis in complex with protein-bound methionine 
(PDB 1NWA). 
Figure 2 Structures of ABC inhibitors 1 – 20. Ac = Acetyl. 
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acetoxy-5-hydroxygeranyllinalool (5) , two diterpenoids [43-
44]. 
Phytol (6) is an acyclic isoprenoid, and its EPI activity 
against the ABC pumps of E. coli was assessed in 
combination with nalidixic acid. Additionally, 15 derivatives 
were synthesized. One derivative in particular, compound 7, 
was able to decrease the MIC of nalidixic acid by 16-fold, 
and four other derivatives reduced the MIC by 8-fold. This 
effect was caused by the inhibition of ATP-dependent efflux 
pump and down-regulation of the efflux gene. In silico 
absorption, distribution, metabolism, and excretion (ADME) 
analysis was performed, taking into account parameters such 
as solubility in water, human intestinal absorption, plasma 
protein binding, blood-brain barrier penetration, 
hepatotoxicity and cytochrome P450 (CYP450) inhibition. 
Results showed all five active derivatives presented low 
permeability into the central nervous system and displayed 
moderate intestinal absorption. In terms of plasma protein 
binding level, all five compounds exhibited levels below 
90%, suggesting favorable distribution of the compounds 
into the blood. They also did not present hepatotoxicity, 
unlike reserpine, making them good lead compounds [45]. 
Ursolic acid (8) is a pentacyclic triterpenoid isolated from 
diverse natural sources. Its wide activity includes anti-
inflammatory, antimicrobial, diuretic, and antitumor activity, 
among others. When tested against Escherichia coli strains 
that were resistant and susceptible to nalidixic acid, ursolic 
acid did not display intrinsic antibacterial activity. However, 
ursolic acid (8) was able to reduce the MIC of nalidixic acid 
by 2-fold, when both drugs were used in combination. This 
synergy led to further research on this scaffold. The first 
derivative prepared was the 3-O-acetyl ursolic acid, and 
showed a 4-fold decrease in the MIC of nalidixic acid. The 
lipophilic nature of this derivative, allied with the increased 
potency, led to the synthesis of other lipophilic ester 
derivatives. The methyl and ethyl esters of 3-O-acetyl ursolic 
acid did not show any increment in the activity. However, a 
further increase in the ester carbon chain increased the drug 
reversal potential by 2-fold, in comparison to 3-O-acetyl 
ursolic acid, against the resistant strain. This is the case of 
the isopropyl (9) and the n-butyl (10) derivatives. The 
addition of a pentyl group led to a decrease in activity. 
Furthermore, ursolic acid (8), and derivatives 9 and 10, 
reduced the MIC of tetracycline by 2-fold, 8-fold, and 8-fold, 
respectively. When these compounds were tested against 
ATP-dependent efflux pumps, it was found that derivatives 9 
and 10 were successful in inhibiting these pumps in terms of 
the liberated inorganic phosphate. Molecular modeling 
studies with the YojI pump, using maltose/maltodextrin 
transport ATP-binding protein as a homology model, showed 
that 9 was bound to the nucleophilic Ser-78, to the aromatic 
Phe-81, Trp-85 and Leu-86, the acidic Glu-94 and Glu-144 
and the basic Ala-79, Ala-139, Ala-140, Ala-141, Ala-143, 
Arg-74, Arg-122, Arg-146, Leu-107, Val-80, Lys-96, and 
Ile-123 in the nucleotide binding domain. Derivative 10 was 
also subjected to the same kind of studies using the same 
model, and was predicted to bind in the same region [46]. 
A study with flavones and isoflavones from the plant 
Sophora moorcroftiana revealed that diosmetin (11) was 
able to inhibit three drug resistant strains of S. aureus, 
including the ABC family MsrA overexpressing strain, 
potentiating the effects of norfloxacin and streptomycin [47]. 
These results corroborate the works of Chan et al (2013), 
who had previously studied the effects of diosmetin (11) as 
an EPI [48]. This group observed a synergistic effect of this 
flavonoid with erythromycin, which was 5-fold greater than 
that of verapamil [48]. 
4-Hydroxy-α-tetralone (12) isolated from the plant 
Ammannia multiflora, showed enhancement against nalidixic 
acid resistant strains of Escherichia coli, prompting the 
synthesis of derivatives in order to infer their mechanism of 
action. Five derivatives were synthesized, and it was shown 
that compound 13 was able to inhibit the expression of the 
ABC transporter protein gene yojI, which encodes the ABC 
Figure 3 (cont.) 
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protein YojI, and was successful in combination with 
tetracycline [49]. Molecular modelling studies with 
compound 13 and a homology model of the YojI protein 
revealed the following bound residues: Ser-78 
(nucleophilic), Leu-86, Ile-123, Ala-137, Ala-140, Ala-141, 
and Ala-143 (hydrophobic), Glu-144 (acidic), Arg-122 
(basic), Phe-81 (aromatic), Glu-144 (acidic), Arg-146 and 
Lys-96 (basic), and Trp-85 (hydrophobic), the same region 
as noted for ursolic acid derivatives 9 and 10. Compound 13 
showed good affinity and strong hydrophobic interaction 
with the YojI protein, corroborating the fact that this 
compound acts by the inhibition of ATP dependent efflux 
pumps [49]. 
The plant Portulaca oleraceae is used in folk medicine for 
its anti-inflammatory, anti-septic and diuretic effects, among 
others. A study of its fatty acids demonstrated that linoleic 
(14) and oleic acids (15) had synergistic activity with 
macrolides for the MsrA overexpressing strain of 
methicillin-resistant S. aureus (MRSA). In fact, 
erythromycin’s activity was enhanced when in combination 
with either of these two compounds, likely through the 
inhibition of the MsrA ATP dependent pump. Since these 
fatty acids are essential for humans, low toxicity is expected, 
making them promising agents to use in combination with 
antibiotics [50]. 
Lysergol (16) is a clavine alkaloid of the ergoline family. 
Recently, its EPI activity was studied, and derivatives were 
synthesized [51]. The compounds were tested against 
susceptible and resistant to nalidixic acid strains of E. coli 
and a tetracycline resistant strain. While not possessing 
antibacterial activity, lysergol (16) showed synergy with 
nalidixic acid at the concentration of 10 µg/ml, reducing its 
MIC by 8-fold in the resistant strain of E. coli and 4-fold in 
the susceptible strain. Of the thirteen semi-synthetic 
derivatives prepared, derivatives 17 and 18 reduced nalidixic 
acid’s MIC by 8-fold, twice as much as lysergol (16), in the 
susceptible strain. A 4-fold potentiation of nalidixic acid was 
observed for the three compounds when tested against the 
resistant strain. As for the tetracycline resistant strain, all 
three compounds were able to reduce tetracycline’s MIC by 
8-fold. Further studies were performed, in order to conclude 
whether or not these compounds were capable of interfering 
with ATP-dependent efflux pumps, and it was proven that all 
three compounds inhibited ATPase activity, concerning the 
liberation of inorganic phosphate. A down-regulation of the 
gene yojI was also observed when the tetracycline resistant 
strain was treated with lysergol (16) and its two most potent 
derivatives, 17 and 18, which further confirms the activity of 
these compounds as ABC transporter inhibitors [51]. 
 
2.1.2. Existing Drugs 
As part of a screening program for P-gp inhibitors, 
GG918 (19) was discovered. This synthetic compound had 
already showed success in increasing the intracellular 
concentration of paclitaxel in cancer cells. In S. aureus, this 
compound was able to slightly potentiate the activity of 
norfloxacin in a strain overexpressing the ABC efflux pump 
MsrA, suggesting that it may possess minimal activity over 
this pump [52]. 
The human P-gp inhibitors, vanadates, have been 
studied as inhibitors of the MutS pumps, belonging to the 
ABC ATPase superfamily. In fact, these compounds have 
demonstrated activity against the MutS in P. aeruginosa and 
E. coli. Decavanadate was the most effective, followed by 
orthovanadate (20), and they act non-competitively, possibly 
by replacing the inorganic phosphate. The fact that the ABC 
ATPases inhibited by orthovanadate are phosphorylated 
leads to the assumption that the low inhibitory effect could 
be attributed to the absence of a stable phosphorylation state 
of MutS [53]. 
 
3. MFS 
The MFS is the most extensively studied family of 
transporters, present in both Gram-positive and Gram-
negative bacteria, and comprises uniporters, symporters and 
antiporters. It also constitutes the largest family of secondary 
transporters, with over 10 000 sequenced members. Its 
substrates are diverse, and can range from ions, to 
carbohydrates, lipids, amino acids, nucleosides, among 
others. As many members of the MFS originate bacterial 
MDR, these transporters can pose as a good system for 
modulation studies [7, 19, 38, 54]. 
With the elucidation of the crystal structure of the MFS 
pump EmrD of E. coli (Figure 4, PDB 2GFP) [55], a general 
structure could be proposed for MFS transporters: twelve 
transmembrane helices that form a compact structure, with 
four of these transmembrane helices facing away from the 
interior cavity and the rest forming the internal cavity, 
constituted mostly by hydrophobic residues [7]. 
 
Figure 4 Crystal structure of EmrD, from E. coli (PDB 
2GFP). 
 
The efflux of drugs is only possible if the carrier alternates 
between two conformations, so that the substrate can bind to 
the convenient site in either side of the membrane. However, 
a limitation concerning the energy involved to displace the 
exposed hydrophilic surface of a protein can be inferred. It 
has been proved that either the oligomerization domain or 
the transport subunit provide the support needed to the 
movement of the substrate binding site, through a rigid-body 
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rotation of the substrate binding domain, referred to as the 
“elevator mechanism” [56-57]. For this family, the most 
extensively studied efflux pump is the NorA pump of S. 
aureus. 
The inhibitors that have proven activity against efflux pumps 
of the MFS family are gathered in Figure 5. 
3.1. MFS inhibitors 
3.1.1. Natural Products and Derivatives 
Terpenes and terpenoids, existent in the essential oils of 
plants, have showed promising therapeutic potential in 
various fields. Therefore, studies about EPI potential of these 
Figure 5 Structures of MFS inhibitors 21 – 115. Ac = Acetyl. 
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compounds were carried out. Monoterpenes nerol (21), 
estragole (22), and dimethyl-octanol (23) were tested against 
S. aureus. Compounds 21 and 23 were able to enhance the 
activity of norfloxacin, decreasing its MIC against the NorA 
overexpressing strain while not displaying intrinsic 
antibacterial activity. These open chain terpenes proved to be 
more effective than 22, which carried a benzene ring, at 
inhibiting the NorA pumps [58]. 
Citronellal (24) and citral (25) are monoterpenes, and were 
chosen as starting material for the synthesis of new amide 
derivatives. The basis for this study was the fact that 
aromatic amides are recognized as potent EPIs, whereas 
alkyl, alkenyl, and alkynil amides had not yet been explored. 
The compounds obtained were 5,9-dimethyldeca-2,4,8-
trienoic acid amides and 5,9-dimethyldeca-2,8-dienoic acid 
amides, whose activity for the potentiation of ciprofloxacin 
in S. aureus was assessed. Of the first 22 synthesized 
compounds, seven were able to reduce ciprofloxacin’s MIC 
by 4-fold. Further modifications were performed, and the C-
9 methyl group was replaced by an amide, yielding 
compounds with similar potency as the previous ones. 
Derivatives subjected to hydrogenation led to decreased 
activity, which reveals that unsaturation is an important 
feature for antimicrobial potentiation. The mechanism of 
inhibition was assessed through ethidium bromide efflux, 
confirming these compounds act by inhibiting NorA, being 
compound 26, a 9-formyl-5-methyldeca-2,4,8-trienoic acid 
amide, the most potent inhibitor [59]. 
Ferruginol (27), a diterpene, showed efficiency in inhibiting 
the efflux of ethidium bromide, proving its activity as a 
NorA inhibitor. It also showed a decrease in norfloxacin 
efflux in S. aureus [60]. Totarol (28), a phenolic diterpene, 
also showed a reduction in ethidium bromide efflux, 
suggesting activity against NorA pump, even though its 
mechanism is not yet known [61]. 
The triterpene ginsenoside 20(S)-Rh2 (29), a trace compound 
from red ginseng, also enhanced the effect of ciprofloxacin 
against S. aureus, through a NorA-mediated efflux 
inhibition, promoting the antibiotic accumulation in the 
bacteria [62].Reserpine (30) is a natural alkaloid derived 
from Rauwolfia vomitoria, known as an anti-hypertensive 
agent, with inhibitory activity against human P-gp and breast 
cancer resistance protein (BCRP) [63-64]. Reserpine (30) 
has proven to be an effective inhibitor of the Bmr multidrug 
transporter in Bacillus subtilis, diminishing the efflux of 
ethidium bromide. Its structural analogue rescinnamine also 
had EPI activity, in a smaller extension than reserpine (30) 
[65]. Through DNA sequencing of the bmr genes of mutants, 
it was shown that reserpine (30) interacts with the residues 
Phe-143, Val-286, and Phe-306 of Bmr pumps, inhibiting 
drug transport [19]. Compound 30 has shown potential as an 
EPI for the inhibition of NorA efflux pumps in S. aureus, 
which are structurally related to Bmr pumps, reversing 
susceptibility to fluoroquinolones, demonstrating reductions 
up to 4-fold in MIC for some tested strains. It has been 
shown that 30’s effect is more pronounced in hydrophilic 
fluoroquinolones, such as ciprofloxacin [66].  The 
mechanism by which 30 performs the inhibitory activity is 
through direct binding to the transporters that mediate drug 
efflux, acting as a competitive inhibitor [19, 67]. Reserpine 
(30) also succeeded in inhibiting the chloramphenicol efflux 
by CmlR1 and CmlR2 of Streptomyces coelicolor, the 
ciprofloxacin and norfloxacin efflux in Listeria 
monocytogenes’s pump Lde, and the kanamycin and fusidic 
acid efflux by LmrS from a MRSA clinical isolate. On the 
other hand, for L. monocytogenes, 30 was not able to reverse 
susceptibility to linezolid and lincomycin, which suggests 
that 30 does not completely overlap with the structure 
binding sites of efflux pumps, being the inhibition dependent 
on the type and nature of the substrate [19]. However, 
reserpine (30) shows neurotoxicity at the concentration 
required to inhibit NorA, leading to the need to investigate 
new inhibitors [67].Piperine (31), an alkaloid found in the 
fruits of Piper nigrum, was found to be an inhibitor of 
ciprofloxacin efflux in S. aureus, reducing the MIC by 2-
fold. It is thought that compound 31 acts as a direct inhibitor 
of drug efflux. Compound 31 inhibits drug transport of the 
pump MdeA, potentiating the effects of benzalkonium 
chloride, doxorubicin, daunorubicin, novobiocin, 
tetraphenylphosphonium chloride, rhodamine 6G, 
virginiamycin and mupirocin [17, 19-20]; it also inhibits 
ciprofloxacin efflux by NorA [68]. 
Figure 5 (cont.) 
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Given these positive results obtained with piperine (31), 
further research into this scaffold was performed. Kumar et 
al. (2008) performed a screening of about 200 structurally 
diverse compounds for the inhibition of NorA efflux pump, 
choosing ethidium bromide as a substrate, since the only 
mechanism through which this compound is expelled is 
active transport (68). About 50 compounds were able to 
increase the intracellular concentration of ethidium bromide 
by 4-fold, while not displaying antibacterial activity. Five of 
these compounds were more potent than piperine (31), being 
three of these compounds selected for further studies: 32, 33, 
and 34, being 32 and 34 more potent than 31 by 40-fold [18, 
68]. Assumptions regarding structure-activity relationship 
(SAR) studies of these molecules could be drawn (Figure 6). 
It was demonstrated that the introduction of an alkyl group at 
C-4 position, mainly an isopropyl, isobutyl or di-isopropyl 
group, coupled with the substitution of the piperidinyl 
moiety with an aromatic amine, such as aniline, would lead 
to maximum potentiation of ciprofloxacin; if the anilinyl 
moiety is substituted with a 2-hydroxymethyl group or a 
nitrile, regardless of the positional isomery, ciprofloxacin 
activity would increase. Replacing the piperidinyl moiety 
with a phenylacetamide yields good potentiation of 
ciprofloxacin, reducing its MIC by 4-fold, regardless of the 
isomery. Unsaturation is crucial for the potentiation, as well 
as the amide. Lastly, the retention of 3,4-
methylenedioxyphenyl or 4-methoxyphenyl groups in the 
1,3-benzodiol moiety also gives favorable results [68-70]. 
Plants of the Berberis species have the ability to produce the 
alkaloid berberine, which is a plant secondary metabolite 
produced in response to microbial invasion, whose activity is 
enhanced by a flavolignane also produced by these species, 
5’-methoxyhydnocarpin (35) [71]. Compound 35 exists in a 
mixture of anion and neutral compound at physiological pH, 
since it has a phenolic group with a pKa of 7.3. Due to the 
acidic properties of this 7-OH group, 35 is likely to be a 
specific microbial MDR inhibitor, as flavonoids with P-gp 
inhibitor properties usually possess alkylated 7-O groups. In 
fact, when added to a wild type strain of S. aureus, 
compound 35 caused a decrease in norfloxacin’s MIC to 
0.25 µg/ml. Furthermore, when tested with berberine and 
palmatine, 35 appeared to completely inhibit NorA, 
suggesting it acts as a non-competitive inhibitor [71]. 
A number of hydnocarpin-type flavolignanes were 
synthesized in order to perform SAR studies. Flavolignanes 
with and without phenolic groups at the 5 and 7 positions 
had comparable activity. Diosmetin (11), the parent 
compound, presents hydroxyl groups in the A ring and was 
the most potent compound. Peracetate derivatives of 35 have 
approximately the same potency as their parent compounds, 
and could be considered prodrugs, if deacetylated by S. 
aureus, which seems unlikely. Considering the D ring, 
compounds bearing a 3’’-methoxy-4’’-hydroxy moiety 
displayed good activity, and 3’’,5’’-dimethoxy-4’’-hydroxy 
moieties conferred a slightly less active compound. As for 
the B ring, the presence of an H or an OH is not critical for 
activity [72]. In addition, a flavone isolated from Alkanna 
orientalis, sarothrin (36), blocked ethidium bromide efflux 
by S. aureus, suggesting its potential activity as a NorA 
inhibitor [73]. 
Biochanin A (37), an isoflavone, also showed potentiation of 
norfloxacin and berberine against wild-type S. aureus and 
Bacillus megaterium. An analogue of luteolin, orobol (38), 
was quite active as a NorA inhibitor, unlike luteolin itself. It 
was shown that flavones which have a single methoxy in its 
B-ring are more potent than flavones with two methoxy 
groups in the B-ring [74]. 
Another flavone, baicalein (39), was capable of potentiating 
the effect of ciprofloxacin in S. aureus. Studies aimed at 
measuring the efflux of ciprofloxacin and pefloxacin, a poor 
NorA substrate, were performed, and showed that compound 
39 was much more potent at restoring ciprofloxacin 
Figure 6 Conclusions from SAR studies for piperine and its derivatives. 
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sensitivity than pefloxacin, leading to the conclusion that this 
flavone acts as a NorA efflux inhibitor, even though its 
mechanism remains unknown [75]. 
Maia et al. (2011) identified six flavonoids from the plant 
Praxelis clematidea: apigenine, genkwanin, 7,4’-
dimethylapigenin, trimethylapigenin, cirsmaritin, and 
tetramethylscutellarein (40) [76]. These methoxylated 
flavones showed no antibacterial activity, but were able to 
reduce the MIC of norfloxacin at least by 2-fold and up to 
16-fold, as was the case of 40, at a concentration of 8 µg/ml, 
being therefore considered NorA efflux pump modulators. It 
is thought that the lipophilicity of the flavonoids, 
strengthened by the presence of methoxyl groups, is 
responsible for this activity [21]. Presence of a methoxy in 
the 4’ position proved to be decisive for activity, as 
flavonoids containing this group were more potent. The 
number of methoxy groups is also essential for potency, 
being the most metoxylated compounds the most active [76]. 
Tiliroside (41), an amphipathic kaempferol glycoside, 
reduced the concentration of antibiotic needed to inhibit the 
growth of bacteria. The lipophilicity of the flavone moiety 
may be a determinant factor for the activity displayed. 
Tiliroside (41) showed no antibacterial activity against S. 
aureus, but showed a decrease in the MIC of 
fluoroquinolones up to 16-fold, when at a concentration of 
64 µg/ml. The reduction in the MIC of biocides, such as 
ethidium bromide and benzalkonium chloride, was 
impressive, with the MIC of acriflavine showing a decrease 
by 128-fold at the concentration of 64 µg/ml and 32 µg/ml. 
These results suggest that 41 might additionally act on 
pumps other than NorA [77]. 
Kaempferol 3-O-α-L-(2, 4-bis-E-p-coumaroyl)rhamnoside 
(42) was also able to potently inhibit in a concentration 
dependent manner NorA-mediated ethidium bromide efflux 
in S. aureus. This compound also increased the antibiotic 
effect of norfloxacin against a wild-type and a NorA 
overexpressing strain of S. aureus. However, it has to be 
considered that 41 and 42 are flavonoid glycosides and 
cinnamoyl esters, and that their activity can become 
compromised with the activity small intestine β-glucosidases 
or plasma esterases, even though the activity might possibly 
lie in the kaempferol moiety, with 41 and 42 acting as 
prodrugs. The authors hypothesized that if the activity of 
compound 42 is compromised, this compound could be used 
as adjuvant of ciprofloxacin for topical infections [78]. 
Since 42 showed promising results as a NorA EPI, the same 
group performed a screening of a library of 117 chalcones, 
due to their structural similarities with the coumaroyl 
substituents [79]. Ten out of the 117 screened chalcones 
presented medium efflux inhibition at 20 µg/ml. The most 
potent chalcones, such as 43, bear a dimethylaminoethoxy 
moiety, which might disrupt the proton gradient, thus 
eliminating the energy source of NorA. Five of these 
chalcones possessed a hydroxyl group at the 4’-position, and 
potentiated the activity of berberine against S. aureus and B. 
cereus, suggesting that this substituent is also important for 
activity. The compound with a methoxy group at position C-
2 has shown to present the best activity. The majority of 
chalcones tested showed a 4-fold reduction of 
ciprofloxacin’s MIC in S. aureus, suggesting the presence of 
a NorA efflux pump inhibitory activity. Compound 43 
showed 8-fold and 16-fold reduction of the MIC of 
ciprofloxacin at 6.25 and 12.5 µg/ml, respectively. However, 
it also showed antibacterial activity at 25 µg/ml. Some 
chalcones also presented antiparasitic activity, namely 
against Leishmania major and Plasmodium yoelii [79]. 
Another chalcone, 4’,6’-dihydroxy-3’,5’-dimethyl-2’-
methoxychalcone (44), showed good activity as a MDR, 
causing complete growth inhibition at a very low 
concentration (3.3 µg/ml) when combined with a sub 
inhibitory concentration of berberine. When tested in 
combination with berberine, erythromycin, and tetracycline 
against strains of S. aureus, there was an increase in the 
activity of all tested compounds in the wild-type S. aureus, 
indicating a mode of action likely related to the NorA pump. 
This compound was also tested against B. cereus, 
potentiating the effects of the tested antibiotics as well, and 
displaying a favorable effect, particularly in the case of 
berberine, where a 30-fold increase in the activity was 
observed [80]. 
Pheophorbide A (45) is an intermediate of the natural 
breakdown of chlorophyll. Concentrations as low as 0.5 
µg/ml of pheophorbide A with sub-inhibitory concentrations 
of berberine were enough to completely inhibit S. aureus 
growth.  When extended to fluoroquinolones, this compound 
also proved efficient in potentiating the effect of norfloxacin 
by 4-fold in a wild-type strain, being its action directed 
towards NorA [81]. 
Orizabins, oligosaccharides from resin glycosides, were 
evaluated for their efflux pump inhibitory activity on strains 
of S. aureus. These amphipathic compounds showed synergy 
with norfloxacin, whilst showing no antibacterial activity by 
themselves. Orizabin IX (46) completely inhibited the 
growth of a NorA overexpressing strain at 1 µg/ml, while 
orizabin XIX (47) reversed norfloxacin resistance by 4-fold 
at 25 µg/ml for the same strain [82]. Murucoidins, which are 
also resin glycosides, strongly potentiated the action of 
norfloxacin against a S. aureus NorA overexpressing strain 
by 4-fold at concentrations ranging from 5 to 25 µg/ml. 
Stoloniferin I potentiated the same activity by 8-fold at a 
concentration of 5 µg/ml [83]. 
A study aiming to find new EPIs from the plant Geranium 
caespitosum led to the isolation of novel acylated 
neohesperidosides. It was found that two compounds, 
compound 48 and 49, were successful at restoring 
susceptibility to berberine, norfloxacin, and ciprofloxacin at 
sub inhibitory concentrations, possibly due to NorA 
inhibition [84].  
Capsaicin (50), the major constituent of the fruits of the 
Capsicum genus, is a known P-gp inhibitor. Studies were 
performed, in order to evaluate if its inhibitory activity was 
also applied to MDR pumps in bacteria. In a strain of S. 
aureus overexpressing the NorA efflux pump, and therefore 
resistant to fluoroquinolones, 50 proved efficient in 
increasing the susceptibility to ciprofloxacin, while reducing 
the emergence of ciprofloxacin-resistant mutants. Molecular 
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modelling studies of the complex capsaicin (50)-NorA, using 
the glycerol-3-phosphate transporter to predict the structure 
of NorA, showed that compound 50 aliphatic chain extended 
into NorA’s hydrophobic cleft. Furthermore, a weak 
hydrogen bond between Arg-98 and the aryl hydroxyl 
contributed to the stability of the complex [85]. 
Studies in the aqueous extract of Artemisia absinthium 
showed promise in the inhibition of MDR efflux pumps. It 
was proven that this activity came from caffeoylquinic acids. 
At a concentration of 20 µM, 4’-5’-O-dicaffeoylquinic acid 
(51) potentiated the activity of berberine by 16-fold and of 
norfloxacin, by 10-fold against a wild-type strain of S. 
aureus, while not displaying effects in a norA-deleted strain, 
confirming this compound’s NorA inhibition ability [86]. 
Olympicin A (52) is an acylphloroglucinol, found in the 
aerial parts of Hypericum olympicum. This molecule had 
some efflux impeding ability, proven by the improvement of 
intracellular accumulation of enoxacin in a NorA 
overexpressing strain of S. aureus, at 50 µg/ml [87]. 
Riparins are natural alkylamides found in the plant Aniba 
riparia. Since the extraction of these compounds comes with 
very low yields, synthetic approaches were developed. As 
such, the fundamental core of riparins, Rip-A (53), was 
synthesized and derivatives were prepared, Rip-B (54) to E 
(55). Rip-E (55) showed good growth inhibitory activity 
against S. aureus, attributed to their lipophilic nature and the 
presence of hydroxyl groups at the benzamide moiety. 
Oppositely, Rip-B (54), with two methoxy groups at the 
phenyl-ethyl moiety did not present antibacterial activity, 
presenting instead a decrease in the MIC of ciprofloxacin 
and norfloxacin, similarly to reserpine. Combined with the 
ability of decreasing ethidium bromide’s MIC, the activity of 
compound 54 was attributed to NorA inhibition, suggesting 
its potential as an EPI [88]. 
Extracts of Mirabilis jalapa have shown good results in 
reversing fluoroquinolone resistance in strains of S. aureus 
overexpressing the NorA efflux pump. One compound in 
particular, N-trans-feruloyl-4’-O-methyldopamine (56), 
caused an 8-fold reduction in the MIC of norfloxacin, 
making it a potential lead in the search for structurally 
similar synthetic alkylamines [89]. 
Synthesis of derivatives was undertaken, taking N-trans-
feruloyl-4’-O-methyldopamine (56) as a model. The aim was 
to identify active compounds from natural sources and, as 
such, couplings between cinnamic acid derivatives and 
natural-occurring amines were chosen. SAR criteria was 
taken into account, as it is known that substitution of the 
aromatic rings, methoxy or hydroxyl substitution, double 
bonds and aromatic ring nature in the amine part influence 
the activity. The lead compound was N-trans-3,4-O-
dimethylcaffeoyl dopamine (57) since it showed the same 
activity as the natural compound. It was found that, for the 
cinnamic moiety, a hydroxyl substitution on the aromatic 
ring appears to be better than a methoxy group or 
unsubstituted derivatives and the double bond is essential for 
activity. As for the amine part, trisubstitution on the aromatic 
ring increases antibacterial activity, at the cost of decreased 
efflux pump inhibition. Methoxy substitution yields 
compounds with better results than hydroxyl substitution, 
which was better than no substitution and tryptamine 
combinations showed the best results (Figure 7). Among the 
compounds tested, compound 58 showed potentiation of 
norfloxacin comparable to that of reserpine (30). At a 
concentration of 30 µM, 58 showed good results for the 
inhibition of ethidium bromide efflux. For these compounds, 
it was shown that the activity reaches its highpoint when the 
phenyl ring is substituted with two hydroxyls [89]. 
Grapefruit oil fractionation led to the isolation of three 
compounds, two coumarin derivatives and one bergamottin 
Figure 7 Conclusions from SAR studies for compound 57. 
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derivative. The bergamottin epoxide (59) showed a reduction 
of ethidium bromide’s MIC by 6-fold on different MRSA 
strains, and a 20-fold reduction in norfloxacin’s MIC. This 
reduction was also achieved when the coumarin epoxide (60) 
was present, and suggests an activity towards NorA efflux 
pumps [90].  
Coumarins isolated from Mesua ferrea were also studied for 
their efflux pump inhibitor activity against clinical strains 
and NorA overexpressing strains of S. aureus. Seven 
coumarins were tested, and showed good results in inhibiting 
ethidium bromide efflux. Two compounds, 61 and 62, 
showed potential EPI activity against the NorA 
overexpressing strain and a MRSA strain, using norfloxacin 
as a substrate, which makes them desirable compounds for 
the synthesis of derivatives [91]. 
Screening of natural products with P-gp inhibitory effects 
(92, 93) led to the identification of two compounds with 
NorA inhibitory activity, osthol (63) and curcumin (64) [36, 
92-93]. Curcumin (64), derived from the rhizomes of 
Curcuma longa, has additionally already shown activity as 
an anti-inflammatory, antioxidant, antiviral, and anticancer 
agent [36, 92-93]. These compounds were effective in 
reducing the MIC of ciprofloxacin by 4- and 8-fold, 
respectively [94]. 
A penta-substituted pyridine, 2,6-dimethyl-4-phenyl-
pyridine-3,5-dicarboxilic acid diethyl ester (65), was isolated 
from the rhizomes of Jatropha elliptica. This compound, 
when in association with ciprofloxacin, showed a strong 
effect against NorA efflux pumps in S. aureus [95]. 
A methanol extract of the plant Dalea spinosa yielded the 
isolation of six compounds, whose EPI potential was 
analyzed against wild-type S. aureus and mutant strains. It 
was shown that spinosan A (66), at a concentration of 48 
µg/ml, and its acetate 67, at a concentration 42 µg/ml, were 
able to decrease berberine’s MIC by 8- and 62-fold, 
respectively, against the wild-type. Other compounds were 
also able to reduce berberine’s MIC, but to a lesser extent. 
Compound 67 also managed to decrease berberine’s MIC in 
the NorA overexpressing strain, suggesting inhibitory 
activity in this efflux pump [96]. 
 
3.1.2. Synthetic Compounds 
The INF series (compounds 68-72) resulted from an initial 
screening of 9600 structurally diverse compounds, in order 
to find NorA inhibitors for B. subtilis, not expressing Bmr. 
The NorA substrate chosen was ethidium bromide [67]. 
Since this screening did not focus on a specific chemical 
group, the most active compounds were divided into several 
groups. Several indole derivatives were active, which did not 
come as a surprise, since reserpine (30) itself has an indole 
moiety. Another large group was the trichloromethylaminal 
containing compounds, which were not further explored as 
their likelihood to be toxic was high. Biphenyl urea 
derivatives were also active, and other compounds, with no 
obvious similarities, showed activity as well. Five 
compounds were selected for further tests, INF 55 (68), INF 
240 (69), INF 271 (70), INF 277 (71) and INF 392 (72). 
These compounds were active at concentrations of 5 µg/ml 
or less, and included the most potent compound, 72, the most 
potent indole, 68, and the most potent biphenyl urea, 71. 
Derivative 72 was able to reduce resistance to ethidium 
bromide and ciprofloxacin by 8-fold at a concentration of 0.4 
µg/ml. All five inhibitors were more potent than reserpine 
(30) at promoting the activity of ciprofloxacin in S. aureus 
and, by being structurally different, it was hypothesized that 
a potent, nontoxic lead would be identified. These 
compounds also proved effective in inhibiting the Bmr 
multidrug transporter in B. subtilis and two compounds, 68 
and 71, also enhance fluoroquinolone activity in 
Streptococcus pneumoniae [67]. 
The results obtained with INF 55 (68) in S. aureus as an 
inhibitor of the NorA efflux pump led to an increased 
interest in this kind of scaffold. SAR studies regarding the C-
5 proved that substitution in this carbon is crucial for 
activity. Substitution with a nitrile group leads to retention of 
potency, and carbonyl based electron-withdrawing groups at 
C-5 would result in molecules with no activity [97]. Three 
dimensional-quantitative structure-activity relationship (3D-
QSAR) studies predicted that 2-aryl indole derivatives would 
be NorA inhibitors. Functionalized INF 55 (68) showed a 
decreased MIC for berberine, a MDR transporter substrate. 
Berberine is an amphipathic cation alkaloid. From the series 
of 2-aryl-5-nitroindoles synthesized by Samosorn et al. 
(2009), the alcohol 73 was the most effective in inhibiting 
berberine efflux, as well as other antibiotics, such as 
ciprofloxacin, in S. aureus [98]. Later, the same group 
developed a strategy that consisted in a molecule presenting 
dual action: an antibiotic and a MDR inhibitor. Therefore, 
they combined berberine, a hydrophobic cation that is a 
MDR substrate, with INF 55 (68), a MFS inhibitor. These 
efforts yielded compound 74 [17-18, 99]. In terms of 
antibacterial activity in S. aureus, the hybrid was about 100 
times more active than berberine alone, and the difference 
was even higher when tested against a NorA overexpressing 
strain of S. aureus. Enterococcus faecalis also presented 
resistance to berberine, but was susceptible to 74. [99] 
Synthesis of sulfur derivatives was achieved based on the 
premise that the activity of 68 is less dependent on the nitro 
group than the 2-arylindole. Benzothiophene, thiophene, and 
benzofuran derivatives, such as compounds 75, 76, and 77, 
respectively, were able to synergize with ciprofloxacin and 
ethidium bromide, increasing their intracellular 
concentration and leading to the conclusion that these 
compounds inhibit NorA in S. aureus. [100]  
Taking into account the fact that the indole NH is not 
essential for efflux pump inhibition, Samosorn et al. (2009) 
simplified the indole moiety of berberine-based hybrids, 
along with the effect of a methylene ether linking group. 
Their results showed that a hybrid molecule with oxygen in 
the linkage chain had stronger antibacterial and MDR pump 
inhibitory activity than the original 74 [101]. On the other 
hand, removal of the indole moiety produced compounds 
with lower dual activity, and this structural simplification led 
to compounds with low antibacterial activity, but with 
retained NorA pump inhibitory activity. These data suggest 
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that while the indole moiety is not necessary for NorA pump 
inhibition, it is required for the antibacterial activity of 
hybrid compounds [101]. 
A recent study identified a novel class of NorA EPIs with a 
polysubstituted indole moiety. Twenty molecules were 
highly active in inhibiting ethidium bromide efflux in S. 
aureus. However, the best results were obtained with 
compounds 78 and 79, which were derivatives that presented 
three and four carbon atom chains, respectively. Compound 
78 presented the best half maximal inhibitory concentration 
(IC50), with a concentration of 1.8 µM. Compound 79 
exhibited similar IC50 (2 µM) and ethidium bromide 
inhibition as 78. Compounds with shorter or longer carbon 
chains did not present such good results, leading to the 
conclusion that three or four carbons make up the right 
distance between the indole scaffold and the basic center, 
thus presenting the best inhibitory effect. When tested for 
their synergy with ciprofloxacin, both 78 and 79 were able to 
restore the antibiotic’s activity [102]. It was found that the 
substitution of the C-5 in the indole results in a potent EPI, 
particularly if there is a propoxyl chain carrying terminal 
cyclic amino groups, which appears to be crucial for NorA 
inhibition at low concentrations. The presence of the N-
benzyl moiety preserves inhibition and contributes to the 
modulation of the biological effects and ADME properties, 
depending on its substituents [103]. 
Another successful example of a hybrid antibacterial/EPI is 
the fluoroquinolone scaffold accommodating a bis-aryl urea 
EPI moiety at the C-7 position. This kind of compounds was 
successful in inhibiting NorA pumps in S. aureus. 
Compound 80, which incorporates a bis-aryl urea motif into 
the ofloxacin core, proved to be a potent inhibitor of MFS 
efflux pump systems, achieving 84 % inhibition rate at 10 
µM. Moreover, these compounds also successfully inhibit 
MepA pump systems from the MATE family [17-18, 104]. 
Fluoroquinolones containing a thiopyranopyridine moiety at 
the C-7 position were synthesized and their activity was 
tested against strains of S. aureus. However, these 
derivatives did not seem to be NorA substrates. Further 
investigations into thiopyranopyridinylquinolone esters were 
carried out. Some of the synthesized compounds displayed 
better inhibitory activity than reserpine (30), namely 
quinolone esters 81, 82 and 83, and showed significant MIC 
reduction of ciprofloxacin.  Compounds 82 and 83 also 
showed a 32-fold MIC reduction of ciprofloxacin for strains 
of S. aureus overexpressing MepA pumps from the MATE 
family [18, 105]. In terms of established SAR, these 
compounds definitely do not need the fluorine atom at the C-
6 position for the antibacterial activity of 
thiopyridinylquinolones. A methyl at the C-8 position yields 
a compound with enhanced activity against Gram-positive 
bacteria for 6-amino derivatives. The thiopyranopyridine 
moiety at the C-7 position is crucial for NorA and MepA 
inhibition (Figure 8) [105]. 
Derivatives of 2-(4-propoxyphenyl)quinolone were 
synthesized based on the premise that its large hydrophobic 
area and ability to establish an electrostatic interaction would 
make them suitable inhibitors of NorA. These derivatives 
also mimic the quinolone antibacterial core and possess a 
versatile scaffold, making it prone to be very simply 
chemically modified. These classes of compounds were 
obtained by performing modifications in the 2-phenyl-4H-
chromen-4-one moiety, which is a common feature of 
flavone and flavolignane EPIs [106]. 
Studies showed that the O-substituted 2-phenyl-4-
hydroxyquinoline derivatives displayed the best activity as 
NorA inhibitors. Compounds 84 and 85 showed synergistic 
activity against a strain of S. aureus overexpressing NorA 
Figure 8 Conclusions from SAR studies for fluoroquinolone 81 derivatives. 
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efflux pumps comparable to reserpine (30) and, comparing 
the results obtained with a mutant strain, absent of NorA, it 
was found that these compounds are able to completely 
restore the antibacterial activity of ciprofloxacin in the 
resistant strain [18, 106]. Preliminary SAR studies for this 
new class of EPIs showed that the best activity is when the 
quinolone core is replaced with the 2-phenyl-4-
hydroxyquinoline group with an alkylation in the C-4 
hydroxyl group. 2-Ethylamino chains inserted at the N-1 
position of the quinolone nucleus or at the C-4 hydroxyl of 
the quinoline moiety provided compounds with better 
activity than those carrying the same chain at the C-2 of the 
phenyl ring. The best substituent for the C-2 phenyl ring 
appears to be the C-4’ propoxy group (Figure 9) [106]. 
Taking these results into account, efforts have been placed to 
obtain more potent NorA inhibitors, introducing O-alkyl or 
different O-alkylamino chains at the C-4 position. The 
strategy was to determine the essential 3D structural 
requirements for the inhibition of NorA, based on the NorA 
EPIs described in literature through the use of computational 
methods, since the 3D structure of this pump was not 
elucidated yet. The results led to the building of a possible 
pharmacophore, which was used to design novel compounds, 
with different substituents at the C-4 position, which were 
synthesized and biologically evaluated [107]. The 
compounds were assayed for their ability to reduce the MIC 
of ciprofloxacin in S. aureus strains, and all compounds 
displayed this decrease for the strain overexpressing NorA 
pumps. One compound in particular, 86, showed a 16-fold 
reduction in this strain for ciprofloxacin’s MIC. SAR studies 
for this emerging class show that the best activities come 
from the compounds bearing the 2-ethylaminoalkyl chains 
linked to the C-4 hydroxyl group, such as compound 87. The 
inclusion of an aliphatic ring including the side chain 
nitrogen atom led to retention of activity, whereas inclusion 
in an aromatic ring led to loss of activity, where the nitrogen 
nucleophilicity was reduced. The mono-substituted 
compounds, like 88, with a benzyl group were well tolerated, 
and showed higher ethidium bromide inhibitory activity than 
compounds with two benzyl groups as substituents (Figure 
9) [107]. 
3-(Dihydronaphtyl)-propenoic acid amines were evaluated 
for their EPI activity. Five compounds were synthesized, and 
two of them showed good results in inhibiting ciprofloxacin 
efflux in strains of wild-type and NorA overexpressing S. 
aureus. Further studies were performed, given the low EPI 
activity of this kind of compounds. Fifteen different 
compounds were synthesized, taking α-tetralone (12) as 
starting material. Out of these, four compounds showed 
significant MIC reductions for ciprofloxacin for the NorA 
overexpressing strain. One compound, 89, even displayed a 
16-fold reduction, while other remained in the range of 4- to 
8-fold. These studies allowed SAR to be established. 
Addition of methoxy or allyloxy substituents at the 6,7-
position of the 3,4-dihydronaphtalene leads to lower or no 
activity, whereas no substitution originated better EPIs. 
Saturation of the double bonds lowered the potentiating 
Figure 9 Conclusions from SAR studies for 2-phenyl-4-hydroxyquinoline derivatives 84 and 86. 
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activity (about 2-fold), while unsaturated derivatives made 
much more potent compounds [108]. 
Boronic species have been described for a variety of 
activities, namely antimicrobial and antineoplasic. 
Organoboron compounds, oxazaborolidines, boronic esters, 
and boronic acids are of particular interest, within this class. 
Fontaine et al. (2014) developed studies on these molecules, 
starting from a screening of a library of approximately 150 
compounds, out of which 24 were hit compounds 
(exemplified with compounds 90 and 91), and were able to 
restore the activity of ciprofloxacin by 4-fold at 
concentrations of 0.5 to 8 µg/ml against the NorA 
overexpressing strain of S. aureus [109]. Preliminary SAR 
studies demonstrated the need of the boron atom for activity. 
Most pyridine-3-boronic acids showed best potentiating 
activity (e.g., compound 90), whereas pyridine-4-boronic 
derivatives showed no activity, with exceptions, including a 
fluorinated ester. The shift of the boronic moiety from C-3 to 
C-4 led to a loss of activity and the trigonal boronic acid 
function gave better results that the sodium boronate salts 
and the potassium trifluoroborate. Concerning the pyridine-
3-boronic acids, the most promising compounds appear to be 
the 6- and the 5,6-disubstituted ones, being the latter 
compounds less potent. Cyclisation at the C-5 and C-6 
positions was well tolerated, as was the introduction of a 
methyl at the C-5 position. For the benzene analogues, which 
displayed good activity, cyclisation at the C-3 or C-4 was 
also well tolerated, as was the introduction of a methyl. A 
substituent at the para position to the boronic moiety proved 
to be very important. Two compounds were particularly 
efficient in inhibiting NorA, and did not display intrinsic 
antibacterial activity and cytotoxicity: the 6-
benzyloxypridine-3-boronic acid 90, which displayed the 
highest activity, potentiating ciprofloxacin by 4-fold at a 
concentration of 16 µg/ml, and the 4-benzylxybenzene 
boronic acid 91 [109]. 
Compound 90, being the most promising compound, was 
considered a hit, and its structure was used as a model for the 
synthesis of new derivatives. Therefore, the 6-benzyloxy 
group was substituted with (aryl)alkoxy chains with variable 
lengths (compounds 92 and 93 as examples), in an attempt to 
explore the putative hydrophobic binding site of NorA, and 
substituents were added to the phenyl ring. The ether linkage 
between the pyridine ring and the 6-benzyloxy group was 
substituted as well. The first substitution made was the 
replacement of the 6-benzyloxy group with alkoxy chains of 
diverse lengths, as to explore the size of the hydrophobic 
pocket of NorA. The potency of the compounds increased 
with the increase of the size of the side chain, although the 
compound with a 11-carbon side chain displayed no activity 
whatsoever. A new series of compounds with a phenyl ring 
at the end of the side chain were synthesized, with the aim of 
enhancing hydrophobicity, and the results showed these 
compounds were more efficient. It was concluded that the 
compound with the best performance possessed a side chain 
with seven carbon atoms and a phenyl group: compounds 92, 
6-(3-phenylpropoxy)pyridine-3-boronic acid, and 93, 6-(4-
phenylbutoxy)pyridine-3-boronic acid, showed the highest 
activity in the potentiation of ciprofloxacin (4-fold). The 
introduction of substituents in the phenyl ring of compound 
90 led to unsatisfactory results, with the best compound 
displaying moderate antibacterial activity. A methyl group in 
the C-5 position did not show influence on the activity, and 
the modification of the ether linkage led to varied effects: 
introduction of a sulfanyl, thus conserving the H-bonding 
acceptor capacity, led to similar potentiating activity, 
whereas the introduction of an amine linkage, an H-bond 
donor, led to a decrease in the activity. Finally, the shift of 
the benzyloxy group from the C-6 to the C-5 resulted in no 
activity [110]. 
Compounds AE-848/42434549 (94) and AN-465/42885978 
(95) were hits in a virtual screening of novel NorA efflux 
pump inhibitors in S. aureus. The structures deemed as 
active in silico were later synthesized and evaluated on their 
ability to prevent ethidium bromide efflux, as well as 
ciprofloxacin potentiation. Compound 94 and 95 were as 
potent as reserpine (30) for ethidium bromide efflux and 
more potent at synergizing with ciprofloxacin. These hit 
compounds 94 and 95 paved way for the synthesis of new 
analogues, which allowed SAR studies to be made, in order 
to assess which parts of their structure were determinant for 
the inhibition of NorA. For compound 94, it was shown that 
limited modifications to the sulfone and amide group do not 
cause significant changes in activity. On the other hand, 
modifications to the imidazole ring result in a reduction of 
activity. Replacement of the 1-methylpyrrole ring with a 
furan also shows a decrease in the activity of the compound. 
As for compound 95, the O-benzyl group is essential and the 
introduction of a benzyl in the secondary nitrogen leads to a 
complete loss of activity. Furthermore, the methyl group of 
the 2-(1-phenyl-1-propanol) moiety can be replaced with a 2-
(1-phenyl-1-ethanol) portion without a decrease in the 
activity [111]. 
 
3.1.3. Existing Drugs 
Several drugs already available for the treatment of various 
diseases have shown potential to be used as MFS EPIs. 
Reserpine (30), mentioned before, is one of them. Other 
drugs include verapamil, omeprazole, paroxetine and 
chlorpromazine. Even though bacterial MFS transporters and 
mammalian ABC efflux systems, as P-gp, lack structural 
homology, they share similar substrate profiles, which means 
that mammalian MDR inhibitors can also present bacterial 
efflux inhibition. However, the concentrations needed for 
efflux pump inhibition are too high, which means that toxic 
effects can arise if these compounds are used for this purpose 
[18], [112]. In fact, the addition of verapamil to 
chemotherapy was accompanied with cardiac arrhythmia and 
hypotension [113]. This leads to the requirement of 
developing analogues of these existing drugs maintaining the 
desired EPI activity at concentrations that do not display 
toxicity [112]. 
The antiarrhythmic verapamil, a known P-gp inhibitor, has 
shown moderate NorA inhibitory activity in both B. subtilis 
and S. aureus, enhancing fluoroquinolone activity [114-115]. 
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However, the best results were obtained with proton pump 
inhibitors omeprazole (96) and lansoprazole. Therefore, a 
series of pyrrolo[1,2-a]quinoxaline derivatives mimicking 
the omeprazole structure (96) were designed, with the aim of 
evaluating their EPI activity against NorA. All the eleven 
derivatives showed a reduction in norfloxacin’s MIC, being 
compound 97 the most active, reducing the MIC by 16-fold 
at 128 µg/ml. These compounds did not show disturbance of 
the electrical potential and the transmembrane pH, excluding 
the alteration of the proton-dependent pump as the 
mechanism of action. Instead, it is thought that these 
compounds interact directly with NorA. It was shown that 
the benzimidazole moiety is critical for the activity of these 
compounds (Figure 10), and replacing it with an imidazole, 
a pyridine or a pyrrolo[1,2-a]quinoxaline ring resulted in 
loss of potency. Furthermore, if there is a methoxy-
substituent in the benzimidazole ring, potency increases. 
Introduction of chlorine in the C-7 of the pyrroloquinoxaline 
heterocycle provided an efficient restoration of norfloxacin’s 
bactericidal activity. Finally, the benzimidazolyl group was 
also important for activity [112].  
This was not the first time that pyrrolo[1,2-a]quinoxaline 
derivatives were described as EPIs. In fact, a previous study 
by the same group produced 12 new 4-[116]pyrrolo[1,2-
a]quinoxalines and one pyrrolo[1,2-α]thieno[3,2-e]pyrazine 
compound. Two compounds, 98 and 99, were more active 
than reserpine (30), diminishing norfloxacin’s MIC by 16-
fold in a NorA overexpressing strain of S. aureus. This study 
showed that 4-[116]pyrrolo[1,2-a]quinoxalines and their 7-
methoxy analogues were more active, in contrast with the 
chlorine- and 8-phenyl-substituted compounds, that 
presented the lowest effects. Replacement of the N,N-
diethylamino group by pyrrolidine, its isomer with restricted 
conformation, led to enhanced EPI activity, whereas 
replacing it with a piperidine ring led to more flexible and, 
consequently, less active compounds. The 
pyrrolothienopyrazine 99 moiety yielded the best results, 
suggesting that sulfur, an electron-rich atom, potentiates the 
EPI activity [116]. 
GG918 (19) was discovered in a screening program aimed to 
identify inhibitors of mammalian P-gp, and was able to 
increase the concentrations of paclitaxel. This compound did 
not present antibacterial activity against the strains of S. 
aureus tested. However, the co-administration with 
norfloxacin resulted in a 4-fold reduction in the MIC of the 
NorA overexpressing strain [52]. 
Two mammalian MDR inhibitors, biricodar (100) and 
timcodar (101), confer increased drug sensitivity to cells 
expressing both the P-gp and multidrug resistance protein 
(MRP)-1 efflux systems. They also show potentiation of 
multiple antibiotics in Gram-positive bacteria. In fact, both 
compounds were able to potentiate the activity of ethidium 
bromide against S. aureus, E. faecalis, and S. pneumoniae. 
For the specific case of S. aureus, both compounds were able 
to partially reverse fluoroquinolone resistance. The fact that 
the MIC of ethidium bromide was non-saturable for the three 
bacteria tested suggests that 100 targets multiple efflux 
pumps [117]. 
A series of polysubstituted pyrroles was screened for their P-
gp inhibition activity, which made way for the identification 
of a lead, and the compounds were further investigated for 
their bacterial efflux pump inhibition activity. A simplified 
pyrrole alkaloid, 102, displayed dual activity as both a P-gp 
and a NorA inhibitor against S. aureus. This compound led 
to 4-fold improvement in the MIC of ethidium bromide in 
the NorA overexpressing strain. Compound 102 was also 
able to reduce ciprofloxacin’s MIC by 8-fold when at 50 µM 
[118]. 
Tariquidar (103), a third generation MDR modulator, with 
activity in inhibiting P-gp and BCRP efflux systems, has 
shown promise in inhibiting efflux pumps in S. aureus. In 
fact, this compound showed an increase of the isotopic form 
of ciprofloxacin in all investigated strains, displaying best 
results in the strain that overexpresses the NorA pump. [119] 
Figure 10 Conclusions from SAR studies for omeprazole derivatives. 
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The class of phenylpiperidine selective serotonin reuptake 
inhibitors (PSSRI), which includes the antidepressant 
paroxetine (104), showed efflux-related potential against S. 
aureus, particularly that conferred by NorA. In fact, 
paroxetine and its isomer, 105, showed potency with respect 
to inhibition of this efflux pump against ethidium bromide. 
The isomer 105 also interfered with the accumulation of 
norfloxacin by NorA, reducing by 4- to 8-fold its MIC. [120] 
Femoxetine (106) is a paroxetine derivative, with activity as 
an EPI. [120] Studies were performed as to determine which 
moieties in paroxetine- and femoxetine-like PSSRI were 
detrimental for efflux pump inhibition in S. aureus, and 
conclusions from SAR are highlighted in Figure 11. 
Synthesis of derivatives showed that the fluorine atom on the 
phenylpiperidine moiety is not associated with the activity. 
The N-substitution of the piperidine ring yields different 
kinds of activity, suggesting that the NH group forms a 
positive binding contact with the target pump, which does 
not happen if there is a N-substitution (compound 106). The 
phenyl ether substituents also play an important role as 
determining the EPI activity. [121] 
Also for this kind of compounds, a study was performed, in 
order to conclude whether the 4-phenyl ring is required for 
EPI activity and the effects of changes in the two-atom 
aryloxymethyl linker, replacing it with a thioether, amine, 
and alkene linker portions. Compounds 107 and 108 
displayed the lowest MIC against S. aureus. Synthesis of 
multiple derivatives proved that the 4-phenyl moiety is not 
vital for EPI activity and that a variety of two-atom linker 
groups for the 3-aryl piperidine moiety can maintain EPI 
activity [122]. 
The ciclooxigenase-2 (COX-2) inhibitor celecoxib (109) has 
also received attention for its MDR inhibitory activity. There 
had been a link between COX-2 and mdr1 gene expression, 
which has consequences in cancer chemo resistance, and the 
use of celecoxib (109) reversed drug resistance. If this is true 
for mammalian efflux pumps, for bacteria there is no 
evidence of a COX-2-like gene, suggesting that celecoxib 
acts differently in inhibiting MDR in bacteria. A study was 
carried out in order to prove this hypothesis, which 
demonstrated that this drug helped in increasing sensitivity 
to antibiotics in S. aureus and Mycobacterium smegmatis. 
These effects probably occur due to the blockage of MDR 
transporters involved in the efflux of antibiotics, such as 
ampicillin, ciprofloxacin, kanamycin, and chloramphenicol. 
The observation of the accumulation of ethidium bromide 
intracellularly leads to the conclusion that this compound 
acts as a NorA inhibitor [123]. 
As celecoxib (109) demonstrated such promising activity, 
analogues were tested, which bore low or none anti-
inflammatory activity and possessed the 1,4-
dihydropyrazolo[4,3-c]-benzothiazine-5,5-dioxide nucleus. 
Ethidium bromide efflux inhibition was tested first in silico, 
and the 17 molecules that fit the chemical space 
requirements were then reduced to six, based on the activity 
prediction. These compounds were then screened for their in 
vitro NorA inhibitory activity, using an overexpressing strain 
of S. aureus. One derivative in particular, compound 110, 
showed the best activity concerning ethidium bromide efflux 
(76.9%) which is better than celecoxib (109) (64.5%). When 
in combination with ciprofloxacin, 110 displayed results 
comparable to reserpine (30) and better than paroxetine 
(104), which makes it a lead compound for the development 
of inhibitors of this kind [124]. 
Phenothiazine and thioxanthene derivatives are currently 
used as neuroleptic and antiemetic agents, and have been 
described as modest, but broad, antibacterial agents. 
Although their antibacterial activity is not enough to be 
clinically relevant, they have shown synergy with standard 
antibiotic agents, and have also been associated with the 
inhibition of eukaryotic MDR efflux pumps, such as P-gp. 
The mechanism through which these compounds exert their 
antimicrobial potentiation is not yet fully understood. 
However, it is thought that it might have to do with the 
inhibition of efflux pumps [125]. A study focusing on the 
activity of several compounds of these families against S. 
aureus was carried out, with the main aim of showing their 
potential in inhibiting NorA. The compounds tested, 
chlorpromazine, fluphenazine, thioridazine, prochlorperazine 
(111), cis(Z)-flupentixol, and trans(E)-flupentixol (112), 
displayed intrinsic antimicrobial activity and good results 
when ethidium bromide efflux was assayed against a NorA 
overexpressing strains of S. aureus. Additionally, 
phenothiazine 111 and thioxanthene 112 were also able to 
reduce the proton motor force of S. aureus, by reducing the 
transmembrane potential [125]. 
Since the phenothiazine moiety proved itself to work as a 
template for the synthesis of new MDR EPIs, it was chosen 
to be the scaffold for derivatives with improved activity. The 
Figure 11  Conclusions from SAR studies for paroxetine 
derivatives. 
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logic for these studies lied in the elimination of the structural 
features that were responsible for neuroleptic activity. As 
such, drastic modifications were made, such as the 
elimination of one ring of the tricyclic benzothiazine 
backbone and of the chain linked to the N-10 atom, a tertiary 
amine whose protonation is crucial for the interaction with 
the dopaminergic receptor, and the addition of a substituted 
phenyl ring at the C-3 position, to guarantee better 
lipophilicity. Therefore, a prototype of new 3-phenyl-2H-
1,4-benzothiazines was developed. Preliminary screening on 
the derivatives using a wild-type S. aureus strain, both with 
and without ciprofloxacin, showed variable intrinsic and 
synergistic activity. Two compounds, 113 and 114, displayed 
the best activity, while displaying no and weak antibacterial 
activity, respectively. These compounds were able to inhibit 
NorA efflux of ciprofloxacin, being suggested that 114 was 
even able to completely inhibit this pump [126]. 
Thioridazine (115), a phenothiazine, was also tested for its 
antibiotic potentiation, either in racemate or in its 
enantiomeric forms. All the forms were able to reduce the 
MIC of oxacillin in S. aureus and erythromycin in 
Streptococcus pyogenes, being the L-enantiomer more 
effective in the last case [127-128]. 
 
4. RND 
RND pumps are found mostly in Gram-negative bacteria, 
being the most responsible pumps for MDR in this kind of 
organisms. They present a wide variety of lipophilic and 
amphiphilic substrates, which include several classes of 
antibiotics, antiseptics, dyes, and detergents. RND 
transporters present a unique tripartite complex, constituted 
by a minimum of twelve transmembrane segments: the 
transmembrane pump, the outer membrane channel, and the 
periplasmic adaptor protein, which puts the other two 
components in contact. This structural organization makes 
the extrusion of substrates directly into the external medium 
possible [32, 38]. Even though it has always been thought 
that RND transporters were exclusive to Gram-negative 
bacteria, it has recently been identified and characterized 
FarE in S. aureus, homolog to the AcrB protein in E. coli 
[129-130]. 
Within this family, the most studied system is the AcrAB-
TolC, from E. coli. This efflux pump is composed by three 
essential parts: a resistance-nodulation-division transporter, 
AcrB; a membrane fusion protein, AcrA; and a 
multifunctional outer membrane channel, TolC [7, 131-133]. 
It transports a wide variety of toxic compounds from the 
intracellular space directly into the medium, evading the 
periplasm, and using a proton gradient as the energy source 
[132-133]. Pseudomonas aeruginosa also possesses an 
efflux system of the RND family, the MexAB-OprM efflux 
pump, which confers resistance to a wide variety of 
antibiotics. This was the first and best characterized efflux 
system in bacteria. It was found that AcrB (Figure 12, PDB 
4ZLJ) is homolog to MexB (Figure 12, PDB 2V50), being 
their structure very similar [7, 134]. 
Figure 13 comprises all the RND pump inhibitors that will 
be discussed in the following section. 
 
4.1. RND inhibitors 
4.1.1. Natural Products and Derivatives 
One study revealed that the essential oil of Helichrysum 
italicum can reduce the resistance to chloramphenicol in E. 
aerogenes, P. aeruginosa, and A. baumanii. These data 
suggested that one or more EPIs are present within the 
essential oil since it was shown that geraniol (116) produced 
Figure 12 Crystal structures of AcrB (left, PDB 4ZLJ) of E. coli and MexB (right, PDB 2V50) of P. aeruginosa. 
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Figure 13 Structures of RND inhibitors 116 – 154. Boc = tert-Butyloxycarbonyl. 
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Figure 13 (cont.) 
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significant restoration of sensitivity to chloramphenicol by 
16-fold, and rendered a total sensitivity of the organism 
when combined with of phenyl-arginine β-naphtylamide 
(PAβN), which will be discussed further ahead [135]. 
A study published by Aparna et al. (2014) had the aim of 
identifying natural compounds from plants that present 
efficacy in potentiating effects of antibiotics in P. 
aeruginosa overexpressing MexAB-OprM and E. coli 
overexpressing AcrAB-TolC through in silico virtual 
screening and pharmacophore approaches [136]. The 
compounds with the best in silico results were then tested for 
their EPI activity. The two compounds that showed the best 
activity in potentiating the activity of carbenicillin and 
levofloxacin in P. aeruginosa and E. coli were lanatoside C 
(117) and daidzein (118). Lanatoside C (117) is cardiac 
glycoside that inhibits the Na
+
-K
+
-ATPase, which can also 
be the explanation for its EPI activity against MexB and 
AcrB. Daidzein (118) is an isoflavone that has previously 
showed slight EPI activity in Mycobacterium smegmatis and 
as a modulator of P-glycoprotein, in human cervical 
carcinoma KB-V1 cells [136]. 
An in silico study by Ohene-Agyei et al. (2014) identified 
five phytochemicals that could be docked similarly to PAβN 
in the binding pocket of AcrB. Of these five, three of them 
were able to decrease resistance to antibiotics by inhibiting 
the AcrAB-TolC system: plumbagin (119) increased 
sensitivity to erythromycin, chloramphenicol, and 
tetraphenylphosphonium; nordihydroguaretic acid (NDGA) 
(120) potentiated the activity of erythromycin, 
chloramphenicol, tetraphenylphosphonium, novobiocin, and 
tetracycline; and shikonin (121) decreased resistance to 
tetraphenylphosphonium [137]. 
A study proved the usefulness of curcumin (64) as a RND 
EPI at a concentration of 50 µg/ml, increasing the sensitivity 
of carbenicillin, ceftazidime, and meropenem in P. 
aeruginosa, in decreasing order. It also managed to 
circumvent the resistance to gentamicin and ciprofloxacin in 
resistant isolates, which PAβN failed, leading to the 
assumption that curcumin inhibits efflux pumps differently 
from PAβN [138]. 
A screening of 85 000 microbial fermentation extracts 
derived from 3 600 strains of actinomycetes and 3 500 
strains of fungi was made, with the aim of discovering EPIs 
that increased sensitivity of levofloxacin in P. aeruginosa 
overexpressing the MexAB-OprM or the MexEF-OprN 
pump. Two compounds, EA-371α (122) and EA-371-δ 
(123), produced by a strain of Streptomyces sp., 
demonstrated inhibitory activity against MexAB-OprM 
[139]. 
 
4.1.2. Synthetic Compounds 
The first compound with potent inhibition of RND efflux 
pumps was PAβN (124), a dipeptide amine. This dipeptide 
was identified as a hit compound from the screening of 200 
000 samples of small molecules that potentiate the activity of 
antibacterial levofloxacin against strains of P. aeruginosa 
that overexpressed MexAB, MexCD and MexEF pumps [28, 
140]. Compound 124 is a peptidomimetic, developed for 
using in adjunctive therapy. This compound is a substrate for 
RND pumps, acting as a competitive inhibitor of multidrug 
efflux systems, such as MexB, MexD, and MexF, binding to 
the substrate pocket, impeding antibiotic binding and/or 
extrusion. Particularly, this EPI binds in a location close to 
the antibiotic binding site, generating steric hindrance, 
making it more difficult for the antibiotic to bind. In other 
words, less quantity of antibiotic is exported, making its 
intracellular levels higher, thus restoring antibiotic 
sensitivity [11, 25, 27-28, 141-143]. However, 124 can affect 
the integrity of the membrane when used in high 
Figure 13 (cont.) 
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concentrations, making it prone to the emergency of resistant 
profiles, namely the modification of the lipopolysaccharide 
structure, leading to changes in drug penetration [24].  
PAβN (124) has been validated against the AcrAB-TolC in 
Klebsiella pneumonia, E. coli, Salmonella enterica serovar 
Typhimurium and Enterobacter aerogenes, and in multiple 
homologous systems including Acinetobacter baumanii, 
Campylobacter jejuni, and Campylobacter coli [11, 142]. Its 
potency has been demonstrated against the norfloxacin 
resistance conferred by the Mex efflux system of 
Pseudomonas aeruginosa, the AcrAB efflux systems of the 
Enterobacteriaceae, and the erythromycin efflux system of C. 
jejuni [19]. 
Studies of SAR demonstrated that the basic middle amino 
acid, arginine, was detrimental for activity, although a 
substitution with L-lysine showed the same potency as the 
lead, and the introduction of L-ornithine, originating 
compound L-Phe-L-Orn-β-Na, showed a 2-fold increased 
potency. As the ornithine moiety provided a simpler 
synthesis, it became the standard middle residue in 
successive compounds [25, 142, 144]. However, these 
compounds were not stable upon incubation with human 
serum, due to the occurrence of cleavage of peptide linkage 
between both amino acids, which is explained by the fact 
that natural (L) amino acids are contained within its 
structure. In order to overcome this problem, methylation of 
the NH that links both amino acids was achieved, 
maintaining potency and being this derivative able to resist 
serum proteases. Serum stability was also increased by 
replacing the L-amino acid with D-amino acid [25, 142].  In 
the same study, the authors also proved that the amino acid 
in the aa1 position (Figure 13, 124) should be appropriately 
substituted, and the replacement of phenylalanine with a 
homophenylalanine led to improved potency. The problem 
with this compound was the fact that the ornithine moiety 
could easily form a lactam, rendering the compound inactive. 
This was overcome by switching the L-ornithine with the L-
phenylalanine, which originated L-Orn-L-hPhe-β-Na, which 
originated a compound just as potent, but with no propensity 
to form a lactam. As for the β-aminonaphtalene moiety, it 
was proven that replacing it with 3-aminoquinoline led to 
reduced cytotoxicity and intrinsic antibacterial activity, even 
though its potency was slightly reduced [25, 142]. These 
efforts originated the compound L-Orn-L-hPhe-3-NHQ 
(125). In conclusion, the analogues synthesized by Renau et 
al. (1999) did not show improvements in potency when 
compared to PAβN (124), but showed increased stability 
[142]. 
The same group developed further studies with this type of 
molecules and demonstrated that conformational restriction 
of the amino group of ornithine showed less toxicity, while 
maintaining potency. Such compounds were attained by 
adding a proline substituent, thus incorporating the two basic 
residues necessary for activity, which resulted in the 
successful synthesis of constrained derivatives, more potent 
and less toxic than 125. The most interesting derivative, 
compound 126, was as potent as 125, but more than 4-fold 
less toxic. This compound also retained the activity against 
RND efflux pumps MexAB-OprM, MexCD-OprJ and 
MexEF-OprN. Although this compound showed similar 
protein binding in rats as 125, its pharmacokinetic 
parameters were improved, and its efficacy in combination 
with levofloxacin was demonstrated in an in vivo model 
[145]. 
In a latter study developed by the same group, several non-
peptide analogues were synthesized, and it was hypothesized 
that the peptide backbone is not essential for the activity of 
this type of compounds. The results suggested that the 
inhibition of pumps was possible due to the di-cationic 
nature of the compound, the appropriate lipophilicity and a 
disposition similar to that of compound 125 [146]. 
MBX2319 (127) is a pyranopyrimidine EPI inhibitor of 
AcrAB-TolC efflux pump in E.coli and other 
Enterobacteriaceae [141]. Compound 127 did not show any 
antibacterial activity, which is a positive feature for EPIs. It 
also potentiated the antibacterial activity of 
fluoroquinolones, such as ciprofloxacin and levofloxacin, 
and β-lactams, such as piperacillin against strains of E. coli 
that presented AcrAB-TolC efflux pumps [28, 141].  In P. 
aeruginosa, although compound 127 presents activity 
against RND-type pumps, it is unable to penetrate the outer 
membrane, which is highly selective [28]. 
In E. coli, the target of compound 127 is the membrane 
transporter AcrB. This molecule binds to the hydrophobic 
trap of the T protomer, interacting with the hydrophobic 
residues that constitute the deep binding pocket as a 
hydrophobic trap. π-π Interactions also occurs, between the 
pyridine ring of 127 and the aromatic side chain of Phe-628. 
The phenyl and morpholinyl groups also interact with Phe-
178 and Phe-615. The dimethylenesulfide linker and the 
geminal dimethyl group present van der Waals interactions 
between the side chain of Phe-178, and Tyr-327 and Met-
573, respectively [28, 147].  
SAR studies demonstrated that the maintenance of activity 
depended on the geminal dimethyl moiety of the 
tetrahydropyran, the nitrile group and the length of the 
dimethylenesulfide linker. This data is presented in Figure 
14.  On the other hand, the morpholine moiety and aryl 
group are both prone to substitution, originating more stable 
Figure 14 Conclusions from SAR studies for MBX2319 
(127) (adapted from [28]). 
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derivatives in terms of activity, solubility, and metabolism 
[28]. Studies with this scaffold have shown that non-acidic 
substituents can be added to the phenyl group, in order to 
improve potency and CYP450 inhibition, and modifications 
to the morpholinyl group has greater effects on solubility and 
stability [140]. 
Analogues were synthesized by Sjuts et al. (2016), by 
changing the structure and functional groups of compound 
127 (148). They reached the conclusions that the 
introduction of a 2,6-dimethyl to the morpholinyl group 
improved both microsomal stability and EPI activity. The 
replacement of the morpholinyl group with 2-
methoxyethylpiperazinyl improved aqueous solubility, at the 
cost of a slight reduction of EPI activity. Two analogues, 128 
and 129, resultant of the combination of 2,6-
dimethylmorpholinyl and acetamide or acrylamide, 
respectively, on the phenyl group, resulted in a 10-fold to 20-
fold increase in EPI activity against E. coli, respectively, 
comparing to MBX2319 (127) [28, 148]. The increased EPI 
activity of these compounds has its basis in the acetamide 
and acrylamide groups and the morpholinyl group. The 
acetamide groups are engaged in highly ordered and 
complex hydrogen bonds, with its center in a solvent water 
molecule, which plays the role of a hydrogen bond donor to 
the carbonyl backbone oxygen of Ala-286 and Gln-151 side 
chain of AcrB. The acrylamide group forms a bridging 
hydrogen bond through a water molecule to the side chain of 
Gln-176 [28].  
Nguyen et al. (2015) also synthesized a series of analogues, 
with the morpholine scaffold substituted by a 2,6-
dimethylmorpholinyl group (140). Many of these analogues 
exhibited a solubility improvement of 10-fold, compared to 
compound 127. The most potent and promising compounds 
of these series were compounds 130, 131, 132, 133 and 134 
[140]. 
Through a screening of an N-heterocyclic organic compound 
library, Bohnert and Kern (2005) were able to find a novel 
class of EPIs, the arylpiperazines [25, 149]. The aim of their 
work was to find compounds that would potentiate 
levofloxacin potency against strains of E. coli 
overexpressing acrAB and acrEF. This was fulfilled when 
they found phenylpiperazine derivatives with promising 
activity [25, 149]. SAR studies suggested that elongation of 
the spacer between the benzene ring and the piperazine ring 
would enhance potency. Also, substitutions on the benzene 
ring by halogen atoms led to an increase in potency [24, 
149]. On the other hand, the potency would decrease when 
an ethyl or phenyl group was added to the piperazine ring. 
With this, the authors found the most potent 
phenylpiperazine, meta-TFMPP (135), and 
naphthylpiperazine, 1-(1-naphthylmethyl)-piperazine (NMP) 
(136) [149]. 
NMP (136) was the most potent unsubstituted 
arylpiperazine, able to increase the intracellular 
concentration of chloramphenicol, tetracycline, linezolid, 
fluoroquinolones, and macrolides. Although it does not 
display action in P. aeruginosa, it shows effectiveness in A. 
baumanii and several Enterobacteriaceae [11, 23]. EPI 
activity was also reported in clinical isolates of E. coli, most 
relevantly in fluoroquinolone resistance [150]. Through 
computational analysis, it was found that NMP (136) binds 
with high affinity to the lower part of the deep pocket of the 
B monomer, overlapping in part the binding site of 
chloramphenicol [11]. The binding site for NMP (136) 
includes interactions with hydrophobic residues near the 
hydrophobic patch and Gly-617 of the G-loop. This data 
suggests that NMP (136) interferes with the movement of the 
G-loop, important for extruding substrates, thus inhibiting 
the action of AcrB [25]. 
Nakayama et al. (2003) performed a series of syntheses in 
order to attain a compound specific for the inhibition of a 
MexAB-OprM specific EPI [151-152]. They identified a hit, 
compound 137, through high-throughput screening for 
levofloxacin potentiation using a strain of P. aeruginosa 
strain overexpressing MexAB-OprM. The features this group 
was looking for was the effective inhibition of efflux pump 
and the lack of intrinsic antibacterial activity, since efflux 
pumps are not vital for the organism’s survival [151-152]. It 
was shown that this compound effectively potentiated the 
activity of levofloxacin, leading to an 8-fold decrease in the 
antibiotic’s MIC. However, its physicochemical properties 
were problematic: water solubility was poor and it presented 
high affinity to serum albumin. Therefore, they divided the 
molecule into three parts, A, B, and C (137) and looked for 
alternative scaffolds and substituted polar groups, in order to 
reduce serum protein binding [152]. 
It was shown that when a carboxamide was introduced in A, 
the affinity to serum albumin was diminished, as was its 
activity. More polar moieties led to a complete loss of 
activity. The strategy for the styrene portion (B) that was the 
most successful was to substitute the benzene ring to a 3,5-
disubstituted pyridine, which had both good activity and no 
major serum influence. As for the vinyl group in B, it was 
demonstrated that molecules bearing methyloxy and ethylene 
moieties displayed favorable activity profiles. As for part C, 
the basis of the modifications was the fact that the 
introduction of bulky or hydrophilic groups adjacent to the 
carboxyl group would reduce protein binding. An 
enantiomeric pair containing a dioxolane moiety presented 
both activity and serum stability, being the S enantiomer 
more active [152]. 
Regarding the general scaffold, new compounds were 
designed, keeping in mind that the thiazole moiety was 
crucial for activity. Therefore, a molecule having a thiazole 
side chain attached to the C-7 position of a quinolone was 
synthesized. Substitution with a tetrazole portion yielded 
better results than substitution with a carboxylic acid. One 
compound (138) presented the best activity and serum 
stability [153]. 
Further efforts were placed in order to increase the potency 
of this compound. The in vitro activity was enhanced by the 
introduction of a hydrophobic group at the 2-position of the 
pyridopyrimidine scaffold, and hydrophilic substitution 
would not compromise the activity. The most promising 
compound had the inclusion of an olefin spacer between the 
tetrazole and the pyridopyrimidine scaffold, with the 
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limitation of being prone to photoisomerization [154]. To 
circumvent this, the ethylene tether between the 
pyridopyrimidine was replaced with an amide bond, 
providing stability against photoisomerization and, 
unexpectedly, improving potency. However, another 
problem arose: the lack of solubility for intravenous use 
[155]. The following step was the introduction of a 
secondary amine, giving a zwitterionic analogue, with 
retention of activity. C-2 Analogues, namely with cyclic 
substituents, also showed promising results [156]. Once 
again, the problem of solubility arose. Therefore, efforts 
were placed in making the molecule more hydrophilic, with 
the introduction of substituted aromatic moieties. Analogues 
4-substituted were the most potent, and the introduction of a 
morpholine moiety led to increased solubility, maintaining 
the serum stability. Compound 139 was the most balanced 
molecule in terms of the desired features [157]. The last 
refinement made was the introduction of a quaternary 
ammonium salt, which led to D13-9001 (140). Adding to its 
high solubility and safety, it was able to potentiate the 
activity of aztreonam [158]. Figure 15 illustrates the SAR 
established for 140 and derivatives. 
3D Crystal structures of 140 bound to the target, either AcrB 
or MexB, show that the tert-butyl thiazolyl aminocarboxyl 
pyridopyrimidine moiety of this compound binds tightly to a 
narrow depression, designated by hydrophobic trap, close to 
the deep substrate binding pocket. Additionally, the tetrazole 
ring and the piperidine acetoamino ethylene ammonio-
acetate moiety interact with ionic and/or hydrophilic residues 
in the substrate translocation channel. The piperidine 
acetoamino ethylene ammonio-acetate moiety also covers 
part of the minocycline and doxorubicin binding site [23, 28, 
151]. 
Quinoline derivatives with EPI activity include a multiplicity 
of derivatives, including pyrrido-, alkoxy-, thioalkoxy-, 
alkylamino- and chloro- derivatives. These compounds were 
able to restore an intracellular concentration of antibiotic 
drugs expelled by efflux pumps, as well as to induce the 
increase in antibiotic susceptibility, acting as competitive 
inhibitors of the antibiotic flux. In E. aerogenes and K. 
pneumoniae, quinolines were more effective than PAβN 
(124) in inhibiting the activity of the AcrB pump, 
potentiating the activity of fluoroquinolones, tetracycline, 
and chloramphenicol [11, 24, 26].  Among the different 
classes of substituted quinolines, it was proven that the best 
side chain was piperidinoethyl, which potentiated efficiently 
the restoration of drug susceptibility in alkoxy- and 
thioalkoxyquinolines. The heteroatom connecting the side 
chain is also crucial for activity, being the most potent the 
amino substituent, then the thioalkyl-, followed by the oxo-
derivative. The position of the branched substituted groups is 
also detrimental for the EPI activity [24]. Branched side 
chains containing piperidinoethyl and morpholinopropyl 
groups were associated with the most interesting results, 
being compound 141, containing a piperidinoethyl side 
chain, the most active when in combination with 
chloramphenicol [159]. It has been hypothesized that the 
pump inhibition is greatly influenced by the branched side 
chain, and takes place either in the inner-membrane 
transporter or at the junction between the inner pump and the 
outer channel [159]. 
Given these promising results, further research in this kind of 
compounds was performed. Alkoxyquinolines were 
synthesized and tested against a strain of E. aerogenes 
overexpressing the AcrAB efflux pump. Compound 142 
induced an increase in the susceptibility of chloramphenicol, 
tetracycline, and fluoroquinolone. This could happen due to 
interference during active pumping out of the antibiotic 
[160].  
Chloroquinolines also demonstrated efficacy as EPIs, 
modulating chloramphenicol activity, decreasing its MIC 8-
fold for resistant strains. Synthesis of analogues led to the 
conclusion that amino derivatives are more potent than thiol 
derivatives, pointing out the importance of the side chain for 
the efflux inhibition. Protonation of the nitrogen could also 
play an important role at environmental pH, stimulating 
recognition and binding of the drug to the sites located 
within the pump’s cavity. The heteroatom is also crucial for 
the activity, being nitrogen the most efficient. Compound 
143 is the chloroquinoline with the best results found for the 
inhibition of the main efflux pump of E. aerogenes [161].  
Alkylaminoquinazoline derivatives lacking a nitro group 
were also evaluated for their ability to decrease 
chloramphenicol and quinolone efflux in E. aerogenes, 
through the inhibition of AcrAB efflux pump. The results 
obtained suggest that this family of compounds recognizes 
the same pump site responsible for the transport of 
chloramphenicol and quinolones, competing with them. 
Structurally, it has been shown that a morpholine group with 
a propyl chain makes a more active alkylaminoquinazoline. 
Figure 15 Conclusions from SAR studies for 
pyridopyrimidine  and analogues. 
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The most active compound of this family is compound 144 
[162]. 
Benzothiazoles 2-substituted were first tested for the 
potentiation of ciprofloxacin in AdeABC overexpressing A. 
baumanii. These compounds did not show antibacterial 
activity when tested alone in bacteria. However, when 
combined with ciprofloxacin, there was an observation of a 
reversal in antibacterial susceptibility. The synthesis of 
several derivatives of this family led to pharmacophore 
studies, regarding the features of the most promising 
compounds. Using computational methods, it was revealed 
that, in order for the compounds to be biologically active, the 
following features should be present: the nitrogen atom in 
the thiazole ring and the carbonyl oxygen in the amide 
function substituted on the second position of the 
benzothiazole ring must have an hydrogen bonding acceptor 
property; the benzene ring in the fused ring system, the 
phenyl group attached to the second position of the 
benzothiazole ring and the phenyl ring in the 2-
phenylacetamide and/or 3-phenylpropionamide moiety are 
essential, since they provide a hydrophobic aromatic 
property. Of the synthesized compounds, the ones that 
gathered these features and, therefore, presented the most 
promising activity, were compounds 145, 146, and 147 
[163]. These compounds were also tested for their activity 
against AcrAB-TolC, in an overexpressing strain of E. coli, 
reducing the MIC of ciprofloxacin 10-fold, in the case of 146 
and 147, and 8-fold, for 145 [164]. Unlike AdeABC, 
AcrAB-TolC’s crystal structure is elucidated, making 
docking studies possible. This predicted that all three 
compounds act as AcrB substrates, binding to the distal 
pocket site in the AcrB porter domain by blocking or 
inhibiting the ciprofloxacin binding site, generating steric 
hindrance and thus impeding the binding of the antibiotic. 
Furthermore, 146 and 147 showed stronger binding 
interactions than ciprofloxacin [164].  
Indole derivatives have been useful in inhibiting protein 
targets of virus, tumors and bacteria. Since small molecules 
with conjugated aromatic rings, in which indoles fit, present 
high potential as EPIs, efforts were placed in synthesizing 
derivatives that presented this kind of activity. The TolC 3D 
structure has already been disclosed, making possible the 
structure-based design of inhibitors. Indoles 148 and 149 
were proven efficient inhibitors of TolC in E. coli, 
potentiating the effects of chloramphenicol, tetracycline, 
erythromycin, and ciprofloxacin, with decreased MIC values 
of 2-fold for tetracycline and erythromycin and 8-fold for the 
other two [165].  
 
4.1.3. Existing Drugs 
Other drugs used for treatments other than antibacterial have 
demonstrated EPI activity. Tetracycline resistance in P. 
aeruginosa was reduced 8-fold when the phenothiazine 
fluphenazine, an antipsychotic, was present. Chlorpromazine 
(150) also showed EPI-like activity for the BpeAB-OprB 
system in Burkholderia pseudomallei and a reduction of the 
expression of acrB in E. coli and S. enterica samovar 
Typhimurium, suggesting an inhibition of AcrB production 
[11, 27, 128]. 
Selective serotonin-reuptake inhibitors have been studied for 
their ability to act as EPIs for RND efflux pumps in E. coli. 
It was found that sertraline (151) was capable of potentiating 
the activity of fluoroquinolones. However, its activity is 
limited, since it is possible that this compound also acts as an 
inductor of efflux pumps. Studies have shown that this 
compound could accumulate in tissues or cells, and 
therefore, sertraline’s (151) concentration may be higher 
than that measured in plasma. This means that a standard 
dose of this drug could enhance antibiotic efficacy. It has not 
yet been studied if a sertraline (151) metabolite could be 
administered at a dose higher than sertraline. However, it 
was hypothesized that it could have a better EPI activity, 
while causing less undesired effects on the central nervous 
system [166]. 
Through the observation of previously reported EPIs, 
Piddock et al. (2010) suggested that simple heterocyclic 
nitrogen-containing compounds could also act as EPIs and 
synergize with ciprofloxacin in strains of S. enterica serovar 
Typhimurium that overexpressed the AcrAB-TolC efflux 
pump [167]. It has been shown that compounds containing a 
phenylethylamine moiety, as PAβN (126) does, such as 
epinephrine, norepinephrine, and cathinone, are able to 
potentiate the activity of ciprofloxacin. Of the compounds 
tested, trimethoprim (152) and epinephrine (153), showed 
the best results for the tested strains, which included, apart 
from S. enterica serovar Typhimurium, P. aeruginosa, E. 
coli, and K. pneumoniae. These compounds showed synergy 
for the strains where AcrAB-TolC was active, but showed no 
activity when the pump was inactive. Thus, it can be 
hypothesized that these compounds either inhibit the 
expression of the genes encoding AcrAB-TolC, or interact 
directly with the pump [167]. Both compounds possess 
structural features similar to previously described EPIs, such 
as PAβN (124), L-Orn-L-hPhe-3-NHQ (125), and NMP 
(136), such as an aromatic ring linked to a basic nitrogen, in 
the case of epinephrine (153), or a pyrimidine ring, for 
trimethoprim (152). Trimethoprim (152) is already used in 
combination with another antibiotic, sulfamethoxazole, and 
combination with a quinolone was hypothesized to be a 
viable choice. On the other hand, a combination of 
epinephrine (153) with an antibiotic does not seem a viable 
option, because of the likelihood of the occurrence of 
sympathomimetic effects [167]. 
The antimalarial artesunate (154) has also shown EPI 
activity, enhancing the effects of β-lactam antibiotics, such 
as penicillin G, oxacillin, and ampicillin, and novobiocin 
against E. coli. The mechanism through which 154 expresses 
its activity is by the inhibition of the expression of the 
AcrAB-TolC system, not exhibiting antibiotic activity by 
itself [168]. 
 
5. SMR 
The SMR family comprises the smallest drug efflux proteins 
known, possessing only four transmembrane segments in its 
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composition, and are exclusive to bacteria. They are 
involved in the efflux of lipophilic compounds, such as 
quaternary ammonium salts and a variety of antibiotics. 
These pumps also use an electrochemical proton gradient in 
order to exert its efflux activity [7, 32, 38, 169]. 
One example of a SMR-type pump is the EmrE transporter 
(Figure 16, PDB 3B61), present in E. coli. In the absence of 
the ligand, the asymmetric unit of EmrE contains eight EmrE 
monomers, with four transmembrane helices composing 
each of them. If a ligand is present, it can function as an 
inverted homodimer [7, 170]. 
 
Figure 16 Crystal structure of EmrE (PDB 3B61) of E. coli. 
 
There have not been many studies concerning inhibitors of 
this family of efflux pumps, and the few that have been 
performed were only in silico. Figure 17 shows the 
structures of the SMR inhibitors that will be further 
discussed. 
  
  
5.1. SMR inhibitors 
5.1.1. Natural Products 
Quercetin (155) is a flavonol, present in many plants. This 
compound is very well tolerated in humans, as are its 
glycoconjugates, and presents a multiplicity of activities, 
such as antioxidant, anti-inflammatory and 
antimycobacterial. Only docking studies of this compound 
with two pumps belonging to the SMR family, the Mmr, in 
Mycobacterium smegmatis, and the EmrE pumps, in E. coli, 
were carried out. In Mmr, the hydroxyl groups present in the 
3’ and 4’ positions of the B ring of quercetin were predicted 
to interact with Glu-14 in the helix 1, and the keto group of 
the hydroxychromen ring of the ligand interacts with the 
Trp-48 of the helix 1. Additionally, hydrophobic interactions 
were shown by the residues Phe-44, Tyr-40 and Trp-48, and 
π-π interactions were found with Phe-44. Furthermore, 155 
was also predicted of interacting with dimeric forms of the 
protein [171]. In the case of EmrE, the interaction between 
the 3’ and 4’ hydroxyls with Glu-14 can also be observed, as 
can the hydroxyl in the C-7 position with Tyr-60. 
Hydrophobic interactions are present, with the residues Ile-
11, Ser-64, Gly-67 and Leu-70, and π-π interactions exist 
with the residues Tyr-60 and Trp-63. Structural studies 
suggest that EmrE is mostly in the dimer state, which also 
interacts with quercetin (155) [171]. 
 
5.1.2. Synthetic Compounds 
Cation ligands were subjected to docking studies with the 
Mmr protein of the SMR family in Mycobacterium 
tuberculosis and the EmrE dimer from E. coli. The rationale 
behind this study is the fact that SMR can extrude cations. 
This study led to the identification of new virtual leads, 
amongst which is compound 156. ADME studies prove that 
all the molecules present in this study obey the Lipinski rule 
of five and the Jorgenson rule of three, which shows that the 
compounds possess good drug-like properties [172]. 
 
6. MATE 
MATE transporters are responsible for the efflux of cationic, 
lipophilic substances, providing bacteria and cancer cells 
with MDR, using Na
+ 
or H
+
 influx. They have 12 
transmembrane helices, constituted by 400 to 700 amino 
acids. The mechanism of efflux is thought to happen by a 
rocker-switch mechanism. Members of the MATE family 
include the MepA (Figure 18, PDB 1TZP) transporter, in S. 
aureus, even though seventeen MATE proteins have been 
identified in eleven species, capable of extruding antibiotics. 
Ethidium bromide, tetraphenylphosphonium, acriflavine, 
OHO
OH O
OH
4'
3'
OH
OH
B
155
Figure 17 Structures of SMR inhibitors 155 and 156. 
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berberine, and norfloxacin have been reported as MATE 
substrates [38, 173-181]. 
 
 
Figure 18 Crystal structure of MepA (PDB 1TZP) of E. coli 
in its inactive form. 
 
In Figure 19 are compiled the structures of the compounds 
that have so far proven their usefulness as MATE inhibitors. 
6.1. MATE inhibitors 
6.1.1. Natural Products 
A study performed by Kesherwani et al. (2017) 
accomplished the docking of phytochemicals with the NorM 
transporter, belonging to the MATE family [182]. After a 
screening of a library of natural products, three hits were 
identified: derhamnosyl suspenaside (157), prunin 7’’-O-
gallate (158), and quercetin diglucoside (159). These were 
the best compounds, as their results in binding free energy 
calculation were the most favorable. When binding free 
energy decomposition and hydrogen and hydrophobic 
statistics were taken into account, 158 was elected the best 
hit compound. Furthermore, this compound was stable 
during the simulation. Overall, it has been suggested that the 
compounds which interact towards the cation binding 
residue in the central cavity of NorM will have better results, 
and that good inhibitors should have interaction with a few 
key residues, Gln-34, Val-35, Gly-38, Phe-63, Tyr-67, Ile-
68, Glu-261, Tyr-294, and Asp-377, which will lead to 
Figure 19 Structures of MATE inhibitors 157 – 162. 
HO
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maximum stability and affinity with the NorM transporter 
[182]. 
 
6.1.2. Synthetic Compounds 
These compounds have been previously described as MFS 
inhibitors, namely of the NorA pump. However, similar 
activity has been described for the MepA pump, of the 
MATE family. Compound 80 (Figure 5), incorporating a 
bisaryl urea moiety at the 7-position, was able to 
successfully inhibit approximately 84% of ethidium bromide 
efflux in a MepA overexpressing strain of S.aureus [104]. 
Phenylquinoline derivatives also proved efficient against the 
same strain. Differently from what was observed with NorA, 
the compounds that inhibited MepA most efficiently were 86 
(Figure 5) and 160 (Figure 19), which were able to reduce 
ethidium bromide’s MIC by 16-fold at concentrations of 
0.78 and 1.56 µg/ml, respectively, in the MepA 
overexpressing strain. Ethidium bromide was chosen, instead 
of ciprofloxacin, as it is a better MepA substrate and other 
derivatives were able to inhibit both NorA and MepA efflux 
pumps, being able to completely restore the activity of 
ciprofloxacin and ethidium bromide against strains 
overexpressing such pumps [107]. 
Paroxetine derivatives (104), effective against the NorA 
pump, also demonstrated potency in inhibiting the MepA 
pump in S. aureus. Oppositely to NorA, paroxetine 
derivatives do not need the fluorophenyl ring at position 4 to 
be MepA EPIs. In fact, 4-unsubstituted analogues proved to 
be more potent than 4-F-phenyl derivatives in inhibiting the 
MepA pump, as is the case of compound 161 and 162 [122]. 
 
CONCLUSIONS 
Efflux pumps are one of the main causes for antimicrobial 
resistance. Their inhibition can lead to the restoration of 
bacteria susceptibility and antibiotic efficacy. Throughout 
this review, the data presented leads to the conclusion that 
EPIs are promising compounds and can help reversing the 
problem of antimicrobial resistance. However, the research 
into these kind of compounds is still in a very preliminary 
state, since no EPI is yet under clinical trials. 
Even though no general structural features can be pointed out 
for a molecule to be an EPI, it can be observed that small 
molecules with high lipophilicity are most likely to fulfill the 
requirements to inhibit efflux pumps. Hydrophilic 
compounds can also be transported through porins present in 
the membrane.  Heterocyclic compounds also show potential 
as EPIs, mainly nitrogen heterocycles, but also fluorine and 
boron heteroatoms, since the likelihood of bacterial exposure 
to these atoms is very low. The basis for the MDR pumps 
inhibition has to do with the penetration rules, and whether 
or not a compound is capable of penetrating the bacterial 
membrane. Therefore, a library of compounds that are able 
to do that would be something that would bring advances to 
this study field. 
One of the main aims of this review is to present SAR 
studies, so that pharmaceutical chemists can refine molecular 
structures, leading to the achievement of more potent and 
specific compounds. The use of synthetic approaches, either 
to modify molecules obtained from natural sources, or drugs 
that are already in therapeutic use, or even to develop novel 
compounds, is vital for these SAR studies. The search of 
EPIs derived from natural products comes from the fact that 
plants need to protect themselves from pathogenic 
microorganisms, and produce metabolites that act as 
antimicrobial and EPIs, that synergize with each other. 
However, the referred compounds are not specific for the 
pump they have been studied, showing a multitarget 
character: flavonoids, coumarins, cinnamic acids, among 
others, present a multiplicity of activities already described, 
suggesting their promiscuity. 
The advantage of assays with existing drugs lies in their 
safety profile and, most times, their clinical use for 
combination therapy has been characterized. In some cases, 
the compounds were even investigated as inhibitors of 
human efflux pumps, for cancer treatment. This can be 
regarded as an advantage, leading to a new class of drugs 
with dual human/bacterial EPI, particularly useful in cancer 
patients with infections, potentiating the effects of both the 
anticancer and the antibacterial drugs. 
The future in studies in bacterial EPIs should lie either in the 
search for selectivity for the bacterial target, or in the 
disclosure of the common features of the universal bacterial 
EPI, that can successfully target all efflux pumps. The SAR 
studies gathered herein with the 3D structural information 
available are expected to accelerate the structure-based 
design of new EPIs, founded on the existing models.  
 
LIST OF ABBREVIATIONS 
3D-QSAR: Three-dimensional quantitative structure activity 
relationship; ABC: ATP-binding cassette; ADME: 
Absorption, distribution, metabolism and excretion; ATP: 
Adenosine triphosphate; BCRP: Breast cancer resistance 
protein; COX-2: Ciclooxigenase-2; CYP450: Cytochrome 
P450; EPI: Efflux pump inhibitor; IC50: Half maximal 
inhibitory concentration; MATE: Multidrug and toxic 
compound extrusion; MDR: Multidrug resistance; MIC: 
Minimum inhibitory concentration; MFS: Major facilitator 
superfamily; MRP: Multidrug resistance protein; MRSA: 
Methicillin-resistant Staphylococcus aureus; NDGA: 
Nordihydroguaretic acid; NMP: 1-(1-Naphthylmethyl)-
piperazine; P-gp: P-Glycoprotein; PAβN: Phenyl-arginine β-
naphtylamide; PDB: Protein Data Bank; PSSRI: 
Phenylpiperidine selective serotonin reuptake inhibitors; 
RND: Resistance-nodulation-division; SAR: Structure 
activity relationship; SMR: Small multidrug resistance. 
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Figure 1 Representation of the five efflux pump families (adapted from [8]).  
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Figure 2 Crystal structure of MsrA, from Mycobacterium tuberculosis in complex with protein-bound 
methionine (PDB 1NWA).  
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Figure 4 Crystal structure of EmrD, from E. coli (PDB 2GFP).  
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Figure 6 Conclusions from SAR studies for piperine and its derivatives.  
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Figure 7 Conclusions from SAR studies for compound 57.  
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Figure 8 Conclusions from SAR studies for fluoroquinolone 81 derivatives.  
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Figure 9 Conclusions from SAR studies for 2-phenyl-4-hydroxyquinoline derivatives 84 and 86.  
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Figure 10 Conclusions from SAR studies for omeprazole derivatives.  
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Figure 11 Conclusions from SAR studies for paroxetine derivatives.  
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Figure 12 Crystal structures of AcrB (left, PDB 4ZLJ) of E. coli and MexB (right, PDB 2V50) of P. aeruginosa. 
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Figure 14 Conclusions from SAR studies for MBX2319 (127) (adapted from [28]).  
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Figure 15 Conclusions from SAR studies for pyridopyrimidine 140 and analogues.  
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Figure 16 Crystal structure of EmrE (PDB 3B61) of E. coli.  
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Figure 18 Crystal structure of MepA (PDB 1TZP) of E. coli in its inactive form.  
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